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Since its inception, some 50 years ago, the pressurised metered dose inhaler has 
become the most widely prescribed medicament for a number of respiratory 
conditions. Unfortunately, the dosage form has remained virtually static in terms of 
pharmaceutical development, with success measured from clinical perspectives 
being largely viewed as an amelioration of the classic symptoms frequently exhibited.
The complexity of the dosage form has dictated that the fundamental processes of 
aerosol production are not totally characterised, nor fully understood. It was the 
intention, therefore, of this thesis to investigate and appropriate a better 
understanding of the fundamental pharmaceutics of pressurised HFA aerosol 
systems, resulting from the influence of environmental conditions on particle size 
distributions of the aerosol clouds generated.
To facilitate investigations, several, novel, model bronchodilator derivatives were 
synthesised, characterised and formulated as novel pressurised solution based 
inhalers. From the data generated, it was possible to formulate screening and 
production methodologies for both solution and suspension products, and of the 
derivatives synthesised the two chosen for study were the cis butenedioate 
(maleate), and the cis octadecenoate (oleate), as these were both ethanol soluble 
and were hydrophilic and hydrophobic in nature. Theoretically, calculated solubility 
levels correlated well with practical determinations, and, in conjunction, solubility was 
determined in HFA anti-solvent and a range of ethanol and co-solvent mixtures. In 
order to maintain solution stability, when formulated at a clinically therapeutic level, 
15% w/w co solvent and 30% w/w co solvent levels were required for the maleate 
and oleate respectively. Ultimately, from the data generated, it presented a possible 
method to predict solution stability from a theoretical approach rather than purely 
visual empirical levels alone.
The effects of temperature, and thus vapour pressure, on the resulting particle size 
distributions of hydrophilic salt solutions, (formulated at 15 and 20% w/w) in 
pressurised formulations were investigated under a range of standard pharmacopeial 
testing conditions: 4 and 37°C, respectively. Results indicated that particle size 
distribution patterns were not significantly different when compared on an intra 
formulation basis over the range, but stage depositions were statistically different 
when compared on an or inter formulation level, particularly at high temperatures.
Statistical differences were also noted in MMAD, GSD, and fine particle dose and 
throat deposition for a number of combinations. The data lead to the generation of a 
semi-empirical equation to predict the MMAD from the incorporation of inherent 
physicochemical characteristics: pressure, surface tension, viscosity, formulation 
composition and inhaler hardware tolerances.
Finally, a comprehensive matrix of testing was performed over a range of 
temperature and humidity profiles on both the hydrophobic and hydrophilic 
derivatives formulated as solution-based inhalers. The anticipated effects of 
hygroscopicity on the delivery of salbutamol salts to the lung were not as initially 
postulated. It was evident that cloud dynamics were modified depending on the salt 
derivative within both primary and secondary aerosolisation mechanisms. In 
conjunction, the hydrophilic salt gave a different distribution pattern to that of the 
hydrophobic, primarily due as hypothesised, to the chemistries of the molecules. It 
was also evident that the major particle parameters could be manipulated, standard 
lab conditions did not reflect those when tested under simulated in-vivo conditions in 
the lab, and particle deposition morphologies were substantially different. Statistical 
significances were evident for the major particle parameters when compared for both 
intra and inter formulations.
In conclusion it may be possible from the careful selection of drug derivative, 
formulation, and environmental conditions to preferentially deposit therapeutic drug 
particles to specific locations within the lung.
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1 INTRODUCTION
1.1 The Respiratory system: Structure and Function
The delivery of aerosol particles to the respiratory tract is a complex process highly 
dependent upon a number of multifaceted and intrinsically related parameters: the 
composition of the formulation, the method of generation (pMDI, DPI, nebuliser), the 
patient’s ventilatory parameters (e.g. whether sedentary, light or heavy breathing rates 
and inspiratory volumes) and, ultimately, the respiratory system itself (related to the 
structure and unique environmental profiles, i.e. branching patterns, temperature 
gradients and humidity profiles). A schematic representation of the respiratory system, 
together with approximate penetration power of aerosol particles of varying particle size, 














Figure 1.0 A schematic representation of the human respiratory system.
The respiratory system has been described within numerous texts; and, perhaps the 
principal treatise describing its physical structure was proposed by the anatomist Weibel, 
(Weibel, 1963). The main functionality of lungs can be divided into two principal 
categories: those of the respiratory and non-respiratory respectively; respiratory functions 
include gas exchange mechanisms and the maintenance of acid base balance, and the 
non-respiratory functions include modulation of both the endocrine and metabolic 
activities. Respiration, per se , requires gas exchange facilitating the transport of oxygen 
into the blood and the removal of carbon dioxide from the circulation. The airways, 
themselves, provide the path of least resistance to airflow during both inhalation and
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exhalation, and, so, allow gas exchange to take place in the alveoli. Further, the lungs 
themselves, from an anatomical perspective, are divided into two zones or compartments 
namely the conducting zone and the respiratory zone.
Both zones are divided for clarity into "generations”, which describe the major airway 
brancheing patterns. The airway generations commence at the trachea designated 
arbitrarily generation 0, and terminate at the alveolar sacs culminating at generation 
number 23. The conducting zones consist of the first 16 of the aforementioned 
generations, initiating at the trachea, and dichotomously branch into smaller bronchi and 
bronchioles, ending in the terminal bronchioles.
The respiratory zone is defined as the "architectural portion” of the respiratory tract 
participating in gas exchange beginning with the respiratory bronchioles containing the 
alveoli, and these airways further subdivide into additional respiratory bronchioles, 
eventually giving rise to the alveolar ducts and sacs respectively.
The branching patterns of the airways of the respiratory tract have been described 
previously (Horsfield et al 1971 and Menkes et al. 1986), with two primary characteristic 
properties of the branching airways being shown to have a major impact on lung function: 
the decrease airway of calibre and the subsequent increase in surface area. The 
bifurcating airways concomitantly decrease in diameter and length, but their increase in 
number leads to a greater cross sectional area. Thus, the ratio for each bifurcation is 2, 
and with N representing the number branches in each generation, then the number of 
respiratory airways (z) is dictated by the following equation:
N(z) = 2Z Equation 1.0
Where N is the number of branches and z is the airway generation.
The constant decrease of airway diameter and increase in surface area ensures optimal 
flow of bulk air through the system. Couple this with fact that the respiratory bronchioles 
and alveolar ducts change very little with new generations, then the cross sectional area 
effectively doubles with each new airway generation beyond generation 16. The relative 
physical dimensions, cross sectional areas and volumes are given in appendix A 1.1.
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Other structural modifications also assist in airway function. As one descends the lung, 
distal to the oropharynx, the amount of supporting cartilage decreases, and the posterior 
aligned ‘’C " shaped rings located at the trachea to provide physical support diminish, and 
such reductions facilitate airway compliance and patency.
Ancillary morphological features, of the distal airways, which assist in airflow, are the 
collateral channels. These structures namely the pores of Kohn facilitate and allow airflow 
between neighboring acini and alveoli (Menkes et al. 1986), and were once thought to be 
artifacts resulting from microscopic fixation procedures. Their exact physiological 
significance has not been evaluated. In conjunction, other connections exist. For example, 
Martin has demonstrated inter bronchiolar channels in canine lungs (Martin 1966), and 
both Lambert and Boyden have described channels connecting respiratory bronchioles, 
alveolar ducts and sacs in adjacent lung acini found in human tissues (Lambert 1955, 
Boyden 1971). All of these structures provide an alternative pathway for air to flow in the 
event of occlusions occurring, as in diseased states. It is unlikely, however, whether these 
would be of great importance if a major bronchus were obstructed. As well as the 
structures described, other changes occur in histology and morphology throughout the 
respiratory tract that may impart influence on both lung function and pathophysiology. 
These can be summarised briefly as variations in cell types such as epithelial cells, which 
line the airway lumen, mucus secreting glands, airway smooth muscle, respiratory nerves 
and blood vessels
Blood supply to the lungs is divided between the pulmonary and systemic circulations 
(Fishman 1985 and Grover et al 1984). The pulmonary circulation consists of a highly 
vascularised bed that exits the right side of the heart via the pulmonary artery, and, 
subsequently, branches into a vascular capillary bed encasing the alveoli. These finally, 
reconnect to form the pulmonary veins that drain into the left side of the heart. The whole 
cardiac output, therefore, flows through the pulmonary circulation, which operates under 
both low pressure and resistance. The vessels contain very little, if no, arterial smooth 
muscle tone resulting in a mean pressure of 15mm Hg (c.f. systemic circulatory pressures 
of lOOmmHg), and, in conjunction, can distend and collapse. The properties of low 
pressure, distensible vessels and the alveolar pressure of the interstices result in 
asymmetric flow of blood, sensitive to the effects of gravity. The pressure gradients 
resulting from arterial, venous and alveolar pressures result in blood flow independence 
on alveolar pressure depending on cardiovascular parameters (pressure, geometry and 
smooth muscle tone).
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Gas exchange occurs at the alveolar-capillary boundary by diffusion. The concentration 
and partial pressures that exist between the alveolus and the surrounding capillary bed 
dictate this passive transport. Within the alveolus, the partial pressure of oxygen is 
approximately 104 mmHg as compared to that of deoxygenated capillary blood that is 
40mmHg, providing the driving force of oxygen exchange. In conjunction, carbon dioxide 
experiences the opposite concentration gradient having a greater capillary to alveolar 
pressure of 5mmHg, driving transport in the opposite direction.
Blood flow is regulated by both active and passive mechanisms. The passive involves 
dilation of micro-vessels, which accommodates increased blood flow without any large 
changes in pressure; and, the major active mechanism involves the response to alveolar 
hypoxia. In certain circumstances, alveoli may become poorly ventilated resulting in low 
oxygen tension and pulmonary artery constriction, which reduces blood flow to poorly 
ventilated areas redirecting them to areas of higher oxygen tension.
Other functions of the pulmonary circulation involve metabolic processes. For example, 
the conversion of inactive to active hormones i.e. angiotensin II from I by ACE on 
endothelial cells, catabolic processes including molecules such as bradykinin, 5HT, 
tryptamine, peptides and hormones and the release of bioactive mediators into the 
system.
As well as the pulmonary circulation, the lungs receive blood supply from the systemic 
circulation, commonly refered to as the bronchial circulation. The bronchial fraction of the 
pulmonary circulation serves to deliver essential nutrients to the tracheobronchial portion 
of the respiratory tree incorporating tissues, muscle cells, nerves and glands as well as 
the associated arteries, veins and pleura. However, this is separate from the respiratory 
zone, which receives its sustenance from the pulmonary circulation, and, functionally, 
performs several essential tasks:
(a) It assists in the heating and humidification of inspired air,
(b) It assists in gas exchange and essential nutrient support when the pulmonary
circulation is obstructed (by dilation and connections with capillaries helping with 
blood flow),
(c) It is a major player in inflammatory conditions in the lung, being involved in
oedema and transportation of inflammatory cells and mediators to the airways.
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Finally, the bronchial circulation provides the only angiogenic section of the lung that 
provides new blood vessels requisite to vascularise new tissue
5
1.2 Physiology and Pharmacology of the Airways
1.2.1 The epithelium
The entire respiratory tree is covered with a layer of epithelial cells, which have a varied 
and, consequently, wide range of functions as illustrated in table 1.0.
Cell Situation Function
Columnar Trachea toTerminal respiratory Mucocilary escalator Glycoprotein secretion
bronchioles
Basal Trachea and main Bronchi Progenitor cell. Aid in attachment of columnar cell
to basement membrane
Goblet Trachea and main Bronchi Progenitor cell line for ciliated cells; mucus secretor
Clara Bronchioles Glycoprotein secretion, Progenitor for ciliated and
Clara cells, Serous Xenobiotic metabolism
Brush Infrequent Transitional cell
Serous Infrequent Transitional cell
Intermediate Bronchi Paracrine Non-endocrine chemoreceptor function
Alveolar
Airways
Type I Alveoli Gas exchange media up to 97% of alveolar surface
Pneumocyte
Type II Alveoli Surfactant secretion, Type I progenitor cell
Pneumocyte
Table 1.0: The structure and function of cells associated with the airway epithelium.
In essence, the epithelial lining acts as a "barrier” in preventing interaction between 
aeroallergens and the sub-mucosa of the lungs (Holgate 2003), including particulate 
contaminats such as dusts, bacteria, smoke and noxious chemicals. Indeed, 
pharmacologic agents, from a physiologic sense, fall into this category. The structure of 
the lining is enhanced via mucus secretions and from the highly specialised tight
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intercellular junctions. These junctions substantially reduce the amount of material 
reaching sub-epithelial airway structures (Sturgess 1989).
The most prominent cells identified within the epithelium are those of the ciliated columnar 
cells. These line the complete airway from the trachea through to the respiratory 
bronchioles and concomitantly diminish in size and proportion as the airways are 
penetrated. Their primary function is to remove mucus from the lower airways to the 
upper where it is either expectorated or swallowed accordingly. In addition, ciliated cells 
secrete glycoproteins, which contribute to the mucus layer. Epithelial goblet cells also 
secrete mucus and are abundant within the conducting airways, but are absent in the 
bronchiole, and have been implicated as the progenitors for ciliated cells (Evans et al 
1986). Other cell types found include the basal and clara cells. Basal cells also 
predominate within the epithelium, and act as attachments for columnar cells to the 
basement membrane (Evans et al 1989). Clara cells can be situated within the 
bronchioles and like other counterparts secrete mucus but also participate in the 
metabolism of Xenobiotic substances.
Within the alveoli, two cell types are found: type I and type II pneumocytes. Type I are 
responsible for gas diffusion and gas exchange, and type II are responsible for surfactant 
production.
1.2.2 Smooth Muscle
Smooth muscle is distributed through the entire tracheobronchial tree and is separated 
from the epithelium via a layer containing nerves, blood vessels and connective tissue 
commonly known as the lamina propia. And, muscle phenotype depending on location 
exhibits different spatial arrangements. For example, in the trachea it covers the posterior 
surface, while it completely surrounds the centralized bronchi and bronchioles and, acts 
like a sphincter, which contracts when stimulated. The amount and distribution of the 
smooth muscle, like the epithelium, decreases within the lower airways, but strands of 
smooth muscle can be found as far as the terminal bronchioles and have even been 
observed down to the level of the alveolar ducts. During contraction, smooth muscle can 
cause extensive narrowing of the lumen, and when coupled with deposition of mucus 
plugs and cellular debris can cause severe airflow restrictions (As depicted in equation 
1.1). In diseased states, smooth muscle can be stimulated to increase in size and 
number, and hypertrophy and hyperplasia may ensue.
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1.2.3 Submucosal glands
Present in cartilaginous airways, but absent in non-cartilaginous counterparts, these 
structures display four distinct morphological regions extending from their distal to 
proximal ends, which in turn exhibit associated functionality: serous tubules lined with 
secreting cells terminating in acini, mucus tubules with associated secreting cells, 
columnar collecting ducts, and, finally, a ciliary excretory duct. Excreted serous fluid 
carries mucus from the mucus tubules post migration, and travels into the collecting 
ducts, which is finally expelled with the mucus onto the airway epithelial surface. (Meyrick 
et al 1969)
1.2.4 Mucociliary Clearance
The chemistry of the mucus secreted onto the epithelial surface is a complex cocktail of 
compounds including glycoproteins, immunoglobulins, surfactants and a variety of other 
components. Physically, it is biphasic in nature, and has a low viscosity sol layer in 
contact with the epithelial surface, and conversely a high viscosity gel layer that sits on 
the surface top of the sol layer, separated by a biphospholipid layer; functionally, it 
facilitates several important functions
(a) It prevents dehydration,
(b) It saturates incoming air to equilibrate to saturated water vapour content,
(c) It provides a protective barrier through physical ‘trapping’, antimicrobial, and
metabolic action (Basbaum and Finkbeiner 1989).
For example, when an aerosol particle is deposited within the airways, it is carried by 
coordinated cilia beats, transporting foreign particulates upwards to the tracheobronchial 




There is no single, universal and all encompassing definition of asthma. Indeed bronchial 
asthma and chronic obstructive pulmonary disease are generally considered two 
respiratory maladies that share functional abnormalities. The separation of the two 
respiratory conditions relies upon the force of the expiratory flow rates, specifically the 
FENAt value from total lung capacity. Utilising this reliable and non-invasive measurement 
allows subsequent classification of the two syndromes. In asthma the airflow limitation is 
reversible whereas, in COPD the situation is poorly reversible or irreversible (Romagnoli 
et al 1999).
1.3.2 Intrinsic and Extrinsic Asthma
Asthma can be divided into two categories from aetiology: intrinsic and extrinsic. Intrinsic 
asthma tends to occur later in life, and its mechanism of action is not completely 
understood. Extrinsic asthma, which is the more common form of the disease, results 
from an allergic response mediated by Immunoglobulin E (IgE), which results from the 
invasion of foreign proteins, and these present themselves as aeroallergens to those 
atopic and highly susceptible individuals (Finnerty and Holgate 1989). Other extrinsic 
agents such as chemicals such as toluene diisocyante (Maestrelli et al 1995) have also 
been implicated in non-lgE mechanisms, but display a T helper cell Th2/Tc2 profile. In 
these cases, it is difficult to explain what links asthma with atopy and the ability to 
generate IgE as a direct response to commonly recognized environmental allergens that 
predispose only one-seventh of those subjected to develop this disease.
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1.3.3 Physiology and Pharmacology of an asthma attack
At the onset an acute asthma attack both bronchial smooth muscle contraction, and 
hypertrophy of the bronchial muscle occur in chronic conditions, which, in turn, reduces 
the size of the bronchial lumen thus restricting airflow. This restriction in airflow can be 
related to Poiseuille’s law for laminar flow of a fluid through a pipe. Although the bronchial 
tree does not meet all the requirements of the law per se, it provides a useful 
approximation of the resistance to the airflow. The mathematical expression for 
Poiseuille’s law is described in equation (1.1) below:
MPr4 v a aF  = ------------------------------------ Equation 1.1
tj.S.L
Where F is the laminar flow of the fluid, AP is the driving pressure, r is the vessel radius, q 
the fluid viscosity and L is the vessel length.
From this relationship it can be seen, as the radius of an airway decreases, say by a half, 
then, a significant increase in the resistance to flow increases (approximately a 16 fold 
increase). In addition to the reduction in the available space of the lumen, the underlying 
mucosa becomes oedematous, and flooded with a number of inflammatory cells (Dunnill 
et al 1969). Wide ranges of cells are present during the progression of the inflammatory 
mechanisms: mast cells, macrophages, leukocytes and predominantly eosinophils are 
distributed within both in the mucosa and the epithelial lining of the respiratory tract. A 
further morphological consequence post inhalation of an allergen is the denudation of the 
bronchial epithelium, which has been suggested and erstwhile described, as the primary 
barrier to allergens (Holgate 1999). In conjunction, the epithelium as well as being 
implicated as the principal target for the inflammatory response, is also a major source of 
inflammatory cytokines and mediators. These bio-chemicals express different patterns of 
adhesion proteins orchestrating airway remodeling and are the major target for the 
delivery of anti-inflammatory drugs. This highlights the importance of understanding the 




Regrettably, there have been a number of deaths related to asthma, but the data 
accumulated from epidemiological studies dating from the 1960’s have greatly advanced 
our understanding of the disease. Factors relating to the prevalence of asthma can be 
attributed to the following rather limited, but not exhaustive list of examples: air pollution, 
asprin intolerance, the use of beta adrenreceptcr agonists, age and socioeconomic 
variables (damp housing, smoking, urban environment etc). The majority of cases are 
mild (Auerbach et al 1993) and it is estimated that approximately 14 million people are 
affected in the USA alone with the mild form of the disease. It is the most chronic disease 
of childhood (Newacheck et al 1986), and is a common disease of medical emergencies 
(Kerem et al 1990). The burden of asthma appears to be on the increase globally, 
particularly in areas undergoing rapid urbanization and asthma is now a global concern 
(Beasley et al 1992).
Recently the largest increase in world asthma has been in New Zealand (approximately a 
34% increase, Wickens et al 1999). One possible cause behind such an increase can be 
related to the "hygiene theory” . As the country has little pollution and good air quality, it is 
theorised that from the reduction in exposure to a variety of aeroallergens, subjects may 
result in hightened sensitivity, when exposed to such agents in the longer term.
1.4 Salbutamol and the Bronchodilator family
1.4.1 Pharmacology and Mechanism of action
Sympathomimetic agents are one of the most extensively prescribed classes of 
medication for the alleviation of asthma, the use of which dates back to pre-Christian 
times. The efficacy of these compounds stems from their molecular structure, which are 
similar in base architecture and functional group location to natural agents such, as 
ephedrine, which exerts its effect via an indirect release mechanism of catecholamines 
from storage granules, specifically adrenaline whose effects are mediated via direct action 
upon cell membrane receptors. Over the past few decades, developments in 
pharmacology have elucidated a range of membrane receptors that respond with 
specificity and receptivity to different families and classes of therapeutic compounds. 
Classification of alpha and beta-adrenergic receptors was originally proposed in the
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1940’s by Alquist, whereby the alpha forms were those blocked by ergot and beta by 
isoprenaline (Campbell and Soyka 1976).
1.4.2 Receptors and receptor subtypes
The biochemical mechanism of action of |32 agonists is well established, and the smooth 
muscle tone responsible for airway lumen size within the respiratory bronchioles is 
ultimately regulated by intracellular calcium (Ca2+) ion concentration. In essence, the 
cascade mechanisms that occur are complex and beyond the scope of this thesis, but in 
brief, contraction occurs when (Ca2+) enters the smooth muscle cell or is released from 
intracellular stores, which firstly binds with calmodulin. The resulting complex activates a 
second kinase: myosin light chain kinase (MLCK), which in turn phosphorylates myosin 
light chains (MLC’s). From this stage, promotion of the interaction of myosin ATPase and 
actin forms cross-bridge linkages and smooth muscle contraction occurs. However, when 
(32 receptors are activated the enzyme adenylate cyclase initiates the conversion of cyclic 
AMP (cAMP) from ATP. The activation of cAMP protein kinase phosphorylates MLCK 
decreasing its activity, which finally results in a decreased affinity of (Ca2+)-calmodulin for 
MLC kinase and so results in bronchodilation
During the 1960’s (Lands et al 1967), further sub-divided the beta adrenoreceptors into (31 
and (3 2 respectively, with cardiac responses (chronotropy and inotropy) mainly mediated 
through the fa receptor, while the receptors mediating the desired airway effect belonging 
to the fa. The fa receptor is a ubiquitous moeity and can be found in other tissues: 
skeletal muscle, blood vessels and myocardium, which elicit systemic side effects 
(palpitations, tremors) even with the most selective of agents. The final structure of the |32 
receptor has not been fully described. A brief summary of the effects of adrenergic 
stimulation are provided in appendix A 1.2
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1.4.3 Structure Activity Relationships
The efficacy of current synthetic adrenergic agonists results from their structure, which is 
based on the catecholamine sub-unit. They are inactivated in-vivo, swiftly, by one of two 
methods: type I uptake whereby storage vesicles reabsorb the compounds, or type II 
inactivation by the enzyme catecholamine-O-methyl transferase (COMT). The type II 
mechanism further proceeds, after methylation at the 30H position of the benzene ring, 
via oxidation by monoamine oxidase, and to complement deactivation, both the 
gastrointestinal tract and hepatic functions further reduce activity by sulphonation again at 
the 30H position (Reed 1978).
Subtle changes in chemical structure can markedly affect the associated activity of a 
molecule. For example, consider the catecholamine nucleus. Changing the ring positions 
of the hydroxyl substituents from the 3,4 to 3,5 positions significantly reduces the power of 
the COMT enzyme. As a trade off, this modification decreases the affinity for the (32 
receptor, but a longer duration of action ensues, giving rise to a class of compounds 
known as resorcinols. This class of compounds includes ephedrine, pirbuterol, 
metaproterenol, terbutaline and feneterol. Further adaptations to the basic structure leads 
to the development of compounds known as saligenins. A saligenin structure will result 
from the consequence of the transformation of the hydroxy ring substituents to that of a 
methoxy functional grouping, resulting in an orally more active form. Once modified, this 
gives rise to exemplary compounds such as salbutamol and pirbuterol respectively. In 
general, whenever synthetic modifications are made to active molecules two fundamental 
outcomes are sought:
(a) Firstly, in the reduction of systemic side effects, and
(b) Secondly, to facilitate the improvement in the duration of action.
Primarily, in this class of compounds addition or modification to the alpha carbon atom 
and/or the nitrogen atom on the molecule achieves this goal. In addition, to reduce the 
effects of MAO (monoamine oxidase, an enzyme) activity, further manipulation of the 
substituents on the terminal nitrogen moiety is required. An example of this is the 
molecule salmeterol, which is structurally similar to salbutamol with the exception of the 
long lipophillic nitrogen substituent, which it is postulated anchors the molecule to the (32 
receptor protein by intermolecular forces, increasing the contact time of the molecule with 
the receptor (DAIzona et al 1994). This concomitantly increases the effect of duration for
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up to 12 hours and shows an increased selectivity ratio 50,000:1 versus 650: 1 for 
salbutamol. The selectivity, however, has a critical size after which it diminishes with no 
gain (McFadden 1981). Other examples of where the alpha carbon is the choice for 
modification is evident in the alpha ethyl derivatives of isoproterenol and isoetharine 
(George 1981)
1.4.4 Enantiomers
It has been usual practice to deliver the majority of medicaments in the form of a 
racemate, even though it has been long established that stereochemistry and structural 
conformity are significant in physiological activity. Terbutaline, for instance, is 
approximately 3000 times more active in the laevorotatory form than the corresponding 
dextro form in relaxating guinea pig tracheal tissue with the said dextro form lacking any 
affinity for the |3 subtypes in general (Jepperson et al 1984), although even as a racemic 
mixture the overall efficacy is not apparently diminished.
However, considering salbutamol some studies have shown the + / dextro / (S) 
enatiomeric form of to illicit some constrictor functionality, but as illustrated by Ariens 
(Ariens 1984), to accurately evaluate the pharmacokinetics, enatiospecifc analytical 
methods must be employed to accurately compare effects of the individual enantiomers of 
each compound.
The use of single enantiomers confers other problems with the formulation, since 
individual densities, solubilities and melting points, of the eutomer, distomer and 
racemate, will all differ, which effectively necessitates the formulation of a "new” 
medicine. In this respect, and as an example, salt selection is crucial to ensure stability 
with laevo (R) salbutamol currently formulated as the tartrate salt in an MDI. Further, from 
a formulation perspective, peculiarities of single enantiomers have been observed in other 
pharmaceutical inhalation dosage forms, whereby mixtures of lactose and 
enantiomerically pure mandelic acid produced different respirable fractions 
(Nowaseb1998).
In the case of salbutamol, the racemate is composed of equimolar amounts of the (R) 
eutomeric active form, and the (S) distomeric inactive form. In terms of pharmacology, the 
(R) form exhibits the bronchodilator/bronchoprotective and anti-oedatous properties, with 
mast cell inhibitory effects; the (S) form has always been considered biologically inactive. 
However, recent studies have indicated that excessive use of the racemic mixture
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induced negative reactions. The S-form induces pharmacological effects, which cannot be
related to p 2 adrenoreceptor stimulation, and has been demonstrated to cause
hypersensitivity of guinea pig airways, and in conjunction promotes the activation of 
human eosinophils in-vitro (Page and Morley 1999). From a mechanistic viewpoint, the 
distomer increases intracellular calcium ions, which negate the effects of the enzyme 
adenylcyclase by the eutomer. It has also been found that the distomer is metabolised 
more slowly and is retained preferentially within the respiratory tract.
The bronchoconstrictive effect of this enantiomer has been corroborated from its effects 
upon dissociated bovine smooth muscle cells (Mitra et al 1998), and has also been further 
postulated that the distomer binds with muscarinic receptors. It would therefore seem 
prudent to administer the pure laevo (R) form. However, a recent study has concluded in 
terms of cost and efficacy it is neither safer nor cost effective to do so. (Asthmus and 
Hendes, 2000).
1.4.5 Efficacy and Potency
When directly compared, in-vitro and in-vivo effects of bronchodilators do not correlate 
well. Isoproterenol for example, when assessed in an in-vitro situation exhibits a 
significant increase in potency when compared to salbutamol; but, when examined in- 
vivo, after aerosol administration, this significance is reduced and the clinical 
manifestation of the therapeutic action differs depending on the type of asthma. For 
example, the duration of action of these agents are reduced in exercise-induced asthma 
as compared to chronic stable asthma. This therefore necessitates that the comparison of 
such agents should be evaluated from a standardized method of measurement, such as 
illustrated by histamine or methacholine challenge protocols
1.5 Particle Deposition Mechanisms in Human Airways
1.5.1. Introduction
The main influences that dictate the deposition behaviour of inhaled aerosol particles 
incorporate the aerodynamic properties of the aerosol, the inspiratory manoeuvre of the 
patient and the geometry of the respiratory tract. The main deposition mechanisms of 
inhaled aerosol particles are through inertial impaction, gravitational sedimentation and 
the effects of diffusion. Other ancillary mechanisms are known to exist and include those 
of interception and electrostatic induced deposition. But, in the upper airways, large
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particles deposit primarily due to inertial impaction, and in the conducting airways, both 
inertial impaction and sedimentation influence the deposition characteristics of the aerosol 
particles. By manipulating ventilatory parameters such as increasing the force of 
inspiratory airflow greater impaction in the upper airways may ensue. In contrast, 
increasing the breath holding manoeuvre increases the residence time of the aerosol 
dose within the lung thereby increasing deposition by sedimentation and diffusion in the 
respiratory zone. Selective or targeting deposition of inhaled pharmaceuticals to specific 
locations of the respiratory tract is preferred, as diseases are not distributed 
homogeneously throughout the lung. For example, cystic fibrosis may be distributed 
throughout the tracheobronchial tract. Asthma has been identified to localise within the 
large upper, central or smaller lower bronchial airways, whereas, at a specific regionalised 
locations carcinomas have a predilection for bifurcations (Martonen 1992). More recently, 
the respiratory tract has been identified as route for systemic drug delivery, and for this 
mode of therapy the particle size of the therapeutic agents should, ideally, be less than 
1pm in MMAD. The peripheral regions of airways, the alveolar region, are separated from 
the systemic blood circulation via a very thin layer of epithelial cells (<0.2pm). As 
deposition is dominated by diffusion in this region of the lung, the small particle size, 
coupled with large residence time and the large cross-sectional area of the alveoli make 
this an ideal delivery vehicle for portal entry.
1.5.2. Inertial Impaction
Aerosol particles travelling along a gas stream have an inherent momentum (product of 
their mass and velocity). When the gas stream encounters a change of direction, the 
particles inertial force tends to resists this change, causing the particle to revert to its 
original path leading to impaction. If the particles momentum is such that it is not affected 
by the change it instantaneously relaxes into the direction of the flowing air (gas stream). 
This mainly occurs for low density and smaller particle size fraction of the aerosol cloud, 
and particles preferentially deposited by this mechanism end up proximal to the lung in 
the oropharynx. Only a small fraction of particles with aerodynamic particle diameters 
over 15 microns (mouth breathing) and 10 microns (nasal breathing) ever reach the 




Gravity affects particles when they have sufficient mass. The velocities at which these 
particles settle are related to Stokes Law, which is a solution to the generally insoluble 
Navier-Stokes equations, the governing differential equations describing fluid motion. 
These equations are difficult to solve, as they are non-linear partial differential equations, 
but solutions become available by making the following assumptions:
(a) Inertial forces are negligible as compared to viscous forces,
(b) The fluid is incompressible,
(c) There are no boundaries or other particles nearby,
(d) The motion of the particle is constant,
(e) The particle is a rigid sphere, and
(f) The fluid velocity at the particles surface is zero.
In still air the most important force acting on particles of the apprpriate size will be gravity; 
this force will be directly opposed by the buoyancy of particles due to the displaced air. As 
a result the net force Fn on the particles can then be written as,
Where g is the acceleration due to gravity and pp and pa are the densities of the particle 
and that of air respectively. However, inevitable interactions occur with air molecules, and 
create a force that resists gravity, when Kn is small. The total drag force FD on a spherical 
particle moving with a velocity V through the fluid can be described by the following 
expression:
where r| is the viscosity of the medium, V is the particle velocity and d is particle diameter. 
Thus, the particle accelerating under gravity will eventually reach a velocity at which the 
drag force balances the net downward force. The result is the terminal settling velocity Vst.
Fn = gnD p\pp  -  pa) / 6 Eqaution 1.1a




Where Vst is the terminal settling velocity pg is the density of the medium with all other 
terms as per standard nomenclature.
1.5.4 Brownian motion
When the aerodynamic diameter of a cloud of aerosol particles approaches the mean free 
path of gaseous molecules, the continuous bombardment of the aerosol particles by the 
gas molecules may cause them to undergo random motion. The resultant force affects 
their direction. The particles therefore move from a high to a low concentration by 
diffusion, and, subsequently, the particles within the aerosol cloud (the bolus) diffuse from 
the lumen (centre) towards the walls of the respiratory tract. The rate of diffusion is 
inversely proportional to the particle size and is the dominant mechanism for particles 
smaller than 0.5 microns. The diffusion coefficient of a particle is given by,
^ kTCcD  = -------------------  Equation 1.4
1nviDp
Where k is the Boltzman constant, Ccis the Cunningham slip factor, T is the Temperature 
in Kelvin, 77 is the viscosity of the medium and Dpis the particle diameter.
1.6 Aerosol Characteristics and Definitions
1.6.1 Definition
An aerosol is basically the dispersion of solid or liquid particles (typically smaller than 50 
microns) in a gaseous environment (Gonda 1988).
1.6.2 Size Distribution
Ideally, it would be preferential to produce and deliver mono-disperse aerosol particles for 
targeting inhalation delivery. In reality, the aerosols delivered from such systems are poly- 
disperse and can be best described by a logarithmic normal probability function. The 
critical parameters that describe the aerosol are the geometric mean diameter, mass 
mean diameter, mass mean aerodynamic diameter and geometric standard deviations.
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1.6.3 Geometric Mean Diameter (GMD)
The GMD is the /<h root of the product of particles which all have diameters /. Thus, if the 
aerosol generated contains say 6 particles 2 of which are 3 microns, 3 of which are 4 
microns and 1 of 5 microns, the GMD is:
1.6.4 The Mass Median Diameter (MMD)
The mass median diameter, as suggested, divides the distribution of aerosol particles into 
two equal halves as a function of weight. Thus, by weight, 50% of particles will be below 
and 50% above this mass median value. If the logarithmic diameters fall in line with the 
normal probability function then the GMD equals the MMD.
1.6.5 Mass Mean Aerodynamic Diameter (MMAD)
The motion of aerosol particles travelling in a gas stream depends on the intrinsic 
variables of size, shape and density. The MMAD parameter combines these variables and 
is used to express the average cloud deposition within in-vitro and in-vivo models. This 
property is defined as:
‘The diameter of a sphere of unit density, which has the same terminal settling velocity as 
the particle under assessment’.
and is related by the following equation:
D g m d  = 6V32x43x5 
D g m d =  4.45 jam
Equation 1.5
MMAD = MMD Equation1.6
Where p is the density of the disperse phase and p0 is the unit density (1kg m'3)
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1.6.7 Geometric Standard Deviation (GSD, og)
The geometric standard deviation describes the poly-dispersity or spread of an aerosol 
particle distribution. An idealised monodisperse aerosol would have a a N = i and In ag= 0. 
It is practically impossible to produce totally monodisperse aerosols, and, so pragmatically 
monodisperse aerosols are quantified when they reach a value of approximately 1.2. For 
example, if an aerosol distribution has an MMAD of 5 microns and a GSD of 2 microns, 
68% of the aerosol mass occupies the size range of In 5 ± In 2 and 95% of the mass 
occupies the size range In 5± 2 In 2.
1.7 Inhalation aerosol delivery devices 
General Discussion
Several methods can be utilised in generating aerosols in the particle size range requisite 
for respiratory therapy. These are summarised in Table 1.1:
System Reference
Jet Nebulisation, (Fair et al 1984)
Ultrasonic nebuilsation (Sollner, 1936)
Electrohydrodynamic techniques (Rayleigh, 1882)
Dry powder inhalers (DPI’s) (Ganderton et al 1992)
Propellant driven metered dose inhalers (pMDI’s) (US Patent 1960)
Table 1.1 The major aerosol generation techniques used in respiratory therapy
Commercially, jet nebulisers, dry powder inhalers and propellant driven metered dose 
inhalers dominate the inhalation market. These systems are not, however, ideal delivery 
systems with each having inherent advantages and disadvantages. In achieving medicinal 
regulatory standards, they are usually simple in construction (with some exceptions), 
ergonomic, portable and relatively cheap to produce commercially. It has been widely 
accepted from a regulatory and, thus, a clinical viewpoint that the aerosol generated must 
be below 10 microns and ideally within a well-defined size range depending on 
therapeutic application (Usmani et al 2003). The dose delivered must be consistent and 
the respirable fraction suitable for the intended use. The packaging of the device and 
formulation is required to protect the physico-chemical integrity of the medicament and
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excipients and not detrimentally interact with formulation. The system must be easily 
transportable and be ‘patient friendly’.
1.8 Selection of a Delivery System
The selection of a system to deliver drugs to the respiratory tract depends not only on the 
active and the formulation, but also on the disease state, the patient and physicians 
preference. In theory, any medicament can be delivered by the major systems described, 
but some are specifically preferred to others. It could be argued that for peripheral 
delivery of large doses of active (e.g. an antiviral), pMDI’s and DPI’s are inefficient, 
whereas a baffled jet nebuliser e.g. the SPAG-2 (ICN Pharmaceuticals, Costa Mesa, CA) 
would be more efficient for such high dose delivery. Alternatively, DPI’s and pMDI’s may 
be preferred for delivery to the conducting airways in asthmatics, as these devices 
provide a bolus dose necessary for rapid bronchodilation. Biopharmaceuticals are 
generally formulated as an aqueous solution and stabilized with additives, therefore, 
these therapeutic agents currently lend themselves to a nebuliser delivery system.
1.8.1 Nebulisers
The principle of nebulisation has been Known for over a century ( Rayleigh 1882). With 
this type of delivery system, co-ordination of the inhalation breathing cycle, and the need 
to fluidise and disperse the aerosol cloud via an inspirational energy is not required. This 
makes nebulisers excellent for patient groups with poor coordination and poor pulmonary 
function: they have low peak expiratory flow (PEF), low forced expiratory volume curves 
(FEVi), low ventilatory perfusion rates and have increased airway resistance and poor 
lung compliance. These advantages of this system are however negated by its size, as it 
requires a compressor and possibly an electrical supply and thus limits its portability. In 
conjunction, the nebuliser requires a respiratory solution or suspension and ancillary 
componentry making it a non-integrated system.
Air jet nebulisers operate on an external energy (air) supply. Compressed gas is forced 
through a restriction, which, results in an increase in velocity but a subsequent reduction 
in pressure (Bernoulli effect produced via a Venturi nozzle). With the help of capillary 
action, the solution or suspension of the drug is entrained by the negative pressure flow, 
and due to pressure gradients is sheared into a liquid film, which forms into aerosol 
droplets. Larger droplets become trapped by the internal baffle, coalesce and fall under
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gravity to the recirculating solution. The particle size distribution and the density of the 
aerosol particles produced depend on the type of baffle used (Steventon and Wilson 
1986). Smaller droplets escape the impaction experienced by larger particles, leave the 
nebuliser, and travel via the exit tubing to the patient. Because the patient generally uses 
a facemask or mouthpiece, minimal patient coordination is required with the patient 
undertaking a normal tidal breathing manouvere.
Problems can occur with nebulisers as the use of dry compressed air can aid evaporation 
of the drug solution/suspension and reduce its temperature, and changes in concentration 
have been reported that fundamentally change the rate of output and equilibrium particle 
size (Clay et al 1983). Further, the drug solution can concentrate and block the 
equipment. This in practice does not usually occur as the material is aerosolised quickly 
and the actives used usually have a high aqueous solubility. However, care is required 
with suspensions, particularly steroid formulations. The particle size of the aerosol 
produced depends as in other systems upon the formulation parameters: the density, 
surface tension, viscosity, added excipients, the design of system, operating conditions, 
and environmental conditions.
The majority of home use nebulisers are operated via small compressors that are very 
inflexible and the operational considerations are not well defined. Together with the 
ambient environmental conditions, patient usage is difficult to standardise.
1.8.2 Dry Powder Inhalers
Dry Powder inhalers store and deliver the medicament of choice in a granulated powder 
form, which is usually a blend of the active with a range of coarser excipients, although 
drug only formulations are known. The basic components of a dry powder inhaler consist 
of the following:
(a) A blister or capsule containing the formulation as a pre-metered system or a
reservoir chamber with a metering mechanism,
(b) A de-aggregation system, which can either be active (the energy for dispersion is
supplied externally); or passive which requires the patients inspirational energy to fluidise 
and disperse the powder formulation into an aerosol cloud,
(c) A suitable mouthpiece, which may contain the de-aggregation mechanism.
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As previously indicated, the particle size range required for delivery to the conducting 
airways is approximately 2-7 micrometers in mass mean aerodynamic diameter (Newman 
and Clarke 1983). For most small non-biological entities, the active is usually in a 
micronised form. However, the particles may also be generated from spray drying or other 
particle engineering approaches utilised in producing particles with the desired shape and 
size. Gravitational effects on sub-1 Opm respirable sized particles, compete with several 
other significant particular forces: electrostatic, Van der Waals and capillary forces, 
respectively (Hickey et al. 1994). To reduce the influence of theses co-operative forces, 
large carrier are co-blended with the active to overcome the cohesive forces and aid the 
powder flow of the formulation during processing and fludisation upon device actuation. 
The de-aggregation and dispersion of the drug particles from the carrier particles are 
influenced by the size of carrier, which increases the drag force experienced by the drug 
particle adhering to the excipient (Ganderton 1992).
Thus, the removal of the drug particles from the excipient particles allows the delivery of 
the aerosol to the lower airways of the respiratory tract, whilst the excipients particles 
impact on the oropharynx due to their higher inertia. Successful delivery of aerosolised 
powders depends upon a closely related number of physico-chemical properties of the 
particles, which influence their fluidisation and dispersion behaviour. Crystallinity 
(including polymorphism (Wadke 1989)), particle size (Lalor and Hickey 1998), 
distribution, shape (Peitsch 1991), hygroscopic nature and moisture content, which may 
also be further modified during processing, affect the aforementioned properties of 
particle delivery from this system.
Fluidisation of the powder occurs either hydrodynamically or mechanically. Hydrodynamic 
(the motion of fluids and objects therein) fluidization utilizes a gas that passed through a 
permeable membrane then through the powder bed (gas assisted), or, by creating a low 
pressure field close to the surface of the powder, which causes a pressure differential of 
the air within the powder voids and the air flowing over the powder resulting in fluidization 
(capillary assisted). Finally, shear force fluidization or saltation can occur whereby a flow 
of gas passes over a powder contained in an open vessel fluidizes particles. Since 
particles on the surface have a smaller particle co-ordination number, separation by shear 
forces (pressure differentials) results in transfer of transitional and rotational energy over 
the powder bed. The impaction from momentum generated causes incipient fluidization. 
Mechanical fluidisation on the other hand, via vibration operates via the use of gravity 
when a powder falls through air e.g. the Spinhaler DPI device. Impaction fluidisation
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occurs when a tangential force is applied to the powder such that the inter-particulate 
forces of the bulk are negated.
The internal geometry of the device is also important in generating the aerosol. The dose 
receptacle and the associated airflow conduits dictate the pressure drop across the 
device and the effort needed to generate the aerosol. Novel approaches have been taken 
to assist delivery. Active devices, where a complementary energy source is used in 
conjunction with inspiratory airflow, are now in use to help free the individual particles 
form the bulk. The materials of construction and geometry are also important since the 
formulation and the polymers may enhance electrostatic interactions (Staniforth 1994) 
and the subsequent accumulation of drug particles in the device.
1.9 Metered Dose Inhalers
1.9.1 Introduction
The development of pressurised systems can be traced back to the 1950’s when Rexall 
laboratories developed the pressurized metered dose inhaler (pMDI) system. The 
development of the pressurized metered dose inhaler into the 21st century has been 
complicated due to their required reformulation facilitated by phasing-out of CFC’s and the 
introduction of HFA propellants. The rationale for the phase out of CFC’s outlined in the 
Montreal protocol, which dates back to the late 80’s, basically describes the steps 
required by industry, to reduce the amount of ozone depleting substances (Ozone 
Secreteriat 1987). The pharmaceutical industry has been required to comply with the 
directive phase in new medications by substituting the compressed liquefied gase 
propellants. To complicate matters, the industry, naively, anticipated that the formulation 
change would be smooth and seamless. Active pharmaceutical ingredients however did 
not behave in a similar fashion and certain excipients were not as soluble as in the CFC 
free counterparts. Possible explanations for changes in formulation behaviour will be 
discussed later, but, essentially, industry is still struggling with the imposed change.
The systems are complex and deficient in a number of areas, due to the high exit velocity 
of the aerosol, poor patient co-ordination of the inhalation manoeuvre, and incorrect 
actuation of the device, all of which probably relates to only a relatively small dose of the 
active ever reaching the patients lung. (Newman et al 1981)
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The main components of a pMDI have evolved very little since its inception. The basic 
components of a pMDI consist of the following:
(a) A container (extruded aluminum canister with the inner surface either coated 
and/or uncoated or a glass bottle)
(b) A metering valve (one of several variants containing multiple polymers and
coatings)
(c) An actuator to generate the aerosol and or a spacer device
(d) The medicament (as either a solution or suspension) and ancillary excipients (co­
solvents and propellant(s))
A schematic representation of a pressurized metered dose inhaler is shown in figure 1.1
Figure 1.1: A representation illustrating a working pMDI
1.9.1(a) Basic Operation
The energy supplied via a pMDI system lies in the vapour pressure of the compressed 
liquefied gas(es), which are held under pressure in the container. Prior to operation the 
metering valve holds a dose of medicament and excipients suspended or dissolved in the 
compressed liquefied gas (CLG). Once the valve stem is depressed, it retreats into the 
body of the valve and the metered dose (MD), emitted as a bolus cloud, travels into the 
actuator sump. The vapour pressure of the formulation exiting the actuator orifice, termed 
the emitted dose, (ED), then equilibrates with that of the surrounding environment 
resulting in a fine spray, with initial velocities approximating 15 ms'1 (Dhand et al 1988). 
The formation of droplets and the underlying factors of spray formation will be considered 
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1.9.1 (b) Disadvantages of Pressurised systems
Although pMDI’s are small, portable, robust and the formulation substantially unaffected 
from the surrounding environment there are a number of other considerations regarding 
their efficiency:
(i) Patient Coordination.
Effective lung deposition necessitates co-coordinated delivery from the device and the 
inspiratory cycle of the patient (Crompton 1982). To compensate for this, breath 
coordinated devices (BCD) and breath-activated devices (BAD) have been developed. In 
BCD systems, mechanisms are in place whereby the dose is actuated by depression of 
the canister but airflow is restricted and timed to coincide with generation of the aerosol 
cloud. In BAD systems, the canister is generally spring-loaded and is balanced on top of a 
flapped valve. As the patient inhales, the flap co-ordinates the depression of the valve 
stem delivering the drug at the start of the inspiratory cycle.
(ii) Incorrect Inhalation Manouvre
Patient information leaflets illustrate the correct procedure for administration of an inhaled 
medicament. A slow continuous breath followed by a long breath hold (10s or so) is 
advisory, which can reduce impaction in the ororpharynx (Newman et al 1980). However, 
in practice, this is almost never complied with and breathing conditions and characteristics 
of inhaled air have been shown to impact on particle deposition mechanisms, (Martonen 
and Yang 1996; and Martonen and Katz 1996).
(iii) Atmospheric Relative Humidity
High humidity and the ingress of moisture into pMDI’s via diffusion can be problematic in 
both solution and suspension systems (Miller 1990), and requires careful selection of 
components e.g. the metering valve (Williams et al 1997). Indeed, HFA propellants have a 
greater affinity (water solubility) than their CFC counterparts. (Pischtiak 1999).
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(iv) Dose Delivery Consistency
Suspension based systems, due to their thermodynamic instability, can deliver 
inconsistent doses of drug. Density differences between the active and propellant mixture, 
insufficient dispersion and distribution of the active, shearing forces by shaking, and delay 
between shaking and inhalation all affect dose delivery and clinical efficacy (Dalby 1992). 
Solution systems, which are easier to manufacture, and exhibit superior drug dose 
uniformity, do have several negative points. Due to molecular segregation of the drug 
reduced stability can occur. Drug can be absorbed into the elastomers and at low 
temperatures can precipitate and crystallize out of solution (via unstable supersaturated 
states), and can lead to a decrease in dose delivery per actuation (Atkins 1991). During 
operation through the life of an inhaler, after each actuation there is a liquid volume loss, 
resulting in a possible a 10-20 % increase in dose towards the use of a 200-dose pMDI 
system (Howlett 1996). Lewis et al. corroborated this finding (Lewis et al 2000).
(v) Particle Size Distributions.
The particle size distributions emitted from solution based HFA pMDI systems have in 
general smaller mass mean aerodynamic sizes particle (MMAD « 1.2 microns ) when 
compared to their CFC counterparts (MMAD 3.5 - 4 microns), ( Leach 1998) and possess 
a different distribution pattern when measured in-vitro. From a regulatory viewpoint, this 
has been negatively received, as a seamless transition between CFC and HFA driven 
systems is the ultimate goal of the medicinal formulator. In-vitro correlation, at ambient 
temperatures, via Andersen cascade impaction is a standard analytical test. But, it does 
not take into account in-vivo conditions of temperature and humidity and therefore may be 
misleading in the interpretation of results, in-vivo correlation of solutions and suspension 
inhalers has indicated major differences. Leach (Leach 1998) demonstrated that 51-56% 
of the dose was distributed through the lungs uniformly, with little oropharyngeal 
deposition (28-30%) for a BDP solution inhaler. In contrast, the suspension CFC 
counterpart deposited mainly in the oropharynx (94%). Possible reasons for the 
differences in deposition can be postulated from the nature of the aerosolised cloud. Even 
though the vapour pressure and therefore the exit velocity of the HFA clouds are greater, 
particles should experience increased impaction. However, the formulations are different 
(namely solution versus suspension), and the solution produces a smaller overall particle 
size distribution. This may be in part due to the nature of the active form: molecular 
versus micron size active ingredients. With solution aerosols the particles are generated
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in a "nascent” fashion. Suspensions inherently are predetermined to a large extent by the 
particle size of the micronised active.
1.10 Pressurised metered Dose Inhalers: The Current Situation
1.10.1 General Discussion
As introduced, the transfer from CFC to HFA propellant systems was perceived, by the 
industry, to be a ‘like for like’ transition with one propellant directly, interchangeable with 
the other. However, the chemistry of the HFA propellants is somewhat different to that of 
the CFC’s, and consequently the conventional surfactants utilised were not soluble to any 
appreciable extent in HFA propellants. However, HFA propellants are good solvents when 
compared to CFC’s and some drugs e.g. steroids are partially soluble necessitating the 
formulation of solution-based systems. Safety issues here have been identified here as 
the respirable fraction and deposition patterns of solution formulations when compared to 
CFC products, e.g. QVAR (3M Pharmaceuticals) may enhance systemic delivery, which 
for a steroid over a long period of time may have clinical significances.
The alternative chemistry of the HFA propellants has led to the conventional toxilogically 
acceptable surfactants, Span’s, Tween’s and Oleic acid to become effectively redundant, 
on grounds of reduced solubility. This has therefore forced pharmaceutical companies to 
take one of three reformulation routes: firstly, the use of ethanol to replace the low volatile 
CFC-11 component. Secondly, direct suspension of micronised active material in 
propellant 134(a) with attempts to reduce particle container reaction by coating the inside 
of the can with a fluorocarbon coating; finally, the synthesis of novel surfactants 
compatible with the propellants. -, e.g. polyoligolactic acids (3M pharmaceuticals 
Minnesota, US)
1.11 Solutions versus Suspensions (Pros and Cons)
1.11.1 General Discussion
The majority of pressurized metered dose systems are formulated as suspensions in 
preference to solutions. Of the common marketed pMDIs only tornalate and QVAR to date 
are solutions (Smyth 2003), and these products are formulated with an ethanol co-solvent 
to aid dissolution of the active compound. Other solution-based systems are indicated in
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the literature in which the MMAD of the aerosol cloud can be directly modulated by the 
addition of non-volatile excipients: glycerol and PEG 400 (Brambilla et al 1999). 
Suspensions, which are unstable thermodynamic systems, are susceptible to several 
problematic areas. Depending on the formulation and metering valve, dose variations 
have been observed (Byron 1994; Cyr et al 1997). Coupled with canister orientation and 
environmental conditions crystal growth via Ostwald ripening can occur, which can lead to 
the dissolution of smaller suspended particles and the subsequent growth of larger 
crystals during storage. This may concomitantly lead to an increase in mean particle size 
of the delivered drug, increasing potential variations in deposition of the aerosol, and this 
may also result in either drug over or under-dosing (Phillips 1993). Other problems related 
with suspension based formulations, particularly with high drug loading, is the potential 
build up of drug on the actuator, which may block the spray orifice. As the drug in 
suspension systems are in a solid form, problems with polymorphism is a major concern. 
Polymorphism affects many intrinsic physico-chemical properties, and can increase 
solubility in the propellant/propellant systems enhancing the aforementioned problems.
Solution based pMDI systems would seem initially to be the preferred dosage form. 
However, there are difficulties formulating soluble ionic forms of drugs in organic solvent 
systems. Indeed it has been found that the solubility of salt forms is generally lower in 
aprotic solvents than that of free bases or acids. This is affirmed from the ethanol level in 
tornalate (Bitolterol Mesylate), presently at 38%w/w (Tzou et al 1997). Whereas non-ionic, 
lipophillic. compounds, particularly steroids, are suited to solution inhalers due to their 
solubility levels in both propellants and ethanol. This is borne out by the fact that an 
organic salbutamol ester could be solubilised directly into propellant 134(a) (Seville et al 
2000), and both butyric acid and Tetrahydocannabinol are soluble in HFA propellants 
Solution systems are obviously prone to chemical degradation as the drug is at the 
molecular level, but with appropriate use of theory and practice, soluble and stable salt 
solutions are possible. In addition to the in-situ, chemical, drawbacks experienced with 
solution-based systems data exists, which indicates that aerosol particles of this type of 
pressurised system is prone to greater changes in particle size than suspension-based 
counterparts (Hiller et al 1979). This is routinely considered to be a disadvantage with 
solutions, as the particle size distribution shifts, and exhibits a greater non-respirable 
fraction; but this has not been fully investigated in the solution setting. Changes in particle 
size ranges may, here, provide pharmaceutical benefits.
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1.12 Aims of the study
1.12.1 Discussion
The main objective of this thesis was to investigate the effects of hygroscopicity on the 
delivery of salbutamol salts to the lung, and to facilitate investigations an holistic approach 
was undertaken.
1.12.2 Experimental Rationale
To achieve such objectives, the following work will be performed:
1.12.3 Salbutamol Derivatives: Synthsesis, practical solubility evaluation and 
predictive solubility theory of novel bronchodilators.
To progress the study, it will be necessary to synthesise novel drug derivatives with the 
capability of being formulated as solution based pressure systems, as no salbutamol 
derivatives, to date have this fumndamental capacity. Initially, theoretical principles will 
apply to salt formation in order to predetermine which candidates would be most suitable 
for subsequent evaluation. Solubility in pure organic media and media blends will also 
require evaluation, in order to formulate thermodynamic and kinetically stable solutions. 
From a practical standpoint, the data generated should allow the application of theory to 
predict solubility as support to current empirical, visual methods.
1.12.4 Pre-formulation Studies: Characterisation of Novel Derivatives
Post-derivative synthesis, the molecules will require physico-chemical investigation. 
Fundamental data relating to structural confirmation, which will assist in describing the 
potential reasons for solubility, allow accurate assay, and cxritically discuss the rationale 
for data generated regarding the nature of the aerosol cloud formation, will be performed 
in conjunction with standard techniques.
30
1.12.5 Formulation Variables: The effect of temperature, co-solvent level 
and drug structure on cloud formation and the semi-empirical prediction of 
particulate aerosol cloud size.
To date in-vitro aerosol measurements have been performed under standard laboratory 
and therefore standard product testing conditions. Being solution systems the nature of 
the integral components (drug, co-solvent and anti-solvent) may be affected by 
temperature and thus pressure. By systematically evaluating the effects on stable 
systems and the resulting cloud dynamics, it may be possible to theoretically predict in 
conjunction with fundamental physicochemical constants and componentry hardware the 
MMAD and GSD of the resulting cloud blous.
1.12.6 Environmental Variables: The effect of temperature, humidity, drug 
structure and formulation on cloud formation.
Studies have indicated that substantial changes may occur in particle size distribution 
when considering simulated physiological conditions when compared to those of 
conventional, standard, ambient in-vitro environments (Hickey and Martonen 1993). Some 
of these studies have conditioned the aerosol cloud formed for tens of seconds at 
elevated humidity and temperature prior to in-vitro testing. In the majority of practical 
cases, such exposure does not occur in-vivo, even with good patience compliance and 
breath holding. Due to the complexity of the dosage form both evaporation and 
condensation processes occur and compete to produce the final particle size distributions. 
In this thesis both temperature and humidity will be varied in a controlled manner, in a 
matrix approach study to observe the effects at ambient and "respiratory like” conditions 
on the novel systems formulated.
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2 METHODS AND MATERIALS
2.1 Materials
The salbutamol base used throughout was supplied in a micronised form (Batch number 
E 19081) and kindly donated by CCL pharmaceuticals (Runcorn, Cheshire, UK). All acids 
utilised in synthesis were of ultrapure grade from Sigma Aldrich chemicals (Poole, Dorset, 
UK), as were all solvents: absolute ethanol (99.5%), acetone and diethyl ether (methanol 
dried). All other reagents utilised were of the appropriate standard for the specific 
analytical technique: far UV-HPLC grade acetonitrile, HPLC grade methanol and 
associated mobile phase additives. Ultra pure water was produced by reverse osmosis 
(MilliQ, Millipore, Molsheim, France).
2.2 Salbutamol Salts: Selection criteria and synthesis.
2.2.1 Rational Drug Salt Selection.
At present there is no single rational approach to drug salt selection for the use in 
pressurised solution based systems; such an approach would assist greatly in inhalation 
therapy. An appreciation of the stability and integrity of the solid material, the solubility 
profiles of the molecular species in the dosage form, and the manipulation of the resultant 
aerosol cloud would assist in clinical applications. Rapid screening processes and 
methodologies for solid compounds have been documented (Morris et al 1994 and Wells 
1988), but for pressurized systems, however, this approach is limited, and there is paucity 
of research in the literature. One study describing salt derivatives and aerosol dosage 
forms has, however, been documented (Sciarra et al 1972). Sciarra et al. produced a 
series of epinephrine (adrenaline) salts and determined the solubility, partition coefficient 
and finally the product stability in a variety of propellant systems. Four salts were 
synthesized: the bitartrate, maleate, malate and the fumarate, respectively. The salts 
were initially prepared according to a previously documented literature sourced method 
(Remington 1970), but it was found necessary to add small quantities of ether to 
inaugurate precipitation due to the unanticipated, elevated solubility of the salts in ethanol. 
Ether was utilised as a non-solvent or antisolvent (precipitating agent) in the study, and its 
use is described later. Interestingly, in the study performed by Sciarra (Sciarra et al 1972) 
the maleate salt was the most soluble in the propellant systems investigated, and the 
solubility of the maleate salt increased as the hydrogen atoms on the propellant molecule
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investigated were replaced with fluorine atoms. The greatest solubilities in the study 
described were for salts within propellant 152(a) difluoroethane, which contained the 
highest fluorine content. The solubility of epinephrine maleate the most soluble salt in the 
remaining propellants, utilised in the study, are shown in table 2.0





Table 2.0: The solubility of epinephrine maleate in various propellants (taken form
Sciarra et al 1972).
As background to this study, investigations into the bronchodilator, salbutamol, revealed
the synthesis of several salts to date. For reference, table 2.1 indicates the salt form and
associated reference.
Salt Reference
Hydrochloride (Single Enantiomers) Hawkins et al 1973
Stearate Jashnani et al 1993
Adi pate Jashnani et al 1993
Acetate Brown et al 1994 (1)
Benzoate Brown et al 1994 (1)
Tosylate Brown etal 1994 (2)
Formate (Methanolate) Brown etal 1994(2)
R / S Tartaric Ferrayoli et al 2000
R / S Mandelic Ferrayoli et al 2000
R / S Dibenzoyl-D-tartaric Ferrayoli et al 2000
+ di-p -  toluoyl-D-tartaric Ferrayoli et al 2000
Table 2.1 A comprehensive list of salbutamol salts synthesised to date.
2.2.2 Salt Characteristics
Salt forms of pharmaceutical actives do little to change the inherent pharmacology of the 
active; they only serve to alter the physical properties of the parent compound (Corrigan 
1997). The changes that occur from the formation of different salts mainly affect the
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solubility, bioavailability and stability of the solid e.g. hygroscopicity. It is imperative, 
therefore, that each candidate must be screened as part of a pre-formulation program to 
study its potential as a candidate drug. The salt form selected may not only have an effect 
on solubility and dissolution rate as described, but may also influence polymorphism, 
melting point and wettability. Salt selection is therefore crucial to a dosage form. And 
fundamentally, to change the attributes of a salt form, manipulations of the counter anion 
are necessary. Increasing the melting point usually reduces solubility, which can be 
readily achieved by using small counter ions (Wells 1988), or by using hydroxy acids and, 
therefore, increasing hydrogen bonding. The properties of salts in pharmaceutical 
formulations are primarily related to aqueous based systems as drug formulations are 
typically formulated or tested within aqueous media. For pressurised aerosols, however, 
the binary solvent system, in which the salt has to remain in solution with, prior to 
dissolution in physiological fluids, is predominantly ethanol and (HFA 134(a)). HFA 134(a) 
is a particularly poor solvent for pharmaceutical actives as charcaterised by its chemical 
parameters, and as solubility and dissolution are dependent on thermodynamics 
properties, kinetics, and the nature of the components, salts were chosen to be readily 
soluble in ethanol. Theoretically, the salt formed had to possess a low lattice energy, a 
high positive solvation energy, preferably be charged, and possess a high dielectric 
constant. Physiologically acceptable acids for use in salt formation (and their percent 
usage) are adapted from Wells (Wells 1988) and are given in table 2.2
Anion pKa % Usage
Hydrochloride -6.10 43
Sulphate -3.00, 1.96 7.5
Tosylate -1.34 0.1








Citrate 3.13; 4.76; 6.40 3.0
Benzoate 4.20 0.5
Succinate 4.21; 5.64 0.4
Acetate 4.76 1.3
Remainder 30.2
Table 2.2: Commonly used physiological acids.
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Table 2.2 introduces the pKa term. The pKa value of a compound can be equated to the 
pH (potential of hydrogen) when 50% of the parent molecule is ionised. If an acid or base 
is "strong”, it will possess a Ka value > 10'2 and will have a corresponding pKa value in 
the region of <2 ; as such it will be fully ionised in solution, with the dissociation constant 
(Ka for acid and Kb for base) indicating the relevant ionic equilibria. This can be 
represented by the following equations:
Ih  f l + \ a ~1
Acid HA + H 20  = H 20 + + A~ then Ka = \ ha \ ~ Equation 2.0
Base B + H 2 0 = BH+ + OH~ then K„ = BH* \OH[5] Equation 2.1
In essence for a successful reaction to occur, in this case a salt adduct to form, the "rule 
of three” is usually applied: there should be a difference of 3 pKa units between acid and 
base. Small inorganic acids tend to predominate as primary the salt formers, probably 
because of their low pKa’s readily forming salts with the majority of bases and can be 
made readily available in liquid form either as an aqueous or organic solution.
2.2.3 Counter Anion and its effects on Salt Character.
The properties of salt adducts prepared from physiologic acids can be partially predicted 
in advance. The counter ions that can be used (as indicated in table 2.2) fall broadly into 
inorganic and organic acid categories. The common acids along with their counter ion 
attributes are shown in table 2.3 Melting points, where applicable, are taken from the 
Merck Index Ninth edition 1976.
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Counterion H 3 0 o Salt Characteristic
Inorganic Acids — Small ion increase mp
Hydriodic — increase lattice energy
Hydrobromic
increase solid state stabilty
Hydrochloric . . . . for processing and handling






Benzene 43 May reduce solubility,
Toluene 70 destroy crystal symmetry
Carboxylic acids
Maleic 131 increase solubility(aq) >pKa < M.P.
Benzoic 122 Hydrogen bonding acids





Stearic 69 Hygroscopicity reduced
Oleic 4 inc stability, inc wettability
Table 2.3: Physiological acceptable 
resulting salt structures.
salt formers and integral their influence on
Due to the low solvency power of the HFA propellant substitutes, it was envisaged the 
addition of an ethanol co-solvent would be required, and depending on thermodynamic 
and kinetic conditions the amount of co-solvent would need to be manipulated for stability 
reasons. As pKa differences, which are required for salt formation, are not solely 
responsible for predicting solubility, other important factors in predicting solubility need to 
be considered. These include lattice and solvation energy, dielectric constant and 
solubility parameters. It is evident that the overall characteristics of the drug are therefore 
highly dependent on anion selection.
2.2.4 Acid Selection: Solubility Considerations
As described, the solubility of the salt derivative can be theoretically modeled by careful 
selection of the counter ion. The following characteristics should be considered:
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(i) A centre for inducing a polarisable charge (unsaturation, to induce dipoles)
(ii) A potential for hydrogen- carbon dipole bonding with hydroxyl or preferably
carboxylic acid groups. Coupled with data from table
(iii) Low melting point,
(iv) The ability to destroy crystal symmetries, and for purposes of this study,
(v) Be highly hydrophilic (water soluble, for this study),
(vi) Be highly hydrophobic (water insoluble, for this study).
Carboxylic acids fulfilled the above criteria particularly the unsaturated moieties: maleic 
acid z butenedioic acid and the Oleic acid z octadecenoic acid. In addition, oleic acid is 
normally used as a pharmaceutical lubricating aid, so it was therefore hypothesized that 
use of this species would lubricate the valve, and may aid in potential long-term valve 
function.
2.2.5 Synthesis of Salt Derivatives
2.2.5.1 Introduction
The method employed for the synthesis of salt derivatives of salbutamol utilised a 
combination of techniques encompassing evaporative, thermal gradient, chemical 
reaction and vapour/liquid diffusion, and where necessary adjustment of the temperature 
and the use of anti-solvents. The difference in pKa values between salbutamol base and 
all the acids in table 2.2 indicated a sufficient difference theoretically to produce salt 
adducts (pKa’s Salbutamol base p l^  9.1, and pKa210.4 (Martindale 2002)). The major 
solvent chosen for these studies was ethanol, for several reasons: it is toxicologically 
acceptable, both the base and free acids are soluble in the solvent and it is easily 
removed post synthesis by conventional methods. Acetone was chosen for oleic acid due 
to its high solubility and ease with which crystallisation could be achieved.
2.2.5.2 Synthesis of Salbutamol cis-butenedioate (Maleate)
Approximately 0.5g (0.004 moles) of maleic acid was dissolved in approximately 4ml 
(3.2g) of absolute ethanol and 3.2 g of diethyl ether by gentle warming and agitating for 
several minutes until complete dissolution had occurred. Approximately 1.0g (0.004 
moles) of salbutamol base were subsequently added to the acid solution. The vessel was 
sealed and then warmed with agitation until the base had completely dissolved. The
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vessel was chilled for 24 hours at approx 2-8°C to induce precipitation. The supernatant 
was removed and a further 5 ml of diethyl ether was added. The resultant oil was 
triturated until a white solid appeared. The solid was then vacuum filtered and air-dried. 
Further investigation indicated that by careful manipulation of the reagents the salt could 
be crystallised directly in the flask. Alternatively, crash precipitation could also be 
achieved by rapid addition of HFA directly to a concentrated solution of the salt in ethanol. 
The rapid method of crystallisation was briefly investigated, and it was discovered, from 
visual obserbvations, that the final particle size of medicament could be manipulated, from 
this in-situ method. This it was postulated may present an alternative method for 
manufacture of suspension aerosols rather than pre-micronising drug to a particle size 
specification.
2.2.5.3 Synthesis of Salbutamol cis-octadecenoate (Oleate)
Approximately 0.33g (0.001 moles) of oleic acid were dissolved in 10ml of acetone with 
warming. To this solution was added approximately 0.25g (0.001 moles) of salbutamol 
base, which formed a milky suspension formed. The vessel was sealed and the 
suspension heated with serial venting until complete dissolution of the base. The solution 
was then chilled and a white oil formed, which was re-dissolved by agitation at room 
temperature, and a white precipitate formed after several minutes. As with the previous 
example, careful manipulation of the reagents resulted in direct precipitation from the 
flask. Large crystals were observed via this method Again the in-situ crash precipitation 
method could be utilised for this salt. Depending on salt derivative, co-solvent 
concentration, temperature of reagents and rate of addition particle sizes of the final 
product could be tailored.
2.2.6 Final Salt Selection
The major discriminating parameter in salt selection for potential use in the study was 
primarily, solubility, in ethanol. Only four salts prepared, although others may exist, 
fulfilled the aforementioned criteria, and required the use of an anti-solvent to induce 
precipitation The remaining organic and inorganic salt derivatives synthesised readily 
precipitated from ethanol, and, as such, therefore would be formulated as suspension- 
based products, and were rejected from any subsequent study. During screening, several 
organic and inorganic derivates were synthesised and subjected to infrared and 
differential scanning calorimetric methods of characterisation. A full table of salts 
synthesised and their melting points is illustrated in appendix A 2. 1. This was the only
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pre-formulation characterization performed, as they were not utilized in any further work. 
Two salts, the adipate and stearate, had been previously synthesised and were prepared 
as a control. These gave similar spectra but different melting points, and the rationale for 
this difference will be discussed in detail later.
Even though the majority of the salts are not suitable as solution based pMDI’s, 
investigation into their intrinsic physicochemical properties, both as crystalline solids and 
aerosolized medicaments, do warrant further study. This point is illustrated from the 
development and production of an enantiomerically pure form of salbutamol i.e. laevo 
salbutamol Xoponex® (i.e the Tartrate was requisite to enable a stable formulation. 
Sepracor, Inc, Marlborough, USA.)
From the salts described in the table in appendix A 2. 1, the maleate and oleate were 
selected for further investigation on the following grounds:
(a) They were freely soluble in ethanol. Visual experiments were performed initially 
before accurate quantitative analysis by HPLC. These indicated short-term stability at low 
levels of the co-solvent. Interestingly, 10-20% w/w ethanol/134(a) propellant combinations 
do not adversely lower the vapour pressure of the system; in fact, the reverse occurs and 
the vapour pressure increases (Smyth et al 2002). The stearate salt although freely 
soluble in ethanol alone required a 50:50 ethanol: 134(a) mixture to remain in solution. It 
was decided to terminate further study of this salt due to the high level of co-solvent 
required to maintain stability.
(b) Both salt derivatives had different water solubilities and therefore, it was inferred, 
may exhibit varying hydrophobic and hydrophilic properties. This would be useful in 
aerosolisation studies under differing environmental conditions, as hygroscopicity has 
been observed for a number of water-soluble entities (Martonen 1982).
(c) They could be synthesised in suitable quantities with good recoveries.
2.3 In-Vitro Particle Size Analysis
2.3.1 Particle Size Distribution Analysis
There are several methods that can be utilised in the evaluation of aerosolised particle 
size distributions; effectively they can be broadly categorised into the following 
techniques, although others exist: mechanical, electrical and optical, and irrespective of 
the technique all are susceptible to errors. Two types of sampling are utilised to evaluate
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particle sizes of aerosol droplets: spatial and temporal. Spatial sampling describes the 
observation and/or measurement of droplets contained in a cloud volume that the 
contents do not change during observation or measurement. This includes optical 
techniques such as photography and holography. Temporal sampling describes the 
measurement of droplets that transverse a fixed area during regular time intervals. 
Inherent within pressurised drop generation techniques smaller droplets decelerate 
quicker than the larger drops leading to increased concentrations of smaller drops 
downstream during measurement.
For this study the cascade impactor was chosen. The cascade impactor operates via a 
temporal mode. The method is based on the principle that particles in an aerosol cloud 
will have a range of mass distributions move with a range of velocity profiles resulting in 
particles with specific momenta. Basically, if a travelling particle has a specific momentum 
in an entrained airflow it will impact on a collection plate. If a particle has insufficient 
momentum it travels to the next collection plate and this "cascade” mechanism of 
particles transferrance continues until impaction occurs. And, it is this impaction that 
dictates its mass mean aerodynamic diameter. The technique has the advantage of being 
able to be sampled isokinetically, as it avoids discrimination at extremes of droplet sizes 
within the spray.
Collection of drug deposited on each stage allowed the calculation of both the total mass 
balance, the recovered drug, and a non-linear least-squares fit of the cumulative 
distribution data (calculated from stage deposition) determined the respective MMAD and 
GSD of the outputs. The total mass deposited in the impactor is a simulation of what 
would be expected from a normal inhalation manoeuvre. In this study data generated from 
the least squares analysis approximated to log normality and was calculated over the 
probability range of -1.5 to +1.5. All results gave a R2 values greater than 0.95 and a 
standard error value of Y less than 0.25 respectively.
2.3.2 The Andersen Cascade Impactor
The choice of particle sizing technique is primarily dependent on the application, the 
environment and particle size distribution under investigation. In this study, the Andersen 
Cascade impactor was chosen, primarily as it is routinely used in bio-aerosol assay, is a 
robust analytical item being able withstand changes in temperature and humidity. 
Functionally, It is designed to measure the mass weighted size distribution of aerosol
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particles in the aerodynamic diameter particle size range from 0.4 to 10 microns 
(Andersen 1979). An impactor is a multistage, multi-jet device that fractionates particles 
into various class sizes according to their inherent inertia. A schematic representation of 
an impactor jet is shown in figure 2.0.
Gas Streamlines
Impaction Stage
Figure 2.0: A schematic representation of a single je t of an impactor stage and the
trajectories of particles of various sizes.
Each stage consists of a series of jets, beneath which is located a collection of plates 
usually manufactured from a variety of metals (aluminium, stainless steel, titanium). For 
correct operation to occur certain dimensions are critical as indicated by the nomenclature 
in the schematic: where w is the diameter of the jet, h is the distance from the base of the 
aperture to the angle of the jet chamfer and s is the distance from the base of the jet 
orifice to the impaction plate for that stage. As the aerosol bolus travels through the 
equipment, the inertial properties of aerosol particles are increased upon passing through 
each jet. If a particle has gained sufficient inertia, as a function of its mass, it will be 
unable to follow the air stream around the plate and will impact on the plate, indicated by 
particles B and C. Particles with insufficient inertia will quickly relax and follow the air 
stream, thereby missing the collection plate and continuing through to the next stage, 
indicated by path A, where the inertia of the particles is further increased.
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The collection efficiency of the system is defined as the number of particles that enter a 
stage and are collected by the associated specific impaction plate, and ideally, collection 
will be stepped: collection occurs, whereby particles greater than the critical size will be 
collected and those smaller will not. In reality, the efficiency follows a sigmoidal shape and 
a proportion of large particles will be missed by the stage; and, conversely a proportion of 
undersized particles will be collected. An impactor consists of several stages and the 
collection efficiency increase with decreasing jet size.
A robust impactor should have approximately the same number of undersized as 
oversized particles, and. the aerodynamic diameter can be related mathematically to the 
density, shape, and slip factors by:
A ^1/2
p  c  v
%dPo dae
Equation 2.2
Where dae is the aerodynamic diameter, dv is the volume equivalent diameter, dp is the 
particle density, dpo is the reference density, X is the shape factor and, C is the 
Cunningham slip factor for particles with a diameter of 0.1 microns or less.
2.3.3 Impactor Calibration and In Study Use
The impactor used in this study was calibrated by the manufacturer, and so the stage cut 
offs utilised were those described by theory. The same impactor was used throughout the 
study so systematic error was effectively reduced. During calibration, impactor plates are 
coated with a suitable solvent, leak tested and calibrated with monodisperse krypton 
irradiated polymer latex or methylene blue particles. Perhaps the most difficult and 
arguably the major difference from standard in-vitro testing and in-vivo manoeuvres is 
equilibration with a krypton irradiation source. Irradiation endeavours to put a uniform 
Boltzman charge on the aerosol particles, effectively giving a residual or minimum charge 
distribution on particles after exposure to a bipolar ion field; this then eliminates a source 
of deposition error. Aerosol particles electrostatically charged, may interact differently with 
each other and effect subsequent deposition patterns. (Griffiths et al 1998). In reality, 
particle charging and thermophoresis occur, and, so, it can be argued that although this 
practice is possibly acceptable for calibration is not totally practical for actual analysis.
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To obtain accurate and precise measurements the study focused on controlling and 
monitoring the following parameters. During analysis the active compounds were 
removed from the impactor with methanol, a universal solvent for both the drug salts and 
co-solvent. Assembly was checked to ensure correct operation and functioning of the 
stage seals as the cut off diameters are related to flow rate, which was checked by use of 
a calibrated flow meter, and as flow rate is related to actual volumetric flow rate by 
temperature and pressure factors, the flow meter was left in thermal equilibrium with the 
equipment, and the flow checked between studies, in the environment of test. This 
removed a source of systematic bias, as it can be shown that at 25°C there is 
approximately a 5% difference in flow rate and at 40°C there is about a 12% difference 
with 100% water saturation. The difference in pressure at 0°C is only about 0.6%, but this 
increases to 3% at 25°C and 6% at 38°C. Post quantitative washing of the impactor 
plates, the apparatus (as chemical analysis of the drug on each impactor stage was 
conducted) was left to air dry in the laboratory at the test condition for a minimum of one 
hour to reach thermal equilibrium with its surroundings, as the importance of thermal 
influences on aanalysis have been highlighted previously (Finlay and Stapleton 1999).
2.4 Statistical Analysis
Statistics is based on probability; and distributions of data sets are mathematical 
functions, which assign probabilities for domain outcomes. Modern theories of statistics 
are based on normally distributed data while the majority of sample means from all 
probability functions tend towards normality for large sample sizes. In this study, data 
generated relating the effects of temperature equilibration on particle size distribution 
chapter 4, and also the effects of temperature and humidity controlled environmental 
testing conditions on particle size distributions on individual salt formulations, intra- 
formulation correlation, was performed by one-way analysis of variance (ANOVA) using 
the Minitab® statistics package version 12.1. ANOVA is a standardised statistical tool, for 
analysing series of data sets. Inter-formulation comparisons were compared using a two 
tailed heteroscedastic student’s t-test with confidence limits set at p 0.05. Basically a 
stage-by-stage comparison of cascade results generated for each salt formulation over all 
testing criteria were compared at a confidence level of p<0.05, after these data had been 
percentage normalised in terms of deposition. Where differences did occur at an inter­
group level, a Tukey’s significant difference test was performed on the data again at the 
95% confidence level in order to identify the were the differences occured.
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2.5 Differential Scanning Calorimetry. (DSC)
2.5 .1 Materials and Methods
Differential scanning calorimetry was performed on approximately 5 mg of material (4.384 
mg Maleate and 3.918 mg Oleate) using a TA 2910 11R, (Thermal Analysis instruments 
Crawley, West Sussex, UK), (University of Bath, Dept of Materials Science). The heating 
rate was set at 10°C per minute and samples were run from ambient 30°C to 150°C. No 
liquid nitrogen cooling was applied; however, the sample and reference materials were 
tested in a dry, inert atmosphere via a positive flow of nitrogen gas, which was perfused 
within the instrument at a rate of 25 ml per minute.
2.5.2 Results and Discussion
The onset temperatures, enthalpy changes and instruments used in determining these 
parameters of the synthesised salts, (with comparisons selected salts in the literature 
donated by onset temperatures with an asterisk), are given in table 2.4. The thermograms 
for each salt are given in figures 2.1 and 2.2 respectively.
Salt Derivative DSC data
Maleate AHfJ/g 72.63
Onset Temp/°C (mass mg) 127.5 (4.384)
Oleate AHfJ/g 85.70
Onset Temp/°C 76.7 (3.918)
Adipate AHfJ/g 37.32
Onset Temp/°C 182* 190.3 (1.460)
Stearate AHfJ/g 93.00
Onset Temp/°C 116* 110.9 (5.794)
Table 2.4 A table illustrating heats of fusion and melting points (onset temperatures) 
or several salbutamol salts cross-referenced where applicable to those 
quoted in the literature. Data marked with asterisk indicates published data.
The major differences between the onset temperatures of that quoted by Jashnani et al 
(Jashnani et al 1997) and this thesis are the solvents utilised in the synthesis. Jashnani 
utilised a crystallizing solution methanolic solution followed by a re-crystallisation step
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from aqueous ethanol for the adipate; the stearate, on the other hand, was precipitated by 
evaporation from a methanolic solution in a 1:1 molar ratio. In this thesis the adipate was 
precipitated from an ethanolic solution and the stearate from an acetone solution.
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Figure 2.1: A DSC thermogram of salbutamol oleate






Heat Flow / mW
3.0
Figure 2.2: A DSC thermogram of salbutamol maleate
The use of different solvents can give rise to pseudo polymorphism: hydrates, solvates 
and clathrates. Solvates and hydrates occur due to the molecular arrangement of the 
solvent its polarity and dielectric constant. When the salt starts to nucleate and then 
precipitate, the molecules physically undergo physical adsorption onto specific crystal 
faces. When analysed by DSC the solvent will boil off at a temperature close to its specific
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boiling point. Clathrates on the other hand again formed due solvent crystal interactions 
actually become trapped within a cage of the crystal, and therefore boil off at a higher 
temperature. In fact as the molecular size of the solvent molecule increases say from 
methanol, ethanol, diethyl ether towards highly substituted ketones e.g.MEK, this 
effectively gives rise to a new crystal structure by differential spatial arrangement of the 
constituents. Other confirmatory techniques would be required to determine number and 
amount of polymorphs present.
The adipate synthsised by Jashnani formed a diethanolate, and although not fully 
investigated this author postulates the stearate formed a methanolate structure. Such 
solvates may account for the differences observed.
2.6 Infrared Spectroscopy
2.6.1 Methods and Materials
Samples of material were analysed using both a Nicolet AVATAR 360 FTIR (direct 
powder loading performed at CCL Pharmaceuticals) and a Perkin Elmer post preparation 
in KBr discs by direct compression to 15 tones. Samples were scanned from 500 to 4000 
cm'1 respectively (University of Bath Dept of Pharmacology).
2.6.2 Results and Discussion
Infra red spectroscopic measurements of both compounds further indicated salt formation 
as confirmed by shifts in the absorption bands when compared to the freebase and acid. 
Salbutamol base is a secondary aliphatic amine and as such exhibits a bending stretch at 
3300 cm'1 and a bending motion at 1650-1550 cm'1. Conversely, free carboxylic acids 
examined as KBr discs will exist as a dimer and a confirmatory stretching band (C=0 
group) appears at 1725-1700 cm'1 when saturated or acyclic. However, when conjugated 
or unsaturated the stretching vibrations are reduced by 20-30 cm'1. This is evident in the 
maleate salt, which has two carboxylic acid groups with only one of which is ionised. 
Evidence of a carboxylate anion is indicated by dual absorptions between 1300 and 1420 
cm'1, both of which are present in the spectrograms.
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For clarity, the free acid and salt traces are overlaid on the same spectrogram. Finally, 
amine salts absorbed around 1500-1550 cm '1 and both these stretching vibrations are 
present.






Figure2.3: An infrared spectrogram of salbutamol maleate illustrating the differences in
absorbance from the free acid.
Intensity/Abs
Wavelength cnY
Figure 2.4: An infrared spectrogram of salbutamol oleate. (Free acid not overlaid)
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2.7 X-Ray Crystallography
2 .7 .1 M a teria ls  and  M ethods
The crystal structure of salbutamol base has been previously identified and documented 
by Beale and Stephenson (Beale and Stephenson 1972). Crystals of size applicable for 
X-ray crystallography were produced for both compounds. The data was collected 
(University of Liverpool X-Ray crystallography dept) using a Stoe IPDS image plate 
diffractometer, using a Molybdenum (Mo K alpha 0.71073A angstroms) radiation source 
at a temperature of 100 Kelvin. The diffractograms of salbutamol maleate and oleate are 
depicted in figs 2.5 and 2.6 and atomic and thermal parameters in appendices A 2.3, A2.4 
A 2.5 and A 2.6 respectively.
2 .7 .2  R esu lts  a nd  D iscuss ion
The definitive structure of salbutamol (z) butenediaote is shown in Figure 2.5.
Figure 2.5: The spatial arrangement of salbutamol maleate by elucidated from XRC
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The space group for salbutamol base has been evaluated as Pbca where a= 2.1654 (10), 
b = 0.8798(4), c = 1.4565(7) nm Z=8, with an observed density of 1.15gcm'3. For 
salbutamol maleate, data determined that the molecule had an orthorhombic structure, 
unit cell parameters of a=8.4487(8), b=15.4327 (15), c= 13.8712 (13), a volume of 1808.6 
A3, were established. Other important parameters indicated an absorbance of 0.101 mm1 
and an observed density of 1.305gcm’3; the space group was determined to be Pna21. 
The salbutamol base structure has been altered substantially form its original structure 
with the addition of Z butenedioic acid. The molecule from the parent base has effectively 
been ‘bent’ into a W  shape via rotations at the C5, 6, and 7 positions, and the amino and 
hydroxyl groups are in a cis orientation with respect to a plane running through C4, C5 
and C7. Both the cis orientated protons on the amino and hydroxyl groups N1 and 01 are 
orientated towards the 0 7  of the maleate ion. One interesting effect to note was the 80:20 
crystal disorder in the Z butenedioate molecule. In figure the molecule is shown on bold 
lines and grey lines. The bold lines indicate the 80 ratios. In the 20, the molecule has 
‘flipped’ 180 degrees.
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Figure 2.6: A spatial arrangement of salbutamol oleate elucidated from XRC
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Crystallographic data generated for salbutamol oleate gave substantially different lattice 
and group parameters: the crystal structure was determined to be monoclinic, the unit cell 
parameters were, a=14.9781(8), b=18.3004(14), c=11.5501(9), the volume of the crystal 
was 3106.8A3 , the absorbance was evaluated at 0.073mm'1 it had a density of 1.096 
gem'3 and the space group was P21/c.The structure of the Oleate derivative was different 
again from that of the base and maleate, being monoclinic, with rotations at positions C3, 
C5 and C6. Rotation at C6 had orientated the plane of the benzene ring so it is virtually 
parallel with the double bond at positions C21 and C22 of the oleate molecule. Again the 
amino and hydroxyl were in a cis orientation, and protons on these atoms were 
juxtaposed to the carboxylate group of the oleate molecule.
2.8 Fluorescence Spectroscopy
2.8.1 Materials and Methods
Prior to analysis, the emission and excitation wavelengths of synthesised salts were 
scanned over 220 to 800nm to ascertain the maxima for analytical determinations. 
Previously, salbutamol sulphate had been determined and gave an excitation value of 275 
and an emission value of 410nm. In order to determine the respective emission (em) and 
excitation (ex) wavelengths of the salts, a Hitachi F200 fluorimeter was set on to auto 
scan mode and samples were prepared in methanol at concentrations ranging from 25 to 
0.05mcg/ml. Traces analysed exhibited identical maxima for excitation and emission 
spectra. An example of an excitation spectrum is shown in figure 2.8. Prior to analysis, 
acting as a calibration check, standard recoveries on duplicate solutions were performed. 
Calibration checks ensuring system accuracy precision and linearity were also carried out 
before quantitative analysis. Acceptance limits were set at 98.0-102.0%, for duplicate 
solutions as per pharmacoepia for HPLC assay. To ensure linearity, a five-point linear 
regression analysis covering 10-200% of nominal drug mass concentrations were 
routinely performed, and was suitable in terms of quantitation limit and adequate in 
detection terms at 50 ng/ml an order of magnitude less than the lowest drug 
concentrations routinely collected.
50
2.8.2 Results and Discussion
The wavelengths scan of a mid range linear regression solution is shown in figure 2.8. As 
an operational check, the instruments ‘’wavelength accuracy’ was calibrated according to 
manufacturers instructions. Essentially, a new xenon lamp was installed and the signal to 
noise ratio measurements were routinely performed with ultra-pure water. The system 
conformed to manufacturers specifications, and the output is shown in figure 2.9.
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Figure 2.8: A fluorescence spectrogram indicating excitation and emission maxima for
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Figure 2.9: FIuorimeter calibration data
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2.9 High Performance Liquid chromatography
2.9.1 Materials and Methods
High performance liquid chromatography was performed using a Jasco HPLC system 
(Great Dunnow, UK) with UV detection. A UV detection wavelength of 276 nm was used 
for salbutamol upon scanning both salts. The co-anion had no effect on the wavelength 
maxima for salbutamol. Standard recovery on duplicate solutions and five point linear 
regression was performed before analysis. Limits for these variables were set at a 
recovery percentage and regression coefficient of 98.0-102.0% and 0.995 respectively. 
Standards were stored at 4°C and kept for no longer than one month. Working standards 
were also kept at this temperature, but discarded after a week.
2.9.2 Results and Discussion.
An ion-suppressed isocratic method was developed for the salbutamol assay, utilising the 




Figure 2.10: A typical HPLC chromatogram of salbutamol maleate (NB. Salbutamol oleate
gave an identical retention time for an equivalent concentration.
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3 THE EFFECTIVE SOLUBILITY OF SALBUTAMOL SALT 
DERIVATIVES IN pMDI MEDIA
3.1 General Overview
The first step in the characterisation of a compound for its potential use in a 
pharmaceutical dosage form is the determination of its pKa and intrinsic solubility, or the 
solubility in its unionised form (Wells 1981). For solution-based pressurised systems, the 
solubility should be evaluated in a number of solvents and anti-solvents. An anti-solvent 
being the terminology used for a liquid phase of widely dissimilar dielectric constant or 
substantially different physicochemical character to the solute in question. Solubility 
evaluation is necessary since propellant systems and associated co-solvent blends, if in 
certain proportions, may induce instability, which may lead to destabilisation of the 
formulation and crystallisation of the drug from solution upon storage. The use of co­
solvents to fully dissolve partially soluble drugs such as beclomethasone dipropionate, 
which have a limited solubility in propellants to prevent precipitation from solution, have 
become industrially acceptable (Leach et al 1998). The effects of solubility, dissolution 
and crystallisation have been observed in suspension systems (Voorhees 1985).
The stability of this dosage form has historically been based on empiricism and visual 
methods. While adequate, this has not made any links, connections or discussed the 
complex interplay between the intrinsic components, and, as such, poses a fundamental 
question: Can solution stability be predicted from theory based upon thermochemical data 
and practical solubility measurements on individual formulation components?
It is theorized that solubility may increase with temperature, but, at present, this has not 
been substantiated.
3.2 Initial solubility and stability investigations via visual assessment
Physical stability assessment.
Solubility and consequently stability of solution aerosols, as intimated, has largely been 
based on empirical visual methods (Brambilla et al 1999). As such, formulations are 
usually manufactured in a visually suitable medium, either glass or plastic and drug
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loaded at the required concentration per actuation in order to appropriate a therapeutic 
dose. To emulate long-term moisture ingress by passive diffusion, they may be spiked 
with water. To investigate solution stability, formulations are conventionally stored at low 
temperature or alternating temperature regimens (4°C or cycling conditions -5°C to 40°C 
over a defined period of temperature fluctuation) and assessed at specified intervals. 
Later in this chapter, an alternative approach will be introduced and utilised to assess 
solubility and stability of solution based pMDIs. However, in the first instance, visual 
assessments were utilised in primary evaluation as a control to verify later experimental 
findings. Solubility using this method was performed on the following formulation 
compositions:
(i) In order to assess final co-solvent levels for stability, salbutamol maleate and 
oleate formulations (at a drug mass of 100pg per actuation equivalent to the freebase, 
based on equivalent relative molecular masses) were prepared over a range of ethanol 
and 134(a) concentrations, and stored under the standard regulatory pharmaceutical 
temperatures.
(ii) In order to simulate long term solution stability by moisture ingress from increased 
humidity storage, formulations of salbutamol maleate in Ethanol / HFA 134(a) / Spiked 
water systems were prepared. It should be noted that only the maleate salt was utilised in 
the water spiking study, since the oleate salt is water insoluble and was in short supply. 
The spiked mass of water was charged from 5000ppm, which was equivalent to 0.5% w/w 
of the final formulation, to 50000 ppm or 5.0% w/w of the final formulation. This was 
performed in order to ascertain a crude level of stability upon ingression of water. In the 
final phase, maleate formulations were prepared at the optimal co-solvent level, the 
minimum level necessary for stability, and again spiked with water ranging from 5000 to
30,000 ppm and stored at low temperature for prolonged periods.
Chemical stability assessment.
Chemical stability of the salt derivatives within pressurised systems is also an integral part 
of product performance. This was also investigated. Briefly, formulations of exact 
composition (ranging from 10-30% w/w ethanol for each derivative) were stored at 25°C 
and 100% RH and assessed after 3 and 6 months respectively; Initial testing (TO) was 
omitted due to the limited number produced. Assay data widely ranged for both salts and 
is note quoted here primarily due to inadequate optimization of the analytical method:
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Upon opening of the units large proportions of active were lost from violent propellant 
evaporation.
3.2.1 Methods and Materials
Plastic coated glass pMDI bottles (St Gobain, France) were weighed on a validated 
balance (Sartorius UK) and tared after first undergoing a rinse with clean and dry 
compressed air. Drug was weighed accurately by difference in order to give an equivalent 
of 100mcg freebase per actuation related to molecular mass of the salt and the 
formulation density. The same procedure was repeated for absolute ethanol (Fisher 
scientific Poole, UK). A continuous spray valve was then crimped on (Bespak, Kings 
Lynn, UK), according to manufacturers specifications and the bottle then sonicated 
(Decon FS 3006) for several minutes to induce complete dissolution of the drug. The 
bottle was then dried and once again tared on the balance. HFA 134(a) was subsequently 
charged through the valve using a Pamasol 2002 hand gasser crimper (DH Industries, 
Laindon, Essex, UK). The final formulation preparation was sonicated for a further several 
minutes to ensure complete dissolution. Formulations were then stored at specified 
temperatures and assessed periodically. All solutions were prepared in duplicate.
3.2.2 Results and Discussion
Figures 3.1 A to D depict solution stability profiles for maleate formulations prepared at 
the following co-solvent levels: 10, 12.5, 15 and 20% w/w after storage at the following 
temperatures ambient 25°C, 0°C and -23.5°C. The co-solvent level (% w/w ethanol) of 
the formulations are indicated in figure 3.1 A. The order/sequence of the bottles were 
identical for figures 3.1 B-D inclusive thus indicating the relative formulation. The side 
elevations indicated, in Fig 3.1 A and C and, for clarity, recumbent plan views B and D 
system, destabilisation, highlighted by drug precipitation. (View respective arrows on the 
10 and 12.5% w/w co-solvent level photographs for the maleate derivative). No 
indications of crystallisation at co-solvent levels above 15% w/w were observed. For 
further descriptions of visual observations see Appendix 3 table A 3.1(c). Finally, figures
3.1 A and B indicate the results for the formulations when stored at ambient 25°C, and 
3.1C and D for those stored at low temperature -23.5 .5°C.
The oleate salt formulations depicted in figures 3.2 A to D, indicated that a minimum of 
30%w/w co-solvent was required for stability. It should be noted that for the maleate
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system, crystals aggregated at the base of the vessel, whereas those of the maleate 
formed at the liquid vapour interface possibly due to the density of the solids in the 
medium and the fact that the oleate derivative being a surfactant would preferentially align 
at this boundary. The size of the crystals were also different. The maleate salt crystals 
tended to be large and aggregated while the oleate crystals were small and discrete. For 
a further description of the visual observations made see appendix 3 table A 3.1 (d).
Figure 3.3 illustrated the results for the moisture spiking study, indicating that at the 
optimal co-solvent level (15% w/w for the maleate) solution stability could be acheived 
(shown by a single phase) when moisture levels, up to levels of 30,000 ppm or 3% w/w 
were incorporated into the final formulation. After this, at low temperature storage, the
30,000 p.p.m solution formed a "cloudy” two phase system. This re-dispersed into a 
single phase with equilibration to room temperature. Documented observations relating to 
these systems can be found in appendix A 3.2, tables 3.1(c-e).
3.2.3 Conclusion
In general, using the visual method, the maleate salt required only a 15% w/w co-solvent 
level (1.5g per 10g formulation) to remain as a stable single-phase solution exhibiting no 
observable crystal growth, equating to about 0.25% w/w drug concentration with respect 
to the final formulation (see Figures 3.1A-D).
The oleate, however, required approximately 30% w/w co-solvent levels (3.0g per 10g 
formulation) to remain stable, crystal free and as a single phase. In this case, the drug 
concentration equated to approximately 0.37%w/w. However, instability did not manifest 
itself instantaneously. Even for the 10% w/w co-solvent level the solution remained stable 
for approximately 3 days before de-stabilisation by thermodynamic and kinetic factors. 
Other possible factors for solution stability may have been the container surface 
roughness or the presence of extraneous fibers, which may instigate heterogenous 
nucleation.
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Figures 3.1 A and B: Photographic images of salbutamol maleate formulations after 
prolonged storage at ambient temperature (25°C) equilibration (A = side elevation and B = 
plan view). Co-solvent concentrations (ethanol) as a %w/w of the final formulation are 
depicted in ,A and the sequence is ref elected in B.C and D respectively.
10%w/w 12.5%w/w 15%w/w 20%w/w
Figures 3.1 C and D: Photographic images of salbutamol maleate formulations after 
prolonged storage at low temperature (0 and -23.5°C) equilibration (C = side elevation and D 
= plan view)
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Figure 3.2 A to D: Visual solubility of salbutamol oleate solutions. Arrows indicate
instability due to precipitation. Small salt crystals can be seen at the liquid gas interface. 
This indicated that 30% w/e co-solvent was necessary for dissolution. The respective level 
of co-solvent is indicated at the botton left hand of the figure.
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Figure 3.3: A photographic image illustrating the effect of water spiking on physical
3.3 Theoretical Evaluation of derivative solubility as a function of the 
Co-solvent.
3.3 .1 General Discussion
Prior to practical determination of solute solubility in the co-solvent, theoretical predictions 
of solubility for both synthetic derivatives were determined primarily as an initial step in 
facilitating any possible links between theory and experimentation. Ideal behaviour 
assumes there is a complete absence of attractive or repulsive intra and inter-molecular 
forces and solubility per se is effectively independent of the solvent present. In this case, 
the solubility depends upon the temperature, molar heat of fusion (A H  f ), where the heat
of solution is equivalent to this value. During the mixing process heat exchang occurs 
adiabatically and the ideal solubility is given by the following relationship:
Where Xi is the ideal mole fraction of dissolved solid, To is the melting point of the solute, 
Tm is the melting point of the pure solute, T is the ambient temperature, R is the universal 
gas constant and ACp is the change in specific heat capacity. However, the second term 
of the equation may be omitted as the specific heat capacity changes very little with
stability of Salbutamol maleate solutions. Visual stability indicates single­






temperature. Real solutions approximate to Raoult’s law (for the solvent component) and 
Henry’s law (or the solid component) particularly well when dilute and chemically similar.
When a solid is left in contact with a solvent, over a period, it will dissolve depending on 
thermodynamics and kinetics until a saturated solution is generated. At this point, the 
chemical potential of the pure material is equivalent to the chemical potential of the solute 
in the solution, which it saturated, and when saturation occurs the following relationship 
applies:
i * {solid) = i l l iqu id) = i * {liquid) + RT In xj3 Equation 3.1
Where I* (liquid) is the chemical potential of the pure liquid solute, i* (solid) is the 
chemical potential of the pure solid, R is the gas constant T is the temperature in Kelvin 
and x(i is the mole fraction of the solid in solution. Since we can determine the heat of 
fusion and melting point from DSC experiments, an approximate measurement of the 
molality at the melting point of the pure solid compound when AGf = 0 and intuitively when 
A Gf(T*)
RT
= 0 can be determined. The chemical potential of the solid can be related to the
Gibbs free energy of fusion, via:
In xfd — —





it also follows that:
In xR =  -
AH f
R y  y  *
Equation 3.3
Over the temperature range of interest it can be assumed that AS and AH change very 
little and so the fraction of solid that will dissolve can be calculated from equations 3.3. 
Close to the melting temperature T«T* and so the following relationship may be used
x /t  = exp
A H f V
R
- - — I
y  y  *  ^ Equation 3.4
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3 . 3.2 Theoretical Determination of Solubility
It is common practice to calculate the molality of the solid in said solvent, which is the 
amount of solid per 1000g of solvent. The theoretical mole fractions and molalities of 
several salts are summarized in table 3.0.





Salbutamol maleate 78.47 403.20
x/3 (mole fraction) 0.055
n/3 (molality mol Kg'1) 1.259
Salbutamol Stearate 93.00 384.07
x/3 (mole fraction) 0.0123
n/3 (molality mol Kg'1) 0.270
Salbutamol Oleate 85.7 349.85
x/3 (mole fraction) 0.0696
n/3 (molality mol Kg'1) 1.624
Table 3.0: Theoretically calculated molality values for salbutamol salts in ethanol from 
experimentally determined enthalpy values.
From the data in Table 3.0, the following table 3.1 was constructed to indicate the 
theoretical solubility as a percent weight / weight over common pharmaceutically 
encountered temperatures.
Theoretical Solubility % w/w
Salt Derivative 0°C 4°C 25°C 37°C
Maleate 13.231 15.797 37.047 57.251
Stearate 1.417 1.931 8.559 18.307
Oleate 9.261 12.305 48.280 97.033
Table 3.1: Theoretical solubilities of salbutamol salts based on enthalpy of fusion and 
melting temperatures in ethanol.
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3.2.3. Conclusion
Thermodynamical calculations predicted that solutes with high melting points and high 
heats of fusion would have low solubilities. Based on such calculations, the maleate 
should have be slightly more soluble at lower temperatures and the oleate at higher 
temperatures; with the stearate having a lower solubility overall. Overall, the data 
indicated that all of the synthetic derivatives would be suitable for formulation in pMDI 
solution systems.
3.4 Experimentally Determined Solubility of Salt Derivatives as a 
Function of Co-solvent.
3.4.1 Introduction
Solubility, as formerly described, is routinely evaluated by forming a saturated solution of 
the compound of interest, agitating for a prolonged period to ensure equilibrium followed 
by filtration of the saturated solution and chemical assay. In this case, a preliminary visual 
assessment (active was sequentially added in small increments quantitatively to a volume 
of approximately 3 ml of ethanol) indicated this approach was not wholly acceptable. All 
salts were found to be freely soluble in ethanol, and, in relative terms, large quantities of 
solid was required to form a saturated solution. However, as the oleate salt was in limited 
supply and was observed to be particularly soluble, compared to the other derivatives, 
and formed a colloidal gel at very high concentrations, the stearate was substituted for the 
oleate, based on the fact that it was a C18 fatty saturated acid and structurally 
comparable. From the preliminary assessment, the standard approach for solubility in all 
solvent and propellant combinations was taken.
3.4.2 Methods and Materials
The salbutamol salt (maleate approximately 0.123g and stearate 0.126g) was 
quantitatively added to separate 25ml volumetric flasks. Before addition, the maleate 
material was triturated in a pestle and mortar in order to de-aggregate the material and 
ensure a fine free flowing powder was produced. Absolute ethanol was then added in 
small aliquots and the flask agitated between each addition until the level of the ethanol in 
the flask covered the salt, forming a saturated solution. Approximately 5g of ethanol were 
required for this purpose. The flask was then agitated and transferred to a water bath,
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which was set at a prescribed temperature. The water bath had an integrated agitation 
function to keep the solute in constant movement with the solvent. To confirm the actual 
temperature of the bath, the thermostat reading was checked against standardised 
mercury in a glass thermometer.
3.4.3 Results and Discussion
Theoretical and experimental solubility determinations of salbutamol maleate, and the 
theoretical solubility of salbutamol oleate in ethanol are illustrated in figure 3.4. The 
theoretical and corresponding experimental solubilities of salbutamol stearate in ethanol 
are depicted in figure 3.5.
Theoretically, the predicted and practical determinations of the solubility of salbutamol 
maleate correlated well. Experimental solubility of salbutamol maleate showed, however, 
a slightly higher propensity than predicted from theory particularly at extremes of high and 
low temperature. Theoretical predictions of the solubility of salbutamol oleate 
corroborated the difficulty in appropriating a saturated solution of the unsaturated fatty 
acid (oleate) derivative, as the solubility was approximately 99% w/w, compared to that of 
the maleate, 58% w/w at 40°C in ethanol. This trend was reflected at other temperatures, 
with a predicted solubility of 48% w/w for the oleate and 37% for the maleate at 29.5°C; 
while at 4°C the solubility the maleate salt was predicted to have a slightly higher solubility 
than the oleate.
The stearate salt had been abandoned early in the initial solubility study due to the level 
of co-solvent required for solution stability. Approximately a 50%w/w ethanol/134(a) 
solution was required to stabilise this salt at 4°C, and vapour pressure of solutions at very 
high co-solvent levels would not be expected to produce a viable aerosol. The solubility 
determination of the stearate salt was in excess of the theoretical prediction.
Differences in the experimental results versus the theoretically calculated solubilities for 
salbutamol sterarate were 13.99%, 15.75%, 9.02%, and 24.39% at 4, 25, 30 and 37°C, 




All the physiologically acceptable acids, described in chapter two, were capable of 
forming salt derivatives, given their respective pKa’s. Theoretical considerations indicated 
that the chosen acid would benefit from having a centre for inducing a polarized charge, 
thus, enhancing the potential to form hydrogen and carbon-dipole bonding; both free 
carboxylic acid groups and un-saturated moieties perform these functions well. Both the 
novel carboxylic acid derivatives fulfilled these criteria, and in conjunction had the added 
water miscible (maleate) and immiscible (oleate) characteristics, required for the 
necessary future aerosol studies.
Theoretical predictions of solubility assuming an ideal behaviour, derived from Raoult’s 
law, dictated that the maleate and oleate salts were preferred for use in solutions rather 
than the stearate. This was subsequently corroborated by the experimental 
measurements, with the solubility of the oleate predicted to be higher than that of the 
maleate. This rationale is in agreement with theoretical predictions, since at a given 
temperature solutes with high melting points and large enthalpies of solution relate to a 
low solubility (Atkins 1982). However, at lower temperatures, this trend reversed in favour 
of the maleate. Solubility depends upon specific surface energy, molecular mass and 
shape factors. At lower temperatures, compounds will have greater crystal symmetries, 
leading towards lower chemical potentials and lower solubilities.
The actual solubility of the oleate could not be fully determined due to a paucity of raw 
material, but the correlation between theoretical prediction and experimental data 
generated for maleate and stearate derivatives (See figures 3.4 and 3.5) predicted a 
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A graphical representation of the theoretical and experimental solubilities of 
salbutamol maleate and the theoretically predicted solubility of salbutamol 
oleate.
50  i  Theoretically predicted solubility of salbutamol stearate in ethanol.
O  Experimentally determined solubility of salbutamol stearate in ethanol.
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A graphical representation of the theoretical and experimental solubility of 
salbutamol stearate.
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•  Theoretiaclly predicted solubility of salbutamol maleate in ethanol.
O  Experimentally determined solubility of salbutamol maleate in ethanol. 





3.5 Experimentally Determined Solubility of Salt Derivatives as a 
Function of 134(a) the Anti-solvent.
3.5.1 Introduction.
The measurement of solute solubility in liquefied propellant systems naturally imparts 
difficulties in quantitative determination. An experimental apparatus has been previously 
utilised for pressurized systems (Dalby et al 1991). The equipment comprised two piastic 
coated glass bottles communicated together via a suitable filter housing. In one was the 
parent suspension of micronised drug with varying levels of a CFC propellant: mixtures of 
P11 and P12. The receiving container, the second glass bottle, which had been pre­
purged and was connected to the first via a 0.22pm filter. Once the valve containing the 
suspension was depressed the soluble portion of the drug in propellant passed through 
the filter into the receiving flask. The procedure was validated using different 
concentrations of suspended material with investigation of equilibration times, followed by 
replicate sample manufacture and blank determinations. The equipment cited formed the 
basis for the development of a novel propellant solubility-measuring device.
3.5.2 Methods and materials
3.5.2 (a) A novel drug solubility apparatus: Design and manufacture
Figure 3.6 illustrates a schematic representation of the designed solubility device. The 
device was manufactured and used experimentally throughout the study, and differed 
considerably from the previous system.
The body (2) was constructed from stainless steel and the base (5) from aluminium. This 
was intentionally designed into the apparatus to allow a gas tight seal to form from the 
connection between the two dissimilar metals. The base was machine turned so that a 
recessed shoulder and a well were formed. The well itself formed the powdered drug 
receptacle. The shoulder formed on the rim of the well acted as the connection to the 
body allowed a circular metal frit (4) with a pore size of 0.2pm which when assembled 
formed a seal, effectively allowing only dissolved solute to pass through. Particle size 
determination of bulk-synthesised drug, by laser diffraction indicated a particle size 
distribution was in excess of this cut-off diameter. The filter frit was held in place and 
sealed to prevent leakage of propellant/co-solvent mixture via 2 "O” rings (3) that sat
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above and below the filter. A suitable valve (1) was crimped on to the stainless-steel body 
of the device.










Figure 3.6: A front /  side elevation of the novel solubility apparatus (NSA).
The main advantages of the NSA were:
(a) It was constructed of metal and is intrinsically safer than plastic coated glass bottles. 
Glass is not routinely utilised in inhalers given the transition from CFC’s to HFA’s.
(b) The device was reusable and allows consistency within determinations as the same 
can/valve assembly is used.
(c ) The device could be made from any metallic/metallic polymer coated material, which 
would simulate the conditions encountered by the formulation.
(d) The material could be recovered after contact with the metal and analysed for any 
physicochemical changes i.e. polymrophic induction for example.
(e) There was a low potential for drug losses between transfer of solution from bottles, 
as may be encountered with the standard equipment.
(f) With an appropriate metering valve the influence of temperature/moisture ingress 
could be undertaken with a single device.
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3.5.2(b) Sample preparation and analysis
Salbutamol salts were synthesized as described earlier. The salts were accurately 
weighed into the receptacle (base station (5)) of the device and an accurate mass of 
134(a) was charged into the solubility apparatus. The device was equilibrated at a known 
temperature with constant agitation for 24 hours per time-point to ensure thermodynamic 
equilibration. Samples were then prepared for analysis by preparing a solution of the 
solubilised salt. The solution was prepared by placing a small stainless steel tripod in a 50 
ml beaker charged with 25ml of HPLC grade methanol. The tripod was constructed with 
an aperture to accommodate the valve stem, and allow travel into the valve body so that a 
dose actuation was accomplished. The apparatus was accurately weighed by mass 
difference before and actuation so an accurate determination of solubility, expressed as 
drug mass, per mass of 134(a), could be established. Prepared samples were analysed 
by X-ray fluorescence using a standardised and calibrated fluorimeter. System suitability 
was determined by standard recovery and five point linearity curves, (see section 2.8)
3.5.3 Results and Discussion
For solubility measurements, it was essential to ensure that drug was in an equilibrated, 
saturated state within the solvent system. To assess the optimal dissolution time, multiple 
solubility determinations were performed on the 10%w/w co-solvent system at 4°C, after 
equilibration at three specific timepoints: 2, 3 and 72 hours in order to assess if there were 
any statistical differences with equilibration time. The same experimental set-up was 
utilised in order to reduce the number of variables. Comparisons of inter group means 
were performed using a one-way ANOVA with a Tukey’s significant difference test. The 
statistical analysis of the raw solubility data at 4°C as a function of equilibration time (for 
salbutamol maleate in a 10% w/w ethanol/HFA 134a solution) is illustrated in appendix 
A3.1. The low P value (>0.05) indicated that, the null hypothesis should be accepted and 
no significant difference existed between the means of the assay results as a function of 
equilibration time. Thus, a 2 hour equilibration period was acceptable to use as a 
dissolution time as compared to a 72 hour equilibration time. For further validation, the 
Tukey’s honestly significant difference test also indicated no significant difference. (The 
probability of achieving an F (Fisher ratio) of 0.98 from variances of 2 and 14 degrees of 
freedom is 0.4). The graphical illustrations for individual salt solubility profiles in pure 
propellant over equilibrated temperature ranges are depicted in figures 3.7 and 3.8. Both 
curves followed a similar trend. Each indicated an increase in solubility when the 
temperaure was increased. The solubility in 134(a) was not taken above a temperature of
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40°C for two reasons. A temperature of 40° C was close to body temperature of 37°C and 
exposure to higher temperatures may have compromised the seal integrity of the valves 
on the body and the neck of the device. Both salts had an increased solubility over the 
sulphate and base, which are routinely used. The relative changes in solubility with 
temperature profile are highlighted in table 3.2
Change in Solubility %







Table 3.2; Changes in salbutamol salt solubility as a function of temperature range.
The observed changes in solubility were smaller at the extremes of temperature (4-15°C) 
and exhibited the greatest rate of change within the mid-range (15-25°C). The greatest 
increase in solubility of maleate and oleate salts were found between 15 and 25°C with a 
solubility of 60 and 66%, respectively. Although some ranges were not determined (ND), it 
was predicted that intermediate unknown temperature ranges would have revealed 
greater changes for the oleate salt. It was inferred that solubility in pure propellant could 
be attributed to the structure of the salt modified by the counter-ion and from the pH of the 
solution produced as this may have affected the rate of ionization and inter molecular 
attraction. To account for such observed changes, both salts have an unsaturated double 
bond and at least one carboxylic acid group. Indeed solvation at the atomic level has 
been theoretically based on interactions within aqueous systems (Lynden-Bell 2000). 
However the approach can be intuitively correlated to organic based counterparts. In 
these cases, it is hypothesised that the interaction of the solute with the solvent causes a 
cavity of the correct shape and size to form to accommodate the solute molecule. The 
medium is effectively polarized by the electric field of the solute, and can be expressed 
mathematically with the Born model of free energy.
2
^sol = --------------------------T~ Equation 3.5
^m orcav^S ~ e )
Where A SOi is the energy of solvation, q is the charge on the ion, e0 is the dielectric 
constant of the medium and r^v is a cavity formed within the solvent the salts with their
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centers of unsaturation may form strong dipole interactions, particularly being in a cis 
configuration. The dipole of the anion may cause a repulsive effect to occur and inagurate 
and help synergise the formation of a solvent cavity. In conjunction, free carboxylic acid 
groups could form intermolecular hydrogen bonds, and the resonance stabilised 
carboxylate anion may form a bond with the hydrogens present on the propellant. Crystal 
shape may also be important, since the oleate is more soluble in 134(a) and is monoclinic 
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Figure 3.8: A graphical illustration of the solubility of salbutamol oleate in pure 134(a).
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3.6 Experimentally Determined Solubility of Salt Derivatives as a 
Function of Ethanol and 134(a) Mixtures.
3.6.1 Methods and Materials
The same solubility apparatus was utilised for this phase of the study as the previous. As 
ethanol 134(a) mixtures cannot be purchased commercially, mixtures were generated 
according to the following method. The drug was prepared and dried as described 
previously in chapter 2.2.5. It was then quantitatively weighed into the well of the solubility 
apparatus and an aliquot of absolute ethanol dispensed on top of the drug. The apparatus 
was quickly assembled and the apparatus re-weighed. Propellant was charged into the 
device and the mass calculated from gravimeteric measurements to give the appropriate 
concentration of co-solvent. This was repeated for the oleate salt, however due to lack of 
material, and its superior solubility profile, a 5% w/w co-solvent mixture only was prepared 
for this salt.
Figures 3.9 and 3.10 illustrate the experimentally determined solubility profiles of 
salbutamol maleate in varying co-solvent/propellant concentrations over a specific range 
of temperatures: 4°C to cover pharmaceutical stability, 25°C to encompass ambient 
temperature, and 37°C to simulate physiological ‘body temperature’. Included for 
completeness on these graphs are two supporting data sets namely: the solubility in 
100% "pure” propellant (the anti-solvent) and the drug concentration in the ethanolic 
component (the drug concentrate component), and as solubility was different by several 
orders of magnitude for all systems, it should be noted that graphically log scaling was 
required. The second parameter (the concentrate phase) is included graphically, to 
introduce, and assist in the explanation and description of the novel solubility concept.
The results and accompanying discussions are considered within section 3.7. One caveat 
is placed upon the method of determination: sources of errors between solubility as a 
function of both single and dual stage propellant combinations are assumed equal. To 
clarify, solubility from the addition of ethanol followed by 134(a) to the requisite final blend 
is assumed equal to the addition of a pre-prepared blend in a single stage fill.
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3.7 Introduction to a novel model for Predicting Solubility in pMDI 
systems: A Theoretical Approach.
From the solubility data generated, and the individual compositions of the corresponding 
formulations, it has been possible to theoretically predict formulation stability rather than 
use purely solitary empirical methods alone, which can be corroborated by visual stability 
assessments. The concept is simple, but powerful. Fundamentally, the data generated 
indicated that when the solubility of the active (expressed as a percent w/w, in the 
formulation namely co-solvent, and HFA 134(a)), exceeded that of the drug co-solvent 
concentrate alone, then solution stability was highly probable; viewed graphically 
indicated by figures 3.9 and 3.10 summarised in 3.11, and is intuitively correct. By 
plotting the data on a standard solubility versus temperature graph, then the drug 
concentrate phase appeared as a horizontal line parallel to the x-axis. Finally, plotting the 
active solubility in the final formulation, on the same graph resulted in a data plot that lay 
below (10% w/w co-solvent) or above (20% w/w) the drug concentrate line. If it lies below 
the drug concentrate plot (as per the 10% co-solvent level) then the solution was 
predicted to be an unstable system. Conversely, if it lies (as for the 20% co-solvent level) 
above the drug concentrate plot then the system was predicted to be stable.
The graphical representations, figures 3.9-3.10, illustrate the outcomes of the predicted 
theory, described above incorporating the experimental results. Also, for completeness, 
the data for solubility in propellant (anti-solvent) alone are plotted on the same graphs and 
due to the significant reduction in solubility expressed as percent w/w then the Y scale is 
log normalised (relative increase in solubility over the largest change in dielectric 
constant: 134(a) 9.5 to ethanol 24.3). As the dielectric constant changes substantially 
from pure 134(a) to pure ethanol and in conjunction the active concentration within the co­
solvent changes accordingly these combined factors become important solubility 
indicators. The drug concentrate factor is calculated simply as follows and in practice 
actual and not idealized values would be used.
Example Calculation:
Convert the drug mass to the relevant unit: 0.25 %w/w = 0.025g,
Repeat (i) for the co-solvent: 10.0 %w/w = 1.00g
Calculate the drug concentration 0.025/1.00 X 100 = 2.5 % w/w
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3.8 Solubility Data: Comparison of intra-formulation solubility
profiles.
Data in table 3.3 depicts the experimentally determined solubility of salbutamol maleate in 
the relevant pMDI media at specific temperatures. Table 3.4 illustrates the relative intra­
formulation percentage change in respective solubility.
Temperature°C Experimentally determined solubilities of salbutamol maleate at 
10 and 20% w/w Co-solvent levels at specificed temperatures.




Table 3.3: The solubility of salbutamol salts (expressed as % w/w) at varying levels of
co-solvent and HFA 134 (a)
Temp Range °C Change in solubility %




Table 3.4: The relative percentage change in solubility for salbutamol aerosol
formulations.
3.8.1 Intra-formulation evaluation: Data Discussion
The greatest change, for both formulations, was an increase of approximately 483%, 
which was exhibited by the 10% w/w co-solvent formulation over the full operating (4-37° 
C) temperature range, equating to about 1.88 times greater than the change for the 
corresponding 20% w/w formulation. The 10% co-solvent formulation also indicated a 
progressive increase in solubility whereas the 20% w/w co-solvent formultion exhibited 
minima over the 25-37°C-temperature range. The change in solubility over the low range 
4-25°C was deemed important, as crystallisation had a greater propensity to occur over 
this range. As a result, the 20% w/w formulation was superior to that of the 10% 
approximately two fold. Data indicated that the change in solubility when the co-solvent
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levels were increased from 10-20% w/w at 4 and 25°C were in the region of 0.98 and 1.55 
orders of magnitude.
3.9 Application of the novel solubility concept: Theoretical vs. visual 
stability correlation
Principally, the new solubility theory centered on the fundamental concept that, when the 
solubility of the drug expressed as a %w/w within the overall formulation/media was 
greater than that of the drug concentrate alone (again expressed in % w/w terms) 
solubility would be highly probable at any temperature. The new theory predicted that an 
unstable system should result in a formulation containing a co-solvent level of 10%w/w 
and salbutamol maleate at a concentrate level of 2.5% w/w (Ultimately, an overall 
concentration drug of 0.025% w/w with respect to the final formulation). This indeed 
occured over the temperature range studied, and empirical visual data, depicted in figures
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Figure 3.9: A graphical illustration indicating the solubility of salbutamol maleate in a
pMDI formulation containing 10%w/w ethanol.
The theory predicted that for 20% w/w co-solvent level, see figure 3.10, a stable system 
should result at all temperatures, as the solubility of the active in the overall media 
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Figure 3.10: A graphical illustration indicating the solubility of salbutamol maleate in a
pMDI formulation containing 20%w/w ethanol.
The data in figure 3.11 is a composite graphical representation of the solubilities relating 
the 10% w/w co-solvent formulation, the 15% w/w co-solvent formulation and the solubility 
of the drug in pure ethanol (ideal infinite dilution). The horizontal lines, drug concentrates 
values, are for ideal formulations but serve to ilustrate the rationale. The theory predicted 
that the solubility of a 15% w/w co-solvent formulation at 4°C should have an idealized 
solubility of approximately 1.6% w/w (visual solubility observations confirmed stability is 
achieved). Deviations in solubility may occur, but it is reasonable to assume that the 
solubility of a 15% w/w co-solvent formulation when experimentally determined and 
plotted on the graph in 3.11 would lie below the drug concentrate line, as it was unlikely to 
be greater than the 20% w/w system. It was assumed in section 3.6.1 that the two stage 
manufacturing process (ethanol added to excess drug followed by addition of 134(a)) 
would produce similar solubility profiles to that of a single stage process (ethanol and 
134(a) added to excess drug). If the material was initially dissolved in a solvent and 
stabilized it may be thermodynamically and kinetically less favourabe to disrupt the 
solvated components, than solvate them initially in a solvent of reduced dielectric constant 
and ‘liquid structure’. Irrespective of the erstwhile hypothesis it is likely from a kinetic 
viewpoint that at a level between 12.5 and 15% w/w co-solvent, a metastable region is 
likely to exist.
100%  134(a)
0.1 -| o  solubility 20%  ethanol 8 0%  134(a) 
— concentration ethanolic phase
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Solubility of salbutamol maleate in 10% w/w ethanol 90% 134(a).
0  Solubility of salbutamol maleate in 100% ethanol.
— Solubility of salbutamol maleate in 20% w/w ethanol and 80% 134(a).
—V- Drug concentrate in ethanolic component for a 20 %w/w cosolvent formulation.
—■ — Drug concentrate in ethanol component for a 15% w/w cosolvent formulation.
HD- Drug concentrate in ethanolic component for a 10% w/w cosolvent formulation.
Figure 3.11: A graphical illustration indicating salt solubility and ethanol phase
concentrationfor use in solution stability theory.
3.9.1 Conclusion
From visual observations, a 15% w/w co-solvent level was required to stabilise a 0.25% 
w/w drug loading of salbutamol maleate, which effectively equated to a drug/ethanol 
concentrate of approximately 1.64 %w/w. In the final formulation, and for the salbutamol 
oleate, a 30% w/w co-solvent level was required to stabilise a drug loading of 
approximately 0.37% w/w, which effectively equated to a drug ethanol concentrate of 
approximately 1.22% w/w in the final formulation. Due to several factors, the solubility 
theory could not be directly applied to the oleate salt, as the solubility in ethanol and 
propellant blends were not established. Future practical work would be required for this 
derivative to substantiate the theory. In addition, the situation with the oleate salt would be 
further complicated by the fact that it has low water solubility, and stability of this 
derivative in formulations would have to contend with effectively a second anti-solvent. 
The novel theory predicted that the 15% w/w co-solvent system should destabilise below 
25°C. Practically this did occur. Such a deviation may stem from several possible sources: 
the existence of metastable states, changes in media dielectrics, morphology, crystal
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structure and enthalpies of solution i.e. the regions were the rate of formation of crystal 
nuclei is negligible in a supersaturated state.
Considering metastability, nucleation and eventual destabilisation in the systems 
illustrated previously resulting in crystallisation centres upon the critical nucleus size of 
the drug aggregate or the number of molecules congregated around a nucleation site. 
The 15% w/w system due to the stability exhibited indicated its probable existance in the 
metastable state. (Graphical illustrations of these zones are given in figure 3.13). Under 
equilibrium conditions, the rate of aggregation of active molecules and de-aggregation via 
solvation and dissoloution are equal. If the aggregates are smaller than the critical size 
they will re-dissolve, if they are larger than the critical size, they will form stable nuclei for 
crystal growth. The activation energy or barrier to aggregation and growth is largely 
dependent on the purity of the solution and the amount of solid phase and extraneous 
material present. From the methodology utilised in both the synthesis and in the 
preparation of the formulations, the metastable hypothesis is highly probable. This was 
confirmed from visual stability measurements from storage at low temperatures. The 
reader is directed to tables A 3.1 (a) -(c) appendix A 3.2 in relation to the these 
observations. Electronic effects may also be of significance. The rationale behind the 
effects of dielectric properties of formulation blends and their effects are discussed 
extensively in appendix A 3.2. Disruption of the crystal structure and the increase of 
intermolecular distances cement the link between melting point and solubility, and 
thermodynamically is the latent heat of fusion. Quantitatively, the data collected from DSC 
determinations intuitively explained that the low melting points and heats of fusion 
corroborate the high solubilities in ethanolic solutions, as indicated in equation 3.4. The 
nature of the counter-ion has been elaborated previously, however, further investigations 
into the structure of unsaturated carboxylic acid derivatives may help to explain the 
potential differences. The size and orientation of the anion helps to disrupt the crystal 
lattice, and, further, stereochemistry (geometric isomerism) also seems to have a degree 
of importance. For example, cis butenedioate (maleate) is soluble whereas trans 
butenedioate (fumarate) is not. As size and shape affects polarisability (Apell et al 2002) 
the spatial shape of the electron clouds and the orientation of the functional groups, may 
account for increases in solubility in ethanol. Cis isomeric acids from steric considerations 
may form stronger hydrogen and dipole-proton bonds with the solvent. Trans acids may 
lack some of these properties. Indeed cis-trans isomerism is evident in the solubilities of 
the parent acids as maleic is freely soluble in most common solvents whereas fumaric is 







Figure 3.13 : An illustration indicating stable, metastable and unstable solution zones for
a two component system with a positive temperature coefficient.
Following the discussions on stereochemistry and solubility, the majority of derivatives 
synthesized were insoluble in ethanol and precipitated from bulk solution. Although other 
ethanol soluble derivatives were not structurally determined, DSC measurements were 
used to calculate the theoretical solubility to verify, where possible to confirm predictions. 
See appendix A .2 table A 2.1. All derivatives in table 3.5 indicated substantially lower 
solubilities than the organic carboxylate anions and did precipitate from the reaction 
vessel. Theoretically calculated solubility measurements for a selection of inorganic 
derivatives are shown in table 3.5.
Salt Sulphate Phosphate Nitrate Hydrochloride
Solubility %w/w 0.590 2.021 36.579 3.016
Table 3.5: Calculated solubility for a selection of inorganic salbutamol salt derivatives
The solubility data generated on the derivatives in pure solvent indicated the oleate was 
the superior form. Figures 3.7 and 3.8 depict the only direct comparison between the 
salts, as the solubility of the oleate was not performed in identical co-solvent formulations 
to the maleate for reasons previously discussed. The main differences between 
derivatives outlined from crystallographic data were: Bravais lattice structures, space 
groupings, molecular volumes and densities. Shape here may also be an important factor.
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The monoclinic structure (electric field of the solute) of the oleate may polarise the 
continuum/discrete structure of the medium (propellant 134(a) creating a cavity of the 
correct size to accommodate the respective ions (Lynden-Bell 2000). This would seem 
logical. Moreover, the volume of the oleate is approximately twice that of the maleate. 
Again the volume of the cavity, depending upon the solvent, may be important. If more 
than one molecule fits into the cavity inter-molecular attraction may reduce overall 
solubility.
Considering the fundamental question posed at the start of the chapter. It has been 
possible to theoretically model the stability of pMDI solutions by appropriate use of theory 
and experimental data, but deviations occurred. Due to the complex nature of pMDI 
formulations it may be possible to predict deviations, but extensive consideration of 
inherent physical chemistries would be required.
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4.0 IN-VITRO EVALUATION OF NOVEL SOLUTION 
FORMULATIONS UNDER NON-STANDARD LABORATORY 
TESTING CONDITIONS
4.1 Aerosols: An Introduction
The primary deposition mechanisms of aerosols have been discussed in detail in chapter 
I, section 1.5. However, these mechanisms do not describe those inherent within spray 
generation (aerosolisation) and the associated droplet phenomena.
A spray is a type of two-phase flow (Sirignano 1999), involving a liquid as the dispersed or 
discrete phase primarily in the form of droplets or ligaments, and a gas as the continuous 
phase. (A solid can also be the dispersed phase and when this occurs, this is termed 
dusty flow). The second type of flow is ‘bubbly flow’ whereby the gas is the discrete phase 
and is conversely dispersed within a liquid, and during motion, the relative movement 
between the droplets and ambient the gas instigate boundary layers leading to the 
formation of wakes. The fluid dynamics that occur on an individual droplet level, involve 
complex mass and heat transport phenomena, which can also affect motion (Sirignano 
1993), including shear-driven internal circulation of the liquid inside the droplet, Stefan 
flow resulting from vaporisation and condensation, droplet-droplet interactions, interfacial 
flow instabilities, droplet shape distortion and interactions within internal gas flow vortices. 
Importantly, the problem is exacerbated by temperature and concentration gradients and 
coupled particle-particle interactions. In addition, the constant changing gas conditions 
and multi-component liquids compound the problem, and clearly, an interdisciplinary 
approach is prerequisite to provide a full physical description of the complex and 
interlinked processes that occur. A good overview of the science is detailed by Lefebvre 
(Lefebvre 1989).
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4.2 Overview of Droplet Formation Mechanisms.
Droplet sizes within an aerosol cloud are a key parameter in influencing the resulting 
particles behaviour. Depending on the composition of the liquid, the surface tension will 
tend towards reducing the surface of the droplet and produce a spherical shape; and the 
presence of surfactants and co-solvents that alter the surface tension highly influence the 
particle sizes during droplet formation (Seaver et al 1992). Moreover, during atomisation, 
temporal variations occur in droplet sizes, and as a result smaller droplets decelerate and 
accelerate faster than larger droplets, and ultimately, smaller droplets will heat and 
vaporise faster. Injection of liquid streams (pressurised in the case of this study) into a 
gas obviates the initial instability, and can be empirically described in terms of the Weber 
number.where inn turbulent flow fields the net velocity between gas and drop are similar 
and can expressed via the following expression:
„ r pAU2LWe =   ---------------  Equation 4.0
CT
2
Where p  is the density of the gas, AU the relative gas-liquid velocity, I  is a 
characteristic dimension of the stream and <j  is the surface tension of the liquid.
In basic terms, this expression relates the aerodynamic forces (pressure dependent) to 
the surface tensional force, and below the critical Weber number surface tension 
dominates and the stream of liquid is undistorted. (These criteria would become important 
in later experiments where pressure was the driving force for aerosolisation). Higher 
Weber numbers indicate that the aerodynamic forces dominate over those that restore 
droplet integrity. Here atomisation proceeds typically via the formation of liquid ligaments 
with a characteristic length dimension, and during the atomisation process, these 
continually reduce from their original length scale of the stream. This cascade effect 
continues until the decreased length scale drops and brings the Weber number below the 
critical value. It is not easy to describe the atomisation process overall for a simple plain 
orifice atomiser, but Haenlein has described three other distinct regions of droplet break­
up (Haenlein 1932). These are illustrated as follows:
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(1) The first is termed varicose and is independent of air and occurs from jet velocity. 
If the wavelength of the disturbances in the je t are greater than the minimum 
required for stability then disintegration would proceed.
(2) The second mechanism occurs with the influence of air and here the aerodynamic
forces are no longer negligible, accentuating the waves formed in (1).
(3) Wave-like break-up can occur caused by air friction and the influence of
aerodynamic forces and the reduced influence of surface tension. This region is 
usually termed “’sinous” .
(4) Complete and irregular disintegration of the jet.
The most common descriptions of jet disintegration were thosed proposed by Ohnesorge 
who introduced the importance of gravitational, inertial, surface tension and viscous 
effects. From dimensional analysis, it was concluded that the mechanisms of jet break up 
could be generalised into three regions by plotting the Ohnesorge number (obtained from 
dimensional analysis) versus the Reynolds number. This description details four regimes 
of breakup: Rayleigh, first and second wind and finally atomisation
It is postulated that on depression of an MDI metering valve stem, the aerosol cloud 
formed follows the above description, although demarcation around regions is difficult to 
quantitate. This is partially corroborated by dark field photography, as large droplets are 
formed at the front of the stream, and are effectively non-therapeutic being larger than 10 
microns in MMAD. A snapshot of this atomisation process is illustrated in figure 4.0
Large droplets
Figure 4.0 A typical photograph of the aerosol cloud emitted from a pMDI
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4.3 Practical Evaluation of Droplet Formation: Previous Studies
The study of droplet formation has been studied for over a century covering many 
applications (Lefebvre 1989). For therapeutic applications, aqueous solutions have been 
the primary focus (Stapleton and Finlay 1995, Phipps and Gonda 1990), and although 
very different in composition to pMDI’s the same general principles can be applied. The 
complexity of such non-aqueous systems has highlighted that no one theoretical model 
can predict the final particle size output from a metered dose inhaler. The individual 
components affecting particle size output will be considered in detail later, but, for now, 
there are three basic methods of predicting droplet sizes:
(a) The use of empirical methods (the most widely used)
(b) The solution of the Navier-Stokes equations in their inviscid or limiting form, the
Euler equations to predict liquid break-up, and,
(c) The approach, which satisfies maximum entropy in addition to mass and energy
conservation.
Clark (Clark 1996) took the empirical theory approach and applied Rosin -  Rammler 
distributions to his experimental data in order to predict the initial median droplet diameter 
for a suspension-based system with varying levels of surfactants. The relationship 
correlated from the data is given in equation 4.1.
Where D[0.5] is the initial median MMD, qec is the mass fraction of vapour in the expansion 
chamber, p a is the ambient pressure p ec is the pressure in the expansion chamber and 
integers are constants relating to quality of flow, droplet size and pressure to droplet size.
His work considered discharging the aerosol into a stagnant gaseous environment. The 
results approximated to the classical inverse d2 law, as vaporisation occured in a quasi- 
stationary fashion. It is important to recognise that droplet behaviour is different when
Equation 4.1
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aerosols are discharged into stagnant or turbulent flow fields (Hinze 1972). Although 
different propellant mixtures were utilised (CFC’s) the valve was not metered and the 
determinations were made at one temperature, which was not specified, and assumed to 
be ambient.
In the aforementioned study, both droplet velocities and particle diameters were 
considered. As the volume of a droplet has an associated mass and also experienced a 
drag force in terms of particle size changes and velocities, the results generally agree with 
theory (Particle acceleration is inversely proportional to a positive power of the diameter, 
and particle size, to a certain extent is related to the d2 principle, whereby the square of 
the diameter decreases linearly with time).
The fundamental work by Clark highlighted the importance of formulation on spray 
velocity and on oral deposition. Oral deposition has led to a concomitant reduction in 
therapeutic drug delivery to the respiratory tract and has been shown to induce side 
effects, particularly with corticosteroids (Konig 1988). In fact, reduction of throat 
deposition would be advantageous as it had been shown, historically, that only about 10% 
of the dose was delivered to the lungs via MDI systems (Davies 1975). However, with the 
advent of HFA solution systems deposition has shown to be up to 60% (Wildhaber 1998). 
The relationship has illustrated the importance of vapour pressure and aerosol formation 
and has been shown to correlate well with HFA systems (Dunbar et al. 1997).
4.4 Multi-component Aerosol Systems
A number of complications have been shown to arise in multicomponent liquid systems 
utilised for aerosolisation (Landis and Mills 1974). Each component will vaporise at 
different rates, which, in turn, will cause concentration gradients in the liquid phase 
affecting mass diffusion (mass diffusion is slower than heat diffusion in both liquid and gas 
phases), and also solid materials namely the drug substance(s), which also exist within 
the droplets will again affect both the mass and heat transfer rates. The consequence of 
formulation variables within solution systems has been previously illustrated by Gupta, 
whereby the MMAD of a BDP solution formulation increased with increasing solid 
concentration (Gupta et al 2003). The MMAD was shown not to be significantly affected 
by co-solvent level; however, important temperature, and associated vapour pressure 
considerations were not taken into account. Subsequently, Lewis and co-workers have 
generated several data sets comparing a number of variables: co-solvent level, actuator
84
orifice size and sump expansion volumes. They concluded that the MMAD was
independent of both actuator orifice size and HFA 134(a) content over the particular range
studied. However, although, co-solvent level and actuator orifice produced no statistically 
significant changes in MMAD, the spread or GSD of particles was shown to be greater for 
increased co-solvent level, and MMAD was found to be dependent upon the cube root of 
the mass of non-volatile component added, glycerol in this case. For 134(a) and 227ea, 
the MMAD was also dependent upon a constant which was peculiar to the propellant in 
relation to their physiochemica! characters. These constants of proportionality were 
determined for HFA 134a and 227ea as 2.31 and 3.26, respectively (Lewis et al 2004). 
The equations proposed by Lewis are depicted in equations 4.2(a) and 4.2(b).
MMAD !34(a) = 2.31 (%w/w NVC)1/3 Equation 4.2 (a)
MMAD 227(ea) = 3.26 (%w/w NVC)1/3 Equation 4.2 (b)
4.5 Aerosol Device performance
As previously discussed, It is well known that formulation parameters and the device 
hardware influence the aerosol behaviour of a propellant driven MDI (Polli et al 1969). 
The seminal work systematically investigated the effects of changing formulation and 
actuator parameters. By doing so, the resulting MMAD for a suspension-based inhaler 
could be controllably manipulated. The aforementioned criteria have some credence 
when solution systems are considered, but, inevitably, several deviations occur. The main 
problem with solution systems are the ‘finer’ particle size distributions produced and the 
resulting implications that follow related to the therapeutic index (June 1997). In 
conjunction, aerosol devices are currently tested under in-vitro laboratory environments 
by a variety of sizing methods (see methods and materials section Chapter 2, section 
2.3), which measure the aerosol particle size fractions in situ or by fractionating into 
particle size ranges. This allows the calculation of the average particle size, the total drug 
recovered, and the residual drug deposited on the device (actuator). There are, however, 
two major problems with the testing of aerosols by current pharmacopeial methods: firstly, 
when aerosols are measured by different methods results may differ (Hickey and Jones 
2000), and, secondly, all measurements are made at ambient conditions of temperature 
and relative humidity, even though the human body and respiratory tract essentially 
operates at 37°C and 99.5 % relative humidity, and temperature and humidity gradients 
are known to exist, (Swift and Proctor 1977).
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4.6 Aerosol Device Optimisation
Low systemic related effects with an amelioration of clinical symptoms have been deemed 
a measure of success when evaluating device optimisation. Delivery of a therapeutic, 
heterogeneous aerosolised cloud dispersion to elicit a therapeutic effect, for asthma type 
symptoms, should ideally deliver an areosol cloud with an MMAD in the region of 1.8 to 
2.8 microns (Zanen et al 1994 and Clay et al 1986). The range of particle sizes illustrated 
may be due to receptor location as Clay utilised a (32 agonist and Zanen an 
anticholinergic. The particle size distributions of different compounds that maximise the 
therapeutic ratio may be different for varying compounds (Lovtall 2001), so it would be 
beneficial, therefore, to manipulate formulation and environmental conditions to optimise 
the dose, such that the overall conditions dictating aerosol generation and deposition are 
better understood. These will be considered in this chapter and extended in the final 
chapter.
Ultimately, the ideal device would consist of a system, which would deliver optimal drug 
while reducing throat and device deposition, and be relatively independent of patient in 
inspiratory parameters.
4.7 In-vitro determination of PSD’s emitted from a novel solution 
pMDI
4.7.1 Introduction
The following experimental sections describe the systematic investigations into the 
combined effects of temperature and co-solvent levels on the salient particle 
characteristics emitted from solution based metered dose inhalers. The actuator spray 
orifice diameter was kept constant, and, for comparison, to illustrate the differences with a 
suspension-based aerosol of similar co-solvent concentration composition and hydrophilic 
salbutamol salt, a commercially available inhaler (Airomir, 3M, Loughborough, UK B/No 
8E103N) was tested at ambient lab conditions. The suspension-based inhaler was not 
subjected to the temperature equilibration as the solution systems such as temperature, 
as it has been shown to have little effect on particle size distribution within suspension 
dosage forms (Stein and Stefely 2003). Ultimately, the data generated would be used to
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formulate an empirical equation to predict the MMAD of solution systems from their 
inherent composition.
4.7.2 Methods and Materials
Formulations were prepared according to the methodology in chapter 3, section 3.2.1 and 
stored for a minimum of 3 hours to temperature equilibrate, (indicated within the optimal 
time frame from solubility experiments), via a temperature controlled water bath (Grant 
LTDGG, Cambridge, UK). The components utilised for all succeeding formulations 
produced comprised of an aluminium canister (C128, 18ml Presspart, Blackburn, Lancs), 
a 50 pi metering valve (Bespak, Kings Lynn, Norfolk) and these subsequently dischared 
through a salamol Pk 0284 modified actuator (Baker Norton, Waterford, Ireland). For a 
further description of the variables altered in the study the reader is directed to appendix 
A 4.2 in its entirety. Three canisters were equilibrated and were weighed before and after 
ten consecutive actuations into an Andersen cascade impactor, in order to give a precise 
mass balance on recovery based on the formulation composition on an actual weight-by- 
weight basis. The units were primed by actuating 2 shots to waste prior to daily 
experimentation. As solutions, they did not require shaking between shots. In order to 
prevent the canisters equilibrating to room temperature, prior to transfer from storage to 
analysis, they were housed in a specially constructed polystyrene block to insulate the 
canister and prevent heat transfer. In order to assess the effect of temperature on the 
subsequent vapour pressure of ethanol co-solvent mixtures, which may be of significance 
in defining particle size equations, vapour pressure measurements of placebo 
formulations, covering a range necessary to ensure salt solubility (15 and 20% w/w) were 
performed (n=3) and the data is presented in table 4.0 (standard deviations are in 
brackets).






- 4.0 (± 0.28) 6.9 (±0.14)
20 - 3.5 (± 0.14) 6.7 (± 0.14)
30 1.2 (±0) - 6.9 (± 0.12)
Table 4.0: The effect of temperature and co-solvent level on the vapour pressure of
placebo pMDI solutions.
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4.7.2 {a) Device Functionality: Dose Delivery and Performance
As the study was essentially in the development phase, no definitive specifications could 
be established for either delivered or emitted doses in relation to current pharmacopeial 
standards. In addition, temperature equilibration of the units further complicated dosing 
issues as valves and associated formulations are rarely if ever utilised clinically or 
pharmaceutically tested at temperature extremes. Recovered shot weight data calculated 
for both formulations over the equilibration temperatures ranged from 84-117% of theory, 
based on individual thermochemical data of the formulation components. Delivered dose 
data was calculated from said measured shot weights and individual results ranged from 
69.5-90%, mean delivered dose results for each permutation ranged between 76.6-88.3% 
and emitted dose data ranged between 69 and 81%. All results conformed to current EP 
specifications for metered dose inhalers. (For clarity, the delivered dose was the total drug 
recovered from the metering chamber and the emitted that emitted from the actuor).
The actual mean delivered doses (micrograms) recovered from the replicate experiments 
(with the standard deviations in brackets), for each formulation and temperature 
combination of the following sequence, 15%/4°C, 20%/4°C, 15%/37°C, and 20%/37°C, 
were 111.35 (201.18), 114.17 (62.26) 127.76 (65.02) and 112.77 (27.34), respectively.
Table 4.1 summarises the major particle characteristics for formulations analysed post 
temperature equilibration, with standard deviations in brackets. Relevant data from the 
summary table is compounded with the appropriate particle size deposition data where 
applicable for completeness.




15% : 4°C 2.08 (0.06) 2.47 (0.06) 39.07 (0.02) 88.33 (2.39) 79.85(1.90)
20% : 4°C 2.30 (0.19) 2.74 (0.03) 31.20 (0.01) 84.10(1.55) 81.47 (7.35)
15% :37°C 1.67 (0.19) 2.20 (0.03) 49.98 (0.06) 77.41 (6.86) 68.87 (6.11)
20% :37°C 1.96 (0.005) 2.54 (0.001) 37.16(0.61) 76.59 (0.87) 67.66 (0.88)
Table 4.1: Data summary of the major particle parameters generated for salbutamol
maleate solutions over a range of co-solvent levels and equilibration 
temperatures (FPF based on 10 consecutive shots).
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4.7.3 Results and Discussion
4.7.3 (a) Intra-formulation particle size distributions 15% w/w co-solvent 
(salbutamol maleate: hydrophilic salt)
Figure 4.1 graphically illustrates the differences in the delivered particle deposition 
patterns for 15 and 20% w/w solution formulations post equilibration at 4 and 37°C. The 
graph also includes the data generated for a commercially available suspension 
formulation of a hydrophillic salt for comparison to highlight deposition profiles. Data 
statically evaluated by ANOVA with a Tukeys LSD at a p value of 0.95 indicated 
differences on stages 1, 6 and 7. The fine particle fraction increased by about 10% when 
the temperature was increased, but the delivered dose was reduced by about 11% as 
was the emitted. The reduction in emitted dose was about the same when compared to 
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Airomir 15% w/w Salbutamol Sulphate Suspension.
15% w/w co-solvent salbutamol maleate solution equilibrated at 4°C. 
15% w/w co-solvent salbutamol maleate solution equilibrated at 37°C.
■la i —[JuLll
Act Throat Stg 0 Stg 1 Stg 2 Stg 3 Stg 4 Stg 5 Stg 6 Stg TStg filter 
Cascade Stage
Formulation MMAD GSD %FPF % Delivered Dose % Emitted Dose
15% : 4°C 2.08 (0.06) 2.47 (0.06) 39.07 (0.02) 88.33 (2.39) 79.85 (1.90)
15% :37°C 1.67 (0.19) 2.20 (0.03) 49.98 (0.06) 77.41 (6.86) 68.87(6.11)
Figure 4.1: The effect of extremes of temperature on particle size distributions emitted
from a 15% w/w co-solvent salbutamol maleate solution pMDI.
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4.7.3(b) Intra-formulation particle size distributions 20% w/w co-solvent
A similar trend in particle deposition profiles was observed for the 20 % w/w co-solvent 
level of ethanol, see figure 4.2 when compared to that of the 15%w/w (Figure 4.1). The 
data indicated that the solution system produced a finer overall particle size distribution 
over the secondary aerosolisation mechanism stages: a smaller MMAD as compared to 
the suspension counterpart. When evaluated statistically, a similar difference pattern was 
observed as for the 15% solution. Significant differences were observed on the actuator, 
stage 1 and stage 6. The fine particle fraction data indicated an increase of about 6% 
when the temperature was increased, but the delivered dose decreased by about 8%. 
Emitted doses for both formulations also decreaed but this was only 3% when equilibrated 
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Airomir 15% w/w cosolvent salbutamol sulphate SUSPENSIO N.
20%  w/w cosolvent salbutamol maleate solution equilibrated at 4°C. 
20%  w/w co-solvent salbutamol maleate solution equilibrated at 37°C.
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Figure 4.2: The effect of extremes of temperature on particle size distribution on a 20%
w/w co-solvent salbutamol maleate solution pMDI formulation.
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4.7.3(c) Inter-formulation particle size distributions at low temperature
Figure 4.3 depicts the deposition profiles for 15 and 20% w/w co-solvents equilibrated at 
4°C. Formualtions containing a 15 and 20% levels of co-solvents, when measured, 
indicated that there was only 0.5 bar pressure difference (see table 4.0), This can be 
related to the similar trend in fine particle fractions, delivered and emitted dose data. Data 
generated indicated an increase of approximately 8% for the lower co-solvent level 
formulation, with a corresponding increase of about 4% for the delivered dose data. 
Emitted doses differed by only 2%. Statistical analysis (as per previous sections) of the 
data generated indicated significant differences on the actuator and the following cascade 
stages: the throat, 1, 4 and 5.
15% w/w cosolvent salbutamol maleate solution equilibrated at 4°C. 
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Figure 4.3: An inter-formulation comparison of the effect of low temperature
equilibration on particle size distribution.
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4.7.3 (d) Inter-formulation particle size distributions at high temperature
Figure 4.4 graphically represents the data generatd when 15 and 20%w/w co-solvent 
levels were equilibrated at 37°C. Again the deposition profiles follow the same trend for all 
stages. Significant differences in particle size deposition data between these formulations 
were observed on the throat and cascade stages 4, 5, 6 and 7 resepctively.
It should also be noted, that at this temperature very little pressure difference occurred; 
only about 0.2 bar when formulations were comapared. Both the delivered and emitted 












15% w/w cosolvent salbutamol maleate solution equilibrated at 37 C. 
20% w/w cosolvent salbutamol maleate solution equilibrated at 37°C.
nil■■ —
Act Throat Stg 0 Stg 1 Stg 2 Stg 3 Stg 4 Stg 5 Stg 6 Stg 7Stg filter 
Cascade Stage
Formulation MMAD GSD %FPF % Delivered Dose % Emitted Dose
15% :37°C 1.67 (0.19) 2.20 (0.03) 49.98 (0.06) 77.41 (6.86) 68.87 (6.11)
20% :37°C 1.96 (0.005) 2.54 (0.001) 37.16 (0.61) 76.59(0.87) 67.66(0.88)
Figure 4.4: An inter-formulation comparison of the effect of high temperature
equilibration on particle size distribution.
92
4.7.3(e) Effect of co-solvent level and temperature on MMAD.
Figure 4.5 illustrates the data generated for MMAD distributions when both temperature 
and co-solvent levels were varied. Interpretation of the data indicated that temperature, 
vapour pressure, and co-solvent level had a significant effect on MMAD. The MMAD of 
the aerosol cloud tended to increase for higher co-solvent levels and lower temperatures, 
with the novel hydrophilic drug, when inter and intra formulation modes were evaluated 
under test conditions. Statistical significances in MMAD were not observed for the 15 and 
20% formulations at 4°C, but were when permutations of the remaining combinations 
were considered resulting in a value of p=0.001. For the 15% co-solvent level formulation 
(intra-formulation/high temperature) a decrease of 19.7 % in MMAD was observed and for 
the 20% co-solvent level a decrease of 14.5% was calculated. At 4°C, an increase from 
15 to 20% (inter-formulation) in co-solvent levels resulted in a 10.6% increase in MMAD, 
and at 37°C an increase in 17.4% was observed. In general, increasing the co-solvent 
level and decreasing the temperature increased MMAD.
15%@4C 20%@4C 15%@37C 20%@37C
Cosolvent level and Temperature
Component 15% co-solvent 20% co-solvent 15% co-solvent 20% co-solvent
Equilibration Temp / °C 4 4 37 37
MMAD 2.08 (0.06) 2.30 (0.19) 1.67 (0.19) 1.96 (0.001)
Figure 4.5: The effect of co-solvent level and temperature on the resulting MMAD of
aerosol clouds generated form a salbutamol maleate solution pMDI.
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4.7.3(f) The effect of co-solvent level and temperature on GSD
A similar pattern was observed in the amount of polydispersity of the aerosol cloud, when 
the GSD was compared with the MMAD, as depicted by the data in figure 4.6. 
Polydispersity increased with increasing co-solvent level and decreased with increasing 
temperature (the decrease of GSD with increasing temperature occurred when 
considered only for intra formulation comparisons). Statistical evaluation of the data via 
ANOVA at P=0.95 indicated the only conditions that were not significantly different from 
one another were the 15% formulation equilibrated at 4°C and the 20% formulation at 
37°C. When significance was achieved this was at a level of p<0.001 Considering intra 
formulation effects, when the 15% co-solvent level formulation experienced an increase in 
temperature the result was a reduction in cloud polydispersity by about 10.9%; when the 
20% co-solvent formulation was considered the drop was less, with a 7.3% reduction. 
Inter formulation comparisons indicated a similar but reverse trend: an increase in 
polydispersity as both co-solvent level and temperature were increased: an increase of 






15%@4C 20%@4C 15%@37C 20%@37C
Co-solvent level and Equilibration Temperature
Component 15% co-solvent 20% co-solvent 15% co-solvent 20% co-solvent
Equilibration Temp / °C 4 4 37 37
GSD 2.47 (0.06) 2.74 (0.03) 2.20 (0.03) 2.54 (0.001)
Figure 4.6: The effect of co-solvent level and temperature on the resulting GSD of
aerosol clouds generated form a salbutamol maleate solution pMDI
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4.7.3 (g) Effect of co-solvent level and temperature on FPF.
Figure 4.7 illustrated the data generated for the respective fine particle fraction of the 
aerosol cloud when formulations were equilibrated at varying temperatures. When 
analysed statistically, a significant difference between the data sets was established for all 
respective combinations, bar one: the 15% co-solvent level equilibrated at 4°C compared 
with the 20% co-solvent level equilibrated at 37°C, as elucidated by Tukeys LSD. The fine 
particle fraction increased when the temperature was increased for formulations 
compared on an intra-co-solvent level. The greatest fine particle fraction was exhibited by 
the 15% co-solvent formulation equilibrated at 37°C. The change in fine particle fractions, 
for each of the formulations and equilibration conditions, can be directly related to the 
data in the table beneath the graphical representation.










Component 15% co-solvent 20% co-solvent 15% co-solvent 20% co-solvent
Equilibration Temp / °C 4 4 37 37
% FPF 39.07 (0.02) 31.20 (0.01) 49.98 (0.06) 37.16(0.61)
Figure 4.7: The effect of co-solvent level and temperature on the resulting fine particle
dose of aerosol clouds generated form a salbutamol maleate solution pMDI.
20% w/w cosolvent equilibrated at 4°C. 
15% w/w cosolvent equilibrated at 37°C. 
20% w/w cosolvent equilibrated at 37°CI
Cosolvent Level and Temperature
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4.7.3(h) The effect of co-solvent level and equilibration temperature on the Large
Particle Fraction (LPF).
Figure 4.8 illustrated the change in the large particle fractions of the formulations. In 
general, a trend occurred for identical co-solvent levels: the actuator deposition increased 
with temperature, (about 1.5%) but the throat deposition decreased (about 3%). When 
compared on an inter formulation and temperature equilibration mode throat deposition 
increased with cosolvent level increase (about 9%) at 4°C and 37°C, but there was no 
discernable trend in actuator deposition. Significant differences were detected in 
deposition for the following combinations: 15% w/w 4°C and 20% w/w 37°C; 20% w/w 4°C 
and 15%w/w 37°C; and 10%w/w 4°C and 20% w/w 4°C and 20% w/w 37°C at alevel of p= 
0.005. For throat depositions, significance at a level of p=0.001 was achieved for all 










15 % @ 4 C  2 0 % @ 4 C  15 % @ 37 C  2 0 % @ 3 7 C
% Deposition 15% : 4°C 20% : 4°C 15%: 37°C 20%: 37°C
Actuator 9.56 (0.69) 8.89(1.10) 11.03 (0.43) 11.58 (0.43)
Throat 50.43(1.51) 59.71 (2.56) 47.22 (0.85) 56.14(0.76)
Figure 4.8: The effect of co-solvent level and temperature on the actuator and throat




The andersen cascade deposition patterns for both the 15 and 20% cosolvent level 
salbutamol maleate formulations displayed a similar trend irrespective of the temperature 
of equilibration, and statistical significances are delinetaed where appropriate. To 
elucidate why these differences occurred, other critical parameters must be investigated: 
the MMAD and the GSD.
MMAD data generated both differed from and conversely agreed with those in the 
literature. Data generated by Gupta (Gupta et al 2003) predicted a mass mean 
aerodynamic particle size of about 1.2-1.3pm (taken from data extrapolation) for BDP 
solution formulations at co-solvent levels of 15 and 20%; whilst the MMAD increased 
slightly with co-solvent concentration, and it was highly dependent upon solute 
concentration. However, in this study an Andersen cascade was not utilised, instead a 
3320 APS (TSI Inc. Shoreview, MN) attached to a USP throat via a 20cm extension tube 
coupling was chosen. Data from these studies may be open to validation and scrutiny, as 
no calibration was indicated on the optical system, although this may have been 
performed. (Particle refractive indices should be verified under both dry and solvent laden 
"wet conditions, as evaporation will take place during experimentation). The use of a 
standard USP throat would also not compensate for changes to, and the amortisation of 
differing equipment. Further, adding an extension tube may add to particle evaporation 
times as the coupling tube may act as a spacer. Finally all experimentation is assumed to 
be carried out at ambient conditions again this was not documented and could not be 
verified.
Documented MMAD’s generated in this study ranged from 1.67pm to 2.30pm 
respectively. For equivalent co-solvent levels to that of the Gupta et al study, non-volatile 
concentrations would facilitate a drug loading of 0.4% w/w or greater in the final 
formulation,approximately double that here. Extended comparisons of the data indicated 
other differences: throat depositions in the Gupta et al study were less than those in this 
thesis. Namely depositions for the 20% w/w BDP solutions equated to those of the 
equivalent 15% w/w hydrophilic maleate salt, and those of the 20% w/w co-solvent level 
maleate salt formulation were not equitable on the corresponding graphical 
representation. Also the fine particle fractions were different. The 15% w/w hydrophilic 
maleate salt formulation gave a respirable fraction equivalent to a 10% BDP solution
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formulation. Likewise a 20% w/w hydrophilic maleate formulation gave an equivalent 
respirable fraction to a 15% w/w BDP solution formulation.
However, these data do follow a similar trend to those observed by Brambilla and co­
workers (Brambilla et al 1999). They indicated a range of MMAD measurements between 
1.1pm to 1.8pm for co-solvent levels of 15% w/w and drug loadings of 0.085% w/w to 
0.424% w/w for identical actuator orifice diameters, when formulated as BDP solutions. It 
should be noted that the actuators from all studies were different thus would have 
different airflow geometries.
Both of these studies indicated that MMAD increased with non-volatile component and 
was not significantly affected by co-solvent level; although, both noted there was a slight 
increase, with increased co-solvent level. Data presented by Lewis (Lewis et al 2004). 
regarding co-solvent concentrations and the effect on particle size indicated a high p 
value (0.086), but was not far from significance. Both of these studies were conducted at 
ambient inhaler temperature, and while ambient temperature was assumed, neither study 
indicated a laboratory temperature. In this study, temperature equilibration significantly 
changed the vapour pressure, which significantly altered actuator deposition, throat 
deposition, the MMAD and GSD. The added effect of the co-solvent further increased the 
aforementioned effects, and also had an impact on the fine particle dose. Interestingly, an 
increase in spray orifice diameter had the effect of increasing MMAD, whilst decreasing 
FPD.
The change in MMAD can be equated to the overall changes in vapour pressure, surface 
tension and viscosity as a result of temperature change. At low temperature the surface 
tension and viscosity of the formulation all increase. And a liquid drop will remain intact as 
long as the fluctuations, which occur in air pressure around the drop surface, are 
compensated by surface tension. Surface tension forces resist expansion of a liquid 
surface, and to achieve atomization those of the aerodynamic, centrifugal, or pressure 
forces must supersede them. At low temperature, the former will this resist change to a 
greater degree. Intuitively, therefore, the increase in surface tension resists the 
deformation forces.
Liquid viscosity opposes the deformation because aerosol breakup time increases. 
Viscosity also has a marked effect on liquid velocity, namely nozzle flow rate decreases, 
as does the Reynolds number hindering jet instabilities. As the formulation exists the 
actuator thickening the jet occurs raising the flow area delaying disintegration and
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increasing drop size. At high viscosities energy losses are greater and less energy is 
available for atomization. (Lefebvre 1989).
As liquid jet disintegration and conversion into droplet atomisation is proportional to liquid 
velocity, and volumetric flow rate is inversely proportional to the square root of liquid 
density, then the effects of temperature and thus density are important. (Weber 1931) 
(See equations in appendix A 4.0). There is a substantial change in the densities of the 
major volatile propellant: 1282kgm'3 at 4°C and 1160kgm'3 at 37°C. In conjunction at high 
viscosities the Reynolds number is lower and so turbulence on the droplets is therefore 
less, equating to less inertia and, so, reduced particle breakup
The rate of particle evaporation also changes due to changes in the liquid phase. Within 
an array of multicomponent aerosol droplets the more volatile component will vaporise 
faster leaving the less volatile component; in effect mini distillation occurs. It has been 
proposed that micro-explosions equivalent to flash evaporation take place (Landis and 
Mills 1974). Thermodynamically, the enthalpy of the liquid mixture is reduced at lower 
temperatures. Consequently, the heat capacity of the individual droplets within the aerosol 
cloud also changed and are lower at constant ambient pressure.
Intuitively, a low enthalpy value equates to a low internal energy, therefore reduced 
evaporation takes place at reduced liquid temperatures. Ethanol has greater heat capacity 
and enthalpy values compared to the propellant, and its increase in concentration in this 
respect, explains the increased time for evaporation and therefore size change.
Significant changes in aerosol polydispersity (over all combinations) were noted at both 
fifteen and twenty percent co-solvent levels, and the degree of cloud particle size 
dispersion increased for a given co-solvent level and decreased as the temperature was 
increased. A trend was noted here, as with the MMAD, that the 15% formulation at 4°C 
was similar in value to that of the 20% formulation at 37°C. The wide range of particle size 
distributions that occured within the aerosol clouds may be due to droplet-droplet 
interactions within the cloud and droplet gas flow interactions. As isolated droplets come 
close to each other, drops can influence particles several radii away and can even impact 
on each other and coalesce. Alternatively, many other particles may emerge from the 
collision. This tends to occur at higher co-solvent levels and consequently higher surface 
tension and viscosity levels. Indeed coalescence has been implicated as an important 
factor at the injector orifice in petrol engines. The theory predicts increasing average 
droplet size increases downstream from the injector / orifice, which corresponds with the
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data generated here. Although different intrinsic physicochemical data were implicated for 
the petrol injector, basic principles apply to both systems (O’Rourke and Bracco 1980). 
One possible reason for the increase in actuator deposition at high temperature may be 
due to the reduction in surface tension and so increased wetting of droplets and final 
droplet-droplet coalescence. The increased wetting my also account for particle stick to 
such a low surface energy material as polypropylene from which the actuator is made.
As the level of co-solvent rises and the temperature drops, the vapour pressure of a liquid 
droplet is lower, surface tension is greater, viscosity is greater and the temperature 
gradient between the drop and surrounding air is also increased. As indicated, these will 
influence the ambient gas temperature, particle momentum and vaporization by heat and 
mass transfer. Other possible mechanisms may occur whereby at smaller droplets 
vaporise faster leaving the larger droplets, condensation occurs in the colder vapour rich 
regions of the spray near to the spray orifice and the longer wavelength disturbances on 
the jet will take longer to grow and yield larger droplets.
Droplet collisions, primarily two droplets as probability of three droplet collisions are low, 
can lead to several permutations of interaction: permanent droplet-droplet coalescence, 
initial coalescence and separation, separation into two other daughter droplets, separation 
into smaller satellite droplets particle bounce and shatter. Several studies regarding two 
droplet collisions have been made. Qian and Law (1997) distinguished between five 
distinct regions of droplet collisions by plotting the Weber number against the impact 
parameter (the shortest distance given by tangents to the direction of motion at the time of 
impact). Essentially at small impact parameters and increasing Weber number 
coalescence is followed by bounce and followed by coalescence again. This is a 
simplified explanation of a complex phenomenon but helps to explain changes in MMAD 
and polydispersity.
4.8 Current Semi-Empirical Methods to Predict MMAD’s of pMDI’s.
The major parameters that describe an aerosol cloud for medicinal purposes are MMAD, 
GSD, LPD, FPD and the distribution pattern indicated by the stage-by-stage delineation 
and the corresponding cumulative distribution. At present, the physical processes that 
result from atomisation of an aerosol cloud are insufficiently appreciated so that the 
derivation of particle size distributions from basic equations has been limited, and not 
wholly applicable to HFA systems. It would be advantageous to be able to predict the
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MMAD and GSD of a therapeutic aerosol as these parameters have been routinely 
utilised to correlate to the specific therapeutic area. (Stalhofen et al 1989)
From the data collected, it was apparent that the criteria necessary to describe particle 
size from the solution system were dependent upon the non-volatile formulation 
components (drug: salt), low volatile formulation components (ethanol), volatile 
formulation components (134(a)) and pressure (as a function of temperature) of the 
system. However, the literature has indicated that the presence of excipients, and 
changes in physicochemical nature (surface tension, viscosity) and thermodynamics were 
also fundamental to the atomization process (Brambilla et al 1999). Consideration of all 
these processes, allows supports the derivation of an expression to determine the 
equilibrium particle size emitted from a pressurized solution system, analogous to that 
evaluated by Clark and Lewis. (Clark 1996; Lewis et al 2004). Empirical equations exist 
for calculating the MMD, SMD and percentile sizes of particles generated from plain 
orifice atomizers, and it was theorised from the data generated that the MMAD could be 
predicted from empirical equations. However most of the research has been carried out 
on compression ignition engines. The fundamental properties and characteristics of such 
systems that were incorporated to describe the MMAD generated included the following: 
the vapour pressure, actuator orifice diameter, surface tension and the viscosity of non­
volatile and semi-volatile components (Harmon 1955, Giffen and Lamb 1953 Elkotb 
1982).
4.8.1 Derivation of an equation to predict MMAD’s generated from solution based 
pressurized metered dose inhalers.
The derivation of an equation providing a complete description of a multicomponent liquid 
droplet is beset with complications dependent upon the different vaporization rates of the 
components, resulting concentration gradients within the liquid, constant changes of mass 
and heat diffusion rates, to name a few of the multitude of variables.
Consider the liquid particle, its composition can be expressed as the number of moles of 
the individual species where,
W
(g)X m = ------------ Equation 4.3
RM M
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The number of moles of component is Xm, W (g) is the weight of component in grams and 
the relative molecular mass RMM is in grams per mole.
The mole fraction of a species say Mf(a) (active solid) in a quarternary mixture of (a) 
active, (e) (ethanol), water (w) and v (volatile component 134(a)) is then ,
Moles
M f (a\= ------------------------------------------------------------- Equation 4.4
Moles Moles Moles  ^Moles (water^
The relationship between the non-and semi-volatile with the energetic volatile component 
can be described as a ratio between the two, with the universal gas constant utilised to 
mediate for changing temperatures, volumes and energy distributions of the molecular 
components parameters, as depicted in equation 4.5.
{{M f {a)-R .\M f {e)-R \M f(water)R))
----------------------------------------------------------------- Equation 4.5
M f  {v)‘R
As surface tension and viscosity are important parameters in droplet kinetics and 
thermodynamics these have been incorporated into the final equation. The surface 
tension as stated is important in the calculation of the Weber number of the droplets and 
the viscosity in the calculation of the Reynolds number. These variables along with the 
diameter of the spray orifice yielded equation 4.7 to predict the MMAD.




l ( v )
rt{ae)
x d 0 = M MAD Equation4.6
Where, P{atmos) is the ambient atmospheric pressure, P(system) is the pressure of the 
pMDI at specified temperature, Mf(a\(e),{v) are the mole fractions of the (a) active the 
non volatile component, (e) ethanol, the semi volatile component, and (v) 134(a) the 
volatile component. R is the gas constant, o(ae),(v) are the tensions of the active ethanol 
mixtures and the surface tension of the volatile component at a specified temperature and 
finally, 77(02), (v) are the viscosity of the active ethanol mixtures and of the volatile 
component at a specified temperature.The equation, to fit the data, also had a constant x, 
which equated to values of 0.5 at 4°C and 3.5 at 37°C respectively. Table 4.2 indicates
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the values utilised in the calculations of viscosities and surface tensions of ethanol/134(a) 
mixtures used in the solution formulations.
Table 4.3 illustrates both the actual experimental MMAD data generated and the 
corresponding theoretically predicted MMAD’s from the semi-empirical equation 4.6.
Temp°C Viscosity / kgS'2 Surface Tension / Nm'1
Ethanol 134(a) Ethanol 134(a)
0 1.77E-03 2.73E-04 2.41 E-02 1.15E-02
20 1.20E-03 2.11E-04 2.24E-02 8.69E-03
40 8.34E-04 1.62E-04 2.07E-02 6.06E-03
Table 4.2: Thermochemical data utilised in theoretical particle size calculations.
(Data for propellant 134(a) was taken from the Solvay Fluor data sheet 2005 and for
ethanol from the Efunda (engineering fundamentals) web site 2005)
Co-solvent level / Temp/ Active Predicted Actual %





















Table 4.3: The predicted MMAD of solution based metered dose formulation containing
a novel salt utilising equation 4.7 and experimental studies.
Predicted MMAD’s were calculated from equation 4.7 using vapour pressure data 
evaluated from placebo formulations, with theory and practice correlating well with only 
minor deviations. However, to fully validate the particle size distributions proposed by 
equation 4.7 then a range of formulations at varying temperatures would need to be 
analysed and data reviewed with the equation. These would include several actives, co­
solvent levels and spray orifice diameters as all variables are predicted to change the 
particle size distribution of the clouds.
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4.8.2 Evaluation of the Geometric Standard Deviation.
Determination for a value of the GSD of the particle size of an aerosol cloud would be 
invaluable in the calculation of the fine particle fraction emitted from a metered dose 
inhaler as 95% of an aerosol cloud lies within the range of In MMAD ±2 In GSD. Therefore 
amalgamation of both the MMAD and GSD may allow calculation of the therapeutic 
fraction emitted from the inhaler. The values for the GSD could be related relatively simply 
as the GSD was 1.19 times the GSD at 4°C and about 1.31 times the MMAD at 37°C. 
Further it was found that a simple relationship resulted between the key parameters and 
the fine particle fraction: the product of the MMAD and GSD when plotted against the fine 
particle fraction approximated to a linear relationship (R2 = 0.95 line of best fit)
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•  Experimental data.














Product of MMAD and GSD.
Figure 4.9: A graphical illustration of the relationship between MM AD, GSD and Fine
Particei Fraction.
4.8.3 Conclusion
In conclusion, this chapter has evaluated the effect of formulation variables on particle 
size distribution and associated particle characteristics. Temperature and thus pressure 
together with concentration changes in co-solvent had a major impact on inhaler output. 
From these results, an empirical relationship was produced effectively calculating the 
equilibrium MMAD (as a function of the principle physicochemical properties of the 
components of the formulation) and the resulting GSD values. One caveat associated
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with the data relates to the surface tension and viscosity values utilised in the 
calculations. Idealised values at 0, 20 and 40°C were utilised in calculations, as specific 
data for ethanol and 134(a) were not available.
These results challenge current data. Also, if such major effects are observed at ambient 
conditions then evaluation under in-vivo simulations and the effect of drug character 
warrant further evaluation.
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5 THE EFFECTS OF ENVIRONMENTAL CONDITIONS ON THE 
AEROSOL CHARACTERISTICS OF NOVEL SOLUTION PMDI’S
5.1 Introduction
It has been postulated from experimental investigations that the environment of the 
respiratory tract can influence the fate of inhaled aerosol particles (Morrow 1986). In-vitro 
experimentation substantiates theory, as the measured deposition patterns resulting from 
aerosol generation indicate changes in particle size fractions and polydispersity 
dependent upon the physicochemical composition of the cloud and the ensuing 
thermodynamic and kinetic interactions with the testing environment. The human lung 
creates an essentially warm and humid environment, however, the complexity of the 
system renders it practically impossible to quantitate and map the localized temperature 
and humidity profiles present throughout. In fact, it has been shown, the actual 
temperature and humidity profiles that ensue depend on the route of the passage of air; 
for example, differences on the aforementioned profiles have been established depending 
on whether the air has been pre-conditioned by nasal or oral breathing (Proctor and Swift 
1977; and Martonen et al 1993).
Changes within the chemical composition of the formulation, both active and excipients, 
can either accentuate or negate the environmental effects in the presence of varying 
degrees of water vapour. Indeed, many pharmaceutical preparations have been shown to 
be hygroscopic in nature, and strongly interact with water vapour present (Hickey and 
Martonen 1993). Thus, upon interaction of an aerosol particle with the environmental 
water vapour, particles may change in size, shape and density. As a result, particle 
deposition both in terms of mass and specific location may be markedly different to 
conventional estimates (Ferron 1977).
In this thesis, the term thermodynamic environment is used rather than hygroscopicity per 
se, although they have been previously used interchangeably. The rationale for this 
approach is that hygroscopicity implies growth primarily from the absorption of water and 
does not consider the effects of condensation and vapour pressure. Rather than growth, 
particle size retardation may occur via suppression of the evaporation of volatile 
components from an effective increase in localised vapour pressure.
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Independent of the counter-balanced argument between environment or hygroscopicity, 
the delivery of pharmacologic drugs into environments, which differ from those of ambient 
temperature (approx. 20-25°C) and relative humidity (30-65%) has received attention from 
several sources of research (Eisner et al 1990, Ferron and Soderholm 1990, Martonen 
1990, Soderholm and Ferron 1992) and alternative associated applications. (Ferron et al 
1989, Martonen at al 1989, Martonen et al 1993, Soderholm et al 1991 and Ferron et al 
1993).
The implications from the effects of the thermodynamic environment on the fate of aerosol 
particles are therefore fundamental to their final location site in the lung, residence time at 
receptor and the eventual translation into clinical efficacy. Further, the primary technique 
of administration is also an important factor in the overall deposition (namely whether 
aqueous based from a nebuliser, delivered from a dry powder system or generated from a 
pressurized propellant multi-component device, and, also whether the incorporation of 
ancillary spacers or holding chambers are utilised).
5.2 Overview of the Thermodynamic Properties of Inhaled Aerosol 
Particles
5.2.1 Present Theoretical models: A brief review
Ferron expounded some of the first treatises on the phenomenon of hygroscopicity. The 
theory developed by Ferron (Ferron 1977) and expanded by co-workers assumed that 
aerosol particles reached equilibrium within a short time after inhalation, and, that, 
equilibrium conditions were defined as those when the temperature and water vapour 
concentrations of the lung environment were the same as at the surface of the particle. 
The theory is based upon Raoult’s law derived water vapour concentration present at the 
surface of a salt solution as ratio to that of pure water, including the dissociation of the salt 
into individual ions, associated water molecules and their respective molecular masses. 
The pressure exerted by a curved surface is greater than that of a flat surface, and this is 






Where Deq(a),(i) are the equivalent diameters of the particle in air and the dry particle, 
p{a),{i) are the densities of the particle and the initial dry particle, M(s),(w) are the 
molecular weights of the solid and water respectively and i,j,Rw9H  are the number of 
ions which the salt dissociates into, the number of water molecules per salt molecule, the 
vapour pressure of a curved surface and the relative humidity respectively.
This approach has been used in several studies, however, they all pertain to dry or 
aqueous base systems (Groom 1981 Hickey et al 1990). In fact, most studies used 
inorganic salts and their solutions as model compounds during experimental studies, and 
only a few have utilised actual drug formulations, presumably as this was because of their 
implications as atmospheric pollutants (Ferron 1977, Ferron et al 1988, Steele and Hamill 
1981, Cocks and Fernando, Haenel and Zankl 1979).
The main assumption of the theory was that particles which enter a humid environment 
(the respiratory tract) of certain sizes reach equilibrium within certain time-frames: those 
smaller than 0.2pm equilibrated within 1 second, 1.0pm particles equilibrated within 2 
seconds and larger particles would not equilibrate within one respiratory cycle. This also 
assumed that the complex dynamics that occur between particles, such as fluid flow 
(boundaries and wakes) and mass and heat transfer are effectively uncoupled or ignored.
5.2.2 Improved theoretical models.
Many of the improvements to the original theory described have been based on fluid 
dynamics and associated computational methods. Many thorough treatises on sprays 
have been based on other non-therapeutic aerosols, namely those pertaining to 
combustion of fuels and metal slurries, and although not essentially similar in terms of 
formulation principles of heat and mass transfer apply (Sirignano 1999). To further 
complicate the application of theoretical models, in-vivo flow fields through the lung are 
turbulent and unsteady (Martonen et al 1993); but the newer theoretical models do 
incorporate the aforementioned heat and mass transfer effects into the governing 
equations. However, the theory holds only for saline solutions and essentially calculates 
the number of moles of water that constitute a droplet and how mass transfer of 
environmental particles (water vapour) cross the boundary layer (the layer of water 
molecules on the particle surface). Interestingly, the results from calculations indicated
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that the mass heat transfer coefficients affect the rate of equilibration and not the particle 
size.
5.2.3 Experimental investigations of environmental influences on aerosol 
behaviour: An overview of laboratory systems
Particle size changes (specifically growth ratios of the MMAD’s) of aerosolised 
medicaments as a function of both temperature and relative humidity have been 
documented in the literature (See appendix A 5.0). It is, thus, imperative that the 
environmental conditions of the model used and experimental system during aerosol 
experiments need to be tightly controlled and monitored throughout such investigations. 
Several in-vitro methodologies are cited in the literature in relation to temperature and 
humidity controlled apparatus (Hiller et al 1980, Halbert et al 1982, Bell and Ho 1981, 
Tang et al 1977, and Hickey et al 1988).
The system developed by Hickey et al. (based on the original concept of Groom et al., 
1981), involved the use of two independent controls: one to heat and humidify the air, and 
secondly to control the temperature of the system. The apparatus was surrounded by a 
Va thick expanded polystyrene structure to provide insulation from the surrounding 
environment, thus providing dual control of the conditions. A further rationale for this type 
of approach was that if adjustments were made to one part of the system the isothermal 
equilibrium of the other was not disturbed. The apparatus also consisted of a 7.85L 
equilibrium chamber, which retained the aerosol particles for up to 40s, thus providing an 
‘adequate time’ interval for aerosol “growth”. The air supplied through the system was 
also partially diverted and sampled to accurately determine the concentration of the water 
vapour (the % relative humidity (%RH)). All other usual practices were undertaken during 
temperature and humidity control; for example the supply and use of clean filtered air, 
continually monitored of flow rates via calibrated rotameters and adequate equilibration 
time post experiment to ensure isothermal contact. Other cited references (Hiller, Halbert 
and Bell) have employed climatically controlled cabinets, which accommodated control of 
the intake air by direct heating and humidification by using saturated salt solutions. All 
these controlled airflow studies conditioned the aerosol particles generated for extended 
periods e.g. Hiller for 30s and Tang for 20s.
The problem with such long residence times is that even with adequate training in breath 
holding procedures rarely exceed five seconds, and even upon following patient 
information leaflets will reach ten seconds. The only experimental apparatus, which
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monitored short-term equilibration between the aerosol cloud generated and local 
environment was that of Bell and Ho with times ranging from 0.05s -1s (Bell and Ho 
1981).
5.2.4 Experimental Set-up: In-vitro environmental control in this study
Based on equipment set-up and procedures previously described, it was decided to take 
a pragmatic approach to environmental control. Clearly accurate and precise 
measurement and isothermal control of the system were pre-requisite, but an exact mimic 
of the temperature and humidity profiles of mammalian physiology was not. It was 
decided, therefore, in this study to attain a wide range of temperatures both ambient (lab 
approx. 25°C) and high (body approx. 37°C) coupled with accurate measurement of 
relative humidity within a simply engineering scheme. It is true that the absolute water 
content of air varies with temperature but this was negligible when considered at the limits 
of temperature measurement: in the region of ± 0.1 °C. Aerosol residence time was not 
increased by the use of holding chambers or spacers, and the aerosol was allowed to 
transition in "real time” namely it was not interfered with post actuation of the pMDI. This 
was performed in an attempt to simulate actual patient compliance and reduce the 
artificial growth that may have occurred in previous studies. Several studies have 
monitored particle growth in real time but have utilised light scattering methods (Martonen 
1990 and Hiller et al 1980). The following sections detail actual experimental procedures 
and practices.
5.3 Methods and Materials
5.3.1 (a) Control of high temperature and high humidity testing conditions.
All of the recognised temperature and humidity-controlled apparatus cited in the literature 
have encased equipment in isothermal conditions usually via a controlled cabinet, as it is 
imperative that the system is in thermal and hygroscopic equilibrium. The importance of 
keeping the equipment in equilibrium has been previously elaborated upon (Finlay and 
Stapleton 1999) and has been incorporated into this study. Isothermal control was 
accomplished by use of a ‘walk-in’, insulated and externally temperature controlled 
stability cabinet situated at the University of Bath (Department of Pharmacy and 
Pharmacology). A schematic of the equipment is shown in figure 5.0.
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Figure 5.0: A schematic of the temperature and humidity experimental system sampling
of novel experimental pMDI formulations.
Temperature control was accomplished externally and was monitored and recorded 
internally and the measurement verified using both a mercury in glass thermometer, 
(Fisons UK,) and also a dual temperature and hygrometer device (Digitron R 200, 
Digitron, Devon, UK.) to ascertain both the temperature of the air and that of the water in 
the humidifiers. Air was drawn into the apparatus from the room and the flow-rate 
monitored by a calibrated flow meter (Glass Precision Engineering, Hemel Hempstead UK 
indicated in the legend as 1). This was then passed through a 0.2pm filter (Pall, Ann 
Arbour, Michigan 2) and then subsequently passed into two bubble humidifiers (3), which 
contained de-ionised temperature equilibrated MilliQ grade water, the temperatures of 
which were checked prior to experiment. The humidified air then passed through a 
modified actuator (Norton Healthcare, Waterford, Ireland) (4) containing a canister of the 
model formulation. The warmed and humidified air was then drawn through an Andersen 
Cascade Impactor (Copley Instruments, Nottingham,UK 6) via a vacuum pump (Gast, UK 
7) at 28L/min ± 5%. The apparatus was set up in the stability cabinet and left for a 
minimum of 72 hours to achieve thermal equilibrium. Readings were taken with a 
calibrated thermometer to verify equilibration and both digital temperature recorder and 
the glass thermometer agreed to within ± 0.1 °C. The temperature and humidity of the air 
entering the actuator at the point of the spray orifice was also monitored throughout the 
experimental studies. The vacuum pump was set in operation for a minimum of 5 seconds 
prior to the actuation of the canister as part of a ‘dummy-run’ procedure to ensure no dew 
point condensation on the equipment. The delivery tubes of the equipment showed no 
signs of dew, and as a final check the cascade impactor was dismantled and found to be
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dry. The canister prior to experiment was kept at ambient temperature and inserted into 
the actuator just before being actuated, consecutively, 10 times, and the aerosol 
generated was collected on the stages of the Andersen cascade impactor. During transfer 
from ambient conditions to the environmental test condition, the canister was placed in a 
custom made polystyrene insulating block to reduce heat transfer to the formulation. The 
analysis was performed as swiftly as possible, within one minute of set up, so as to 
maintain the ambient vapour pressure of the formulation and restrain the formulation from 
reaching thermal equilibrium with the environment, as an increase in temperature would 
inevitably increase the vapour pressure of the formulation. The actuator, induction port 
and stages were washed down with methanol whilst in the isothermally controlled 
environment, and were never removed from it during the study; this ensured isothermal 
equilibrium was never compromised. The apparatus was then left to dry in the isothermal 
system and reassembled after a period of 30 minutes, which was the approximate time for 
chemical analysis of the stages. The whole procedure was repeated three times for each 
formulation and testing environment combination. For low humidity high temperature 
conditions the bubble humidifiers were removed from the set up and the relative humidity 
of the cabinet used as low humidity environment.
5.3.1(b) Control of low temperature and high humidity testing conditions
The same procedure, as outlined above, was repeated for the determination of particle 
size character at low (ambient) temperature conditions. However, in these studies the 
equipment was equilibrated at ambient laboratory conditions. Again the water and air 
temperatures were monitored and experimentation occurred when there was a difference 
of ±0.1 °C between calibrated mercury in glass and digital thermometers. The flow rate 
and humidity were determined as described above.
5.3.1 (c) Rationale for use of experimental humidity testing conditions
Humidity controls in previously cited studies were achieved via the use of saturated 
solutions of various salts. The activity of a solution (a description of the vapour pressure) 
changes with the nature of the salt employed, and is predominately independent of 
temperature (Robinson and Stokes 1959). Potassium Dichromate has been routinely 
used as a saturated solution of this salt gives an equilibrium vapour pressure of 98% of 
pure water (Handbook of Chemistry and Physics). Depending on the humidity required 
other salts are known to provide specific relative humidities (Davis and Bubb 1978, Hicks
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and Megaw 1985, Martonen et al 1982). In this study water was utilised to provide a 
relative humidity of 100% at the testing temperature, as the objective was to determine 
the effect of humidity on an aerosolised formulation over a range of environmental 
conditions, not to mimic exact in-vivo conditions. A second valid rationale for the use of 
water only was that the humidity in the subglottic area has been suggested to be between 
99-99.8%. (Porstendorfer 1971).
5 .3 .1(d) Hardware modification: Design changes to the actuator.
The actuator used in this study was a modified from a salamol inhaler (Baker Norton, 
Waterford, Ireland) with a 0.33 mm spray orifice diameter. As airflow was externally 
acquired, from a controlled source, to mimic “’inspired” air, several modifications were 
made to the actuator: the open end of the actuator was sealed from the atmosphere by 
covering with a pliable nitrile rubber covering. Secondary sealing of the actuator, from the 
environment, was achieved by sealing with parafilm. This modification also allowed 
depression and return, ‘full travel’ of the valve stem in the lower frustrum of the actuator. 
Air was drawn through the actuator through holes drilled into the sides of the actuator, 
and subsequently connected with plastic tube connector fittings, sealed with a silicone 
polymer. The sealant was allowed to dry and set for 24 hours before use. A diagram of 





Figure 5.1: A diagram of the modified Salamol (Baker Norton) actuator used in the study.
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5.3.1 (e) DataGeneration and Device performance
As per chapter 4, similar methodology was adopted when capturing aerosol particle size 
data. Namely, 10 consecutive actuations from the same device were performed after 2 
priming shots had been taken. The units produced were formulated so that the same 
canister could be utilised for all 12-aerosol experiments, in order to reduce variability. 
Tables 5.0-5.4 describe the critical aerosol particle size characteristics: the MMAD, GSD, 
large particle deposition patterns (namely the actuator and throat depositions), and 
environmental conditions recorded during experimentation, and both the delivered and 
emitted dose data are depicted in tables 5.5 and 5.6, for the maleate and oleate salts 
respectively. Table 5.7 depicts complementary information detailing the composition of 
the ctual formulations and the theoretical emitted dose.
5.4 Results and Discussion
5.4.1 Introduction
The following aerodynamic data illustrated the in-vitro measurements from the coupled 
temperature and humidity study matrices. To study the effect of hygroscopicity on aerosol 
cloud distribution patterns, novel hydrophilic and hydrophobic salbutamol salts were 
synthesised and formulated as solution based systems, with a minimum mass of ethanol 
to attain short term stability (See Appendix chapter 3 tables A 3.1(c-e)). Solution systems 
were chosen in preference to suspension formulations for the following studies as particle 
size changes could be accurately related to the environment since every particle in a 
solution aerosol cloud would contain drug. This would allow an accurate and precise 
description of cloud dynamics in terms of mass and heat transfer effects due to 
condensation, particle evaporation and interaction with surrounding environment 
potenetially resulting in hygroscopic growth or droplet suppression from vapour pressure 
effects (Lange and Finlay 2000).
The differences in molecular masses of the derivatives and the subsequent delivered and 
emitted doses from the inhaler were based on the dose currently utilised in clinical 
practice: salbutamol base, 100 jug per actuated dose, again similar to the experimental 
rationale in chapter 4. Data were systematically evaluated by considering the direct 
influence of each environmental variable sequentially, with all data percentage 
normalised. To clarify, deposition was performed by investigating one variable at a time
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keeping the other variable constant for both salts. Then the primary particle 
characteristics were evaluated: the MMAD, GSD, LPF (Large Particle Fractionin terms of 
actuator and throat deposition) and the FPF (Fine Particle Fraction). Finally, salt 
deposition patterns were directly compared and normalised.
5.4.2 Primary and secondary mechanisms of particle formation and associated 
aerosol fractions: A brief summary of definitions
As previously discussed in chapter 4, both the primary and secondary aerosolisation 
mechanisms were dependent upon the formulation, hardware variables, and the shape 
and oscillation of the liquid stream. Although fully described in the previous chapter what 
follows is a brief set of criteria used in the description of data generated. The critical 
Weber number indicates the demarcation of the division between primary and secondary 
mechanisms of atomisation. At a high critical Weber number, aerodynamic forces 
predominate over viscous forces and the particle may undergo further subdivision into 
satellite droplets. If the sizes of the droplets produced exceed the critical Weber number 
these may be subject to a similar fate and divide also. This describes the secondary 
mechanism of particle production. If, however, the aerosol droplet/particle aerosdynamic 
size does not exceed the critical Weber number (Wecr) it will, in theory, remain unchanged 
in dimension and contine along within the airstream. In this study, primary aerosol 
deposition is postulated to occur at the spray orifice and is described hereafter as the 
patterns associated at the actuator, throat and the non-respirable particle fractions namely 
those on stages 0 and 1 (This it should be noted is not strictly true as secondary 
atomization may occur throughout these stages, but this is assumed to simplify the 
process and evaluate the data). For those that do exceed the critical size and do not 
impact on the higher stages (equivalent to the upper respiratory tract) of the apparatus, 
but travel to the lower stages (equivalent to the respirable or lower stages of the 
respiratory tract), undergo secondary atomisation.
Secondary aerosol atomisation, as generalised for this study, can be related to the fine 
particle or respirable fraction of the aerosol designated by stages 2 to the filter stage. It is 
true to say, and important to note here, that, a particle produced from the primary 
atomisation process may account for drug deposition in the respirable phase: from 
atomisation traverse the apparatus at under the prescribed environment to the lower 
stages.
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In the studies that follow, however, the effective temperature, pressure and viscosity of the 
environments will change accordingly, which will influence the Weber number and aerosol 
characteristics. Because the environment around a particle is not exactly known at any 
one time only “’average” particle size distributions can be described, as such changes in 
stage mass and particle distribution shifts can be utilised to provide inferences the effects 
of environmental conditions on atomisation.
5.4.3 Tabulated Data Summaries
Tables 5.0-5.4 describe the data generated, normalized where appropriate and 
summarised relating to the matrix of aerosol experiments for both hydrophilic and 
hydrophobic salbutamol salts formulated as solution based pressurized metered dose 
inhalers. Table 5.0 summarises the aerosol clouds mass median aerodynamic particle 




Maleate (SD) Oleate (SD) Maleate (SD) Oleate (SD)
LT:LRH 1.48 0.09 1.27 0.24 2.46 0.37 2.63 0.11
LT:HRH 1.35 0.10 1.42 0.20 2.74 0.06 3.10 0.15
HT:LRH 1.11 0.22 0.87 0.08 2.30 0.42 3.69 1.81
HT:HRH 1.21 0.15 1.13 0.14 2.20 0.13 3.20 0.63
Table 5.0: The effective mass mean aerodynamic sizes and cloud polydispersity of
hydrophilic (maleate) and hydrophobic (oleate) salbutamol aerosol 
formulations at 10% w/w ethanol levels
Table 5.1 summarises, succinctly, the critical parameter data into a format that enabled 
interpretation in fundamental terms, when conjugated with the appropriate graphical data, 
of the primary and secondary atomisation processes, as arbritrarily designated earlier: the 
primary indicated by the actuator and throat deposition, and secondary by the fine particle 
fraction.
For clarity, when data is discussed on an intra-formulation percentage basis, reductions 
and increases delineated refer to changes from the first environmental condition quoted; 


















Table 5.1: The effective percent located deposition for critical aerosol characteristics of
hydrophilic (maleate) and hydrophobic (oleate) salbutamol aerosol 
formulations at 10% w/w ethanol levels.
Table 5.2 illustrates the temperature and humidity profiles during aerosol experiments for 
both salt formulations.
Environmental Experimental Testing Conditions
Condition (Recorded values)
Maleate Oleate
T°C %RH T°C %RH
LT:LRH 25.2 30.3 24.6-24.7 29.6-30.1
LT:HRH 24.8 100.0 21.8 100.0
HT:LRH 38.4 25.6-28.6 38.7-39.0 25.5-30.9
HT:HRH 36.8-37.1 94.2-100.0 37.6-37.8 94.7-100.0
Table 5.2: The experimental testing conditions recorded during aerosol measurements
of hydrophilic (maleate) and hydrophobic (oleate) salbutamol aerosol 
formulations at 10% w/w ethanol levels.
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Table 5.3 reviews the percentage normalized individual stage deposition data for the 
maleate salt formulations analysed over the range of testing conditions.
ACI stage LT:LRH LT:HRH HT:LRH HT:HRH
Maleate (sd) Maleate (sd) Maleate (sd) Maleate (sd)
Actuator 8.77 1.57 16.33 2.73 22.00 3.63 27.35 3.26
Throat 42.91 9.61 25.96 6.07 12.74 2.87 11.78 6.40
StgO 2.28 0.42 2.45 0.75 1.17 0.59 1.93 0.31
Stg 1 1.69 1.29 2.38 0.73 0.85 0.20 1.52 0.22
Stg 2 0.68 0.22 2.02 0.18 0.69 0.16 0.80 0.55
Stg 3 1.91 0.62 2.18 0.08 1.57 0.49 1.08 0.43
Stg 4 7.34 1.90 7.89 1.09 4.67 0.48 5.82 0.5
Stg 5 14.61 5.15 17.91 2.3 19.44 4.60 24.02 3.66
Stg 6 10.17 1.15 9.59 1.37 16.90 3.09 13.02 0.47
Stg 7 3.45 0.14 5.26 1.16 9.21 1.12 6.39 0.57
Filter 6.13 1.06 8.02 1.40 10.77 3.67 6.29 3.50
Table 5.3: Andersen Cascade Impaction, stage recovery data (% normalised drug
loadings) of a 10% w/w salbutamol maleate aerosol formulation.
Table 5.4 indicates the percentage normalized stage deposition data for the oleate salt 
formulations over the testing range conditions.
ACI stage LT:LRH LT:HRH HT:LRH HT:HRH
Oleate (sd) Oleate (sd) Oleate (sd) Oleate (sd)
Actuator 6.86 2.54 16.74 3.57 19.54 5.93 20.34 2.61
Throat 17.30 1.61 7.70 2.44 8.82 5.82 7.52 4.46
StgO 1.35 1.10 3.41 0.47 3.39 3.79 2.85 2.27
Stg 1 2.17 0.83 4.27 0.66 0.82 0.74 2.25 0.87
Stg 2 1.63 1.04 2.44 1.11 0.49 0.34 3.38 0.63
Stg 3 8.23 1.37 7.79 0.57 3.13 1.49 4.04 1.10
Stg 4 10.43 1.76 10.98 0.84 6.07 2.53 6.03 1.00
Stg 5 15.92 1.13 14.44 2.32 13.36 6.22 16.59 1.16
Stg 6 17.34 1.51 14.10 1.15 17.85 2.16 15.78 3.62
Stg 7 7.43 2.20 5.52 1.13 6.96 0.57 5.74 1.59
Filter 11.34 5.50 12.60 2.50 19.59 4.69 15.45 5.42
Table 5.4: Andersen Cascade Impaction, stage recovery data (% normalised drug
loadings) of a 10% w/w salbutamol oleate aerosol formulation.
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The dose data for both formulations are given in tables 5.5 and 5.6 respectively. These 
tables depict the actual mean delivered dose by mass and the percentage delivered and 
emitted doses allowing inter-formulation comparisons. To complement the data 
generated, table 5.7 idicates the actual formulations utilised and the associated 
theoretical dose based on the composition. The theoretical dose is what would be 
















LT;LRH 100.8 3.76 93.94 2.90 85.79 3.8
LT;HRH 133.48 5.05 126.59 8.87 105.90 6.77
HT:LRH 88.82 29.27 74.40 9.65 68.96 25.51
HT:HRH 93.96 10.02 89.20 4.66 64.91 6.96
Table 5.5: Intra-formulation shot dose data for a 10% w/w salbutamol maleate pMDI
















LT;LRH 193.90 28.08 85.03 12.71 78.99 9.10
LT;HRH 245.96 5.4.2 116.01 3.99 96.64 7.08
HT:LRH 225.45 8.4.6 110.23 4.93 88.60 6.22
HT:HRH 191.43 55.48 108.68 3.68 100.43 3.08
Table 5.6: Intra-formulation shot dose data for a 10% w/w salbutamol oleate pMDI
aerosol (Delivered and emitted dose data are percentage normalised).
Drug
Active Mass / g Ethanol Mass /g 134(a) Mass /g Dose Theory / Mg
Salbutamol Maleate 0.0272 1.4144 12.7241 110.22
Salbutamol Oleate 0.0418 1.0759 9.0088 236.93
Table 5.7: Formulation composition and theoretical delivered dose form experimental
aersosol formulations.
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5.4.4. The effect of temperature variation and constant relative low humidity 
testing conditions on the deposition patterns of salbutamol salt formulations.
Figures 5.2 and 5.3 illustrate the influence of varying temperature and and low humidity 
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Figure 5.3: Intra formulation comparison of salbutamol oleate at low relative humidity
with varying temperature.
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5.4.4(a) Evaluation of the data relating to the Hydrophilic salt
The low temperature, low relative humidity deposition pattern can be considered the "gold 
standard” or baseline deposition profile, as these are the conditions, which would be 
expected to be encountered under a normal lab-testing regimen. The actual 
environmental readings for these replicated experiments were constant and fluctuated 
very little, as the temperature remained static at 25.2°C and, in conjunction, relative 
humidity remained constant at 30.3%. (See table 5.2). Importantly, it should be noted that 
the deposition pattern that presented iself was not typical of a pressurized solution based 
system as the majority of drug deposition was centered on stage 5 of the impactor. The 
effect of temperature was pronounced at the primary deposition stages, with significant 
changes being observed on the actuator and throat resulting in p values <0.001 for both 
stages. Significance was also observed on stages 6 and 7 returning p values of 0.033 and 
0.001 respectively. Upon testing at elevated temperature the actuator deposition 
increased by approximately 13.2% and the throat dropped by about 30.2%. The 
distribution pattern for the aerosol particles for the two temperatures were similar with 
deposition centered at stage 5 of the impactor, and that varying the temperature while 
maintaining conditions of low relative humidity did not significantly affect the relative 
deposition profile within the in-vitro apparatus. The only difference was that an increase, 
on an identical stage-by-stage deposition, occurred as the temperature was increased. 
This may be associated with the variations within the primary mechanism due to the 
increase in environmental temperature potentially "flash evaporating” the volatile 
propellants, possibly improving, i.e. reducing throat deposition, ultimately leading to a 
therapeutic benefit from a clinical viewpoint.
5.4.4(b) Evaluation of the data relating to the Hydrophobic salt
At low relative humidity and low temperature, the oleate salt produced a different particle 
size deposition profile. The environmental testing conditions fluctuated slightly more see 
table 5.2, although in real terms this equated to only 0.1 °C and 0.5% RH, which was 
within experimental error. Significant difference in deposition patterns as evaluated by 
ANOVA indicated that this only occurred for the actuator and stage three and returned 
values of p<0.01 and p<0.001 respectively. Distribution patterns followed a similar trend 
as per the maleate salt for the fine particle fraction, with the actuator and throat deposition 
patterns changing accordingly. The actuator decreased by approximately 12.7% and the 
throat increased by about 8.5%. Stage three decreased by about 5.1%.
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5.4.5. The effect of temperature variation and constant high relative humidity 
testing conditions on the deposition patterns of salbutamol salt formulations.
Figures 5.4 and 5.5 illustrate the effects of varying temperature and high humidity testing 
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Figure 5.4: Intra formulation comparison of salbutamol maleate at high relative humidity
with varying temperature.
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Figure 5.5: Intra formulation comparison of salbutamol oleate at high relative humidity
with varying temperature.
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5.4.5 (a) Evaluation of the data relating to the Hydrophilic salt.
The deposition patterns from these set of conditions followed a similar distribution profile 
to the low relative humidity condition, with maximal drug deposition centered on stage 5. 
Again the trend was observed that when the temperature of the environment was 
increased the actuator and throat depositions reversed in aerosol deposited. Significant 
cascade stage reductions were observed for only the actuator and stage 2, which both 
achieved p values of 0.001. The percentage change for these stages equated to a 
realative increase of 11.0% and an drop of 1.2%. The throat stage although not significant 
decreased by about 14.2%. Table 5.2 indicated the relative environmental testing 
conditions. And indicated that both the temperature and humidity remained relatively 
constant throughout with fluctuation over a temperature range of 0.3°C and a humidity of 
5.8% RH. Such fluctuations may have been attributable to leaks within equipment seals.
The high temperature and high relative humidity condition had the highest actuator and 
lowest throat deposition when compared to all other combinations. From an aerosol 
mechanistic viewpoint it can be theorised that the increased vapour pressure of 
formulation resulted in rapid and violent droplet break-up, evident from comparison of the 
data for both the MMAD and large particle fractions, as illustrated in tables 5.0 and 5.1. 
The MMAD underwent a reduction from 1.48 to 1.11pm at low RH and 1.35 to 1.21pm at 
high RH. In conjunction there was an increase in actuator deposition about 11% when the 
temperature was increased and a change in fine particle fraction, about 4.5%, occured. It 
was inferred, therefore, from these observations that increased intake air temperatures 
may directly affect the primary atomisation mechanism from the changes illustrated in the 
data. At high relative humidity, namely, higher mole fraction of water in the entrained air 
the aerosol cloud experienced a reduction at the upper stage plates probably by a mixture 
of suppression of droplet evaporation and hygroscopic growth. This in turn may have 
modified and increased the effect of secondary dispersion/particle generation 
mechanisms. The water vapour in the atmosphere present may have retarded 
evaporation and enhanced absorption of water molecules into the salbutamol maleate salt 
droplet.
5.4.5 (b) Evaluation of the data relating to the Hydrophobic salt
Deposition patterns for the hydrophobic salt indicated significant changes on stages 3 and 
4 of the impactor with maximal drug loading on the actuator and for stage 5 within the 
impactor both environmental conditions. P values for both these stages equated to <0.001
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and 0.009 respectively and in terms of percentage changes of 3.7 and 5.0% Table 5.2 
illustrates the testing conditions documented during experimentation. As per the maleate 
salt the low temperature high relative humidity testing condition was relatively static, but 
the temperature varied by 0.2°C and the relative humidity by 5.3% accordingly. 
Temperature fluctuation can be attributed to the control of the room as temperature 
mapping had not been performed prior to experimentation and the vacuum pump close to 
the apparatus may have attributed to such fluctuations. Again the variations in the 
humidity may have been due to equipment seals The change in mass median 
aerodynamic diameter was greater fo this combination of salt and environmental condition 
as compared to the hydrophilic counterpart: 1.42 to 1.13 microns for the oleate and 1.35 
to 1.21 microns for the maleate. The additional combination of little change in fine particle 
fraction and the reduction in MMAD indicated potential suppressive mechanism.
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5.4.6. The effect of relative humidity variation and constant low temperature 
testing conditions on the deposition patterns of salbutamol salt formulations.
Figures 5.6 and 5.7 illustrate the effects of constant low temperature and varying humidity 
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Figure 5.6 Intra formulation comparison of salbutamol maleate at low temperature with 
varying relative humidity.
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Figure 5.7: Intra formulation comparison of salbutamol oleate at low temperature with
varying relative humidity.
125
5.4.6(a) Evaluation of the data relating to the Hydrophilic salt
The effect of high relative humidity when the temperature was controlled at a low and 
ambient level indicated significant differences in deposition pattern for the actuator and 
stage 2, which attained significance values of p<0.001 and p=0.002. This equated to 
percentage increases of 7 and 1.3% respectively. The throat stage although not 
displaying a significant change did result in a 16.9% decrease when the humidity was 
increased. At the low temperature testing condition the MMAD decreased from 1.48 to 
1.35 microns. At high temperature with increasing humidity the MMAD experienced an 
increase from 1.11 to 1.21 microns. Such an decrease when hygroscopic growth is 
postulated is discussed later but is theorised to result from particle density changes. The 
large particle fraction, as a sum of actuator and throat depositions as shown in table 5.1, 
increased by approximately 10% when the humidity was increased.
5.4.6 (b) Evaluation of data relating to the Hydrophobic salt
In the previous studies the deposition pattern of the oleate salt at all testing conditions 
indicated an overall smaller particulate aerosol: higher drug loading on the higher 
secondary mechanism/deposition stages. Significance for this salt under these conditions 
was achieved only at stage 2 exhibiting a p value of 0.004. From a percentage 
perspective the largest changes were centered on the actuator and the throat, which 
returned values of an increase of 9.9% and a decrease of 9.6% respectively. Unlike the 
hydrophilic salt stages 5 and 7 experienced a decrease in percentage deposition.
Changes were also observed in the MMAD as shown in table 5.0 as the mass median 
aerodynamic particle size increased in an upward trend from 1.27 to 1.42. Such a trend, 
effectively a growth rate ratio of 1.12 or 12% may be inferred from interpretation of the 
size distribution graph. The increase on the primary stages may result presumably from 
an increased water vapour concentration and therefore the atmospheric vapour pressure 
suppression of the subsequent vapourisation of the volatile components.
This hypothesis is at least partially confirmed, as salbutamol oleate is highly water 
insoluble and as such would be an unlikely site for nucleation of water molecules. 
However a 12% particle size change is relatively large compared to those previous 
studies of Kim et al (Kim et al 1985) who found a difference of only 4% with a solution 
aerosol Bronkometer®, (Isoetharine Mesylate) Breon Labs, New York, NY. However there 
are major differences between these studies and the aforementioned were that the
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propellant cited was a CFC and the RH of the experiment was 90% approximately. Thus 
some effects of particles as cloud condensation nuclei may occur particularly at small 
MMAD’s. In addition the throat deposition was about 18.3% less than the hydrophilic 
under these environmental conditions.
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5 .4 .7  The e ffec t o f  re la tive  hum id ity  varia tion and  cons tan t h igh  tem pera ture  
tes tin g  cond itions on the deposition  pa tte rns  o f  sa lbu tam o l sa lt form ulations.
Figures 5.8 and 5.9 illustrate the effects of constant high temperature and varying 
humidity testing conditions on the particle size distribution patterns of the novel solution 
inhaler formulations.
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Figure 5.9: Intra formulation comparison of salbutamol oleate at high temperature with
varying relative humidity.
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5.4.7(a) Evaluation of data relating to the Hydrophilic salt
Upon varying the relative humidity at high temperatures («38-39°C), for the hydrophilic 
salt (salbutamol maleate) throat deposition patterns indicated a similar trend. Although not 
significant when conditions were varied the actuator deposition increased by 5.4% and 
the throat decreased by 0.95% from low to high humidity. The only significant change was 
noted on stage 7 which returned a p value of 0.001. All other stage deposition patterns 
followed a similar trend with stage 5 occupying the maximum drug loading, which 
increased by approximately 4.6%, with the high relative humidity condition having slightly 
lower deposition on the higher stages. In effect the particle deposition tended towards the 
lower stages The relative percentage changes for stages 6,7, and filter were 3.9, 2.8 and 
4.5%. Fluctuations in humidity were evident at both testing conditions as indicated in table 
5.2, and a growth rate ratio of 1.09 or 9%, resullted when the humidity increased. The fine 
particle fraction increased by approximately 10%.
5.4.7 (b) Evaluation of data relating to the Hydrophobic salt
At these testing conditions the oleate salt exhibited a similar trend in deposition pattern for 
all stages. The fine particle fractions wereapproximately equal and changed very little The 
growth rate ratio, calculated from data in table 5.0, was 1.30 or 30 % for these intra­
testing conditions. The only significant change resulted on stage 2, which produced a p 
value of 0.001 and a percentage change of 2.9%.
It should be noted that the main stage deposition for the low humidity condition was the 
filter stage. This condition had the highest filter stage of all, for the oleate salt under all 
testing conditions. The high relative humidity also had it main drug loading on the filter 
stage but the preceding stages 5 and 6 were approximately equal, unlike the low RH. This 
can be quantified from the data in table 5.3. A point to note as for the hydrophilic salt was 
that there was fluctuation around the measured relative humidity in approximately the 
same order of magnitude as depicted in table 5.2.
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5.4 .8  The e ffe c t o f  env ironm en ta l testing  cond itions on the M M AD  a nd  o f  
sa lbu tam o l sa lt form ula tions.
Figures 5.10 and 5.1 illu s tra te  the effects of varying environmental testing conditions on 
the MMAD and GSD of the novel solution inhaler formulations.
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Figure 5.10: Intra formulation comparison of the particle size and polydispersity of
salbutamol maleate.
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Figure 5.11 Intra formulation comparison of the particle size and polydispersity of
salbutamol oleate.
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5.4.8(a) Evaluation of data relating to the Hydrophilic salt
In general, the lower temperature environments produced higher MMAD’s and the effect 
of humidity varied depending on the temperature of the entrained. At constant low 
temperature, the MMAD decreased by approximately 9% when the RH was increased. 
(See tables, 5.0 and 5.2 accordingly relating to the following discussions). Conversely, at 
constant high temperature the particle size increased by approximately 9% when the 
relative humidity was increased. When RH was kept at a low and constant value and 
temperature varied, an increase in temperature caused a 25% reduction in MMAD. When 
the RH was kept at an elevated value a corresponding increase in temperature resulted in 
a 10% reduction in MMAD.
No significance for MMAD was observed for any intra temperature combination as a p 
value of 0.066 was calculated.
Polydispersity was shown to decrease at static conditions of humidity when temperature 
was increased. Under static conditions of temperature polydispersity decreased at high 
relative humidity and increased under low temperature and high relative humidity. 
Considering the data systematically, low temperature comparisons indicated an 11% 
increase in GSD for the maleate salt when humidity was increased. When the high 
temperature testing environments were considered a change of about 4% resulted at high 
humidity. When the humidity was held constant, and low, increasing the temperature 
dropped the MMAD by 7% and at high temperature a reduction of about 20% occurred. 
No significant difference was observed as indicated by a p value of 0.188
5.4.8 (b) Evaluation of data relating to the Hydrophobic salt
Data for this salt indicated that significant differences were observed between the low 
temperature high relative humidity and high temperature low relative humidity conditions 
when compared, as indicated by a p value of 0.025.These were the only data sets that 
indicated significant changes. Again, the trend as with the hydrophilic maleate salt was 
that lower temperatures produced higher MMAD’s. Taking the data in tables 5.0 and 5.2, 
at constant low temperature the MMAD increased by about 12%; when the relative 
humidity was increased the MMAD increased by about 30% respectively. When the 
relative humidity was kept at a constant low value, increasing the temperature caused a 
drop in MMAD of 31%; at a constant high relative humidity value the MMAD was reduced 
by approximately 20% when the temperature was increased.
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Aerosol polydispersity was different from that of the hydrophilic salt and no statistical 
significance was encountered for any combination of the environmental testing conditions. 
Considering the low temperature testing conditions, increasing the relative humidity 
resulted in an increase in about 18% and at static high temperature increasing the RH 
resulted in a drop of approximately 13%. Alternatively, when the testing conditions were 
constant at a controlled low/ambient relative humidity increasing the temperature resulted 
in a 40% increase in cloud dynamics. Finally at high relative humidity increasing the 
temperature did not affect the GSD greatly as the change was only 3%.
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5.5. Inter formulation comparisons of the Particle Size Distributions
produced from Novel solution pMDI’s.
Figures 5.12 and 5.13 illustrates the normalized deposition data comparing the inter­
formulation deposition patterns for the novel solution formulations when tested at low 
temperature and varying relative humidity conditions.
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Figure 5.12 Inter formulation comparison of salbutamol salts at low temperature and 
low relative humidity.
Figure 5.13
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Inter formulation comparison of salbutamol salts at low temperature and 
high relative humidity.
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Figures 5.14 and 5.15 illustrates the normalized deposition data comparing the inter­
formulation deposition patterns for the novel solution formulations when tested at high 
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From the data generated and summarized in figures 5.14 -.517 and tables 5.0-5.4, it was 
shown that the salt derivative within the aerosolised formulation had a significant effect on 
both the primary and secondary mechanisms of atomization, and subsequent deposition 
patterns of the aerosolisation of solution based pMDI systems. It was also determined that 
the effect of temperature on the cloud generated also imparted a significant, and, if 
manipulated, a beneficial effect on cloud dynamics. By beneficial effect, the resulting 
implications are that unwanted distribution of drug on stages such as the throat and 
reassignment of drug to other particle size distributions were possible. Such a 
redeployment of drug may be beneficial depending on disease state. The following 
discussion relates to the inter-comparison graphical representation of deposition.
5.5.2 Inter formulation comparisons: The effects of environmental testing 
conditions on particle deposition patterns from novel solution pMDI’s.
The deposition patterns exhibited by both salt formulations were widely different. 
Considering the pattern at low temperature and low humidity and ambient lab conditions 
the oleate gave a deposition pattern that was finer namely more drug was loaded on the 
higher (6,7 and filter) stages, with deposition patterns rising from stage 3 and centered at 
a maximum around stage 6 of the impactor. The maleate formulation, with a lower 
effective solid concentration would have been expected to give a smaller MMAD and 
similar deposition pattern, but this did not occur. At this condition, significant changes in 
deposition pattern were evaluated using a two-tailed heteroscedastic t-test, with t at 95% 
confidence intervals. The stages that indicated significance were the throat (t stat 4.31; t 
crit 4.55), stage 3 (t stat -7.23; t crit 3.18) and stage 6 (t stat -6.54; t crit 2.88). In 
percentage terms the changes indicated a reduction for the throat of approximately 25.6% 
and increase of 6.3 and 7.2% for stages 3 and 6 respectively.
When the effects of hygroscopicity were considered at low temperature and high relative 
humidity, or more correctly at high mole fraction of water vapour within the intake air, data 
indicated different aerososlisation mechanisms. Actuator recovery increased on both, 
roughly doubling, to around 16% for the hydrophilic salt and an almost three fold change 
for the hydrophobic salt. The throat deposition of both salts significantly reduced from 
around 43-26% for the maleate salt and 17-8% for the oleate. The throat deposition in
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relative terms was still greater than that of the actuator and increased from 9-16% for the 
maleate and 7-17% for the oleate. The FPF’s also changed: 43-53% for the maleate and 
72-68% for that of the oleate. Statistically, several stages indicated significance in 
particle size changes: the throat (t stat 4.83; t crit 3.18), stage 1 (t stat -3.32; t crit -2.78), 
stage 3 (t stat 16.92; t crit 4.30), stage 4 (t stat -3.89; t crit 2.78) and stage 6 (t stat -4.38; 
t crit 2.78). In percentage terms this equated to a reductions for the throat of 
approximately 18.3%, for stage 1of approximately 1.9% and increases for stages 3, 4 and 
6 of 5.6, 3.1 and 4.5% respectively.
The high temperature low relative humidity condition indicated no statistical difference on 
any of the impactor stages between the salts. Also there were no major changes in 
percentaage deposition for any stage. Only stages 6 and the filter indicated appreciable 
paercentage changes, as these resulted in a decrease of 6.1 and 8.8% respectively. 
Taking the effects of high temperature and low relative humidity, opposed to low 
temperature and high relative humidity, the oleate was relatively unchanged, and 
deposition on the actuator increases slightly from 19.5 to 20.4%, and the throat reduces 
from 8.8 to 7.5%. The maleate however, increased by 5.3% on the actuator and by only 
decreased by 0.95% on the throat. The changes from this to the final condition, high 
temperature and high relative humidity, were relatively small and insignificant.
The high temeprature high relative humidity condition returned three stages that 
significantly differed from each other: the throat (t stat 2.90; t crit 2.78), stage 2 (t stat- 
5.37; t crit 2.71) and stage 3 (t stat-4.35; t crit 3.18).
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5.6 The effect of environmental testing condition on the major 
primary and secondary particle production mechanisms
Figures 5.16 and 5.17 illustrate the effects of environmental testing conditions on the 
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Intra formulation comparison of the primary aerosol characteristics of 
salbutamol maleate.
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Figure 5.17: Intra formulation comparison of the primary aerosol characteristics of
salbutamol oleate.
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5.6.1 (a) Evaluation of the data relating to the Hydrophilic salt
When tested at ambient lab conditions the highest throat, lowest actuator and lowest fine 
particle fraction was obtained for the hydrophilic salbutamol maleate salt. Upon 
maintaining low conditions of relative humidity, but when the temperature was increased a 
complete change in the primary mechanism and large particle deposition pattern was 
observed. Table 5.4 summarises the normalized stage deposition data and provides a 
direct comparison for intra and inter salt formulations. Actuator deposition increased from 
about 9% to 22%, the throat deposition decreased from 43% to 13% and the fine particle 
fraction increased from 43 to 64% respectively. When the relative humidity was at the 
extreme value, in the region of 100%, and the temperature varied between 24.8°C and 
36.8-37.1°C, a similar trend was observed, whereby the actuator deposition increased 
from approximately 16% to 27% the throat decreased from about 26 to 12% and the fine 
particle fraction increased from around 53% to 57%.
Considering the reverse, when temperature was kept at a low ambient value about 24.8- 
25.2°C and humidity varied 30.2% and 100% relative humidity, under high humidity 
conditions the actuator deposition increased, the throat deposition was reduced and the 
fine particle fraction increased. The approximate relative percentage changes were 9% 
increasing to 16% for the actuator, 44% decreasing to 26% for the throat and 43% 
increasing to 45% for the fine particle fraction.
In general, the actuator and throat deposition was affected by both temperature and 
humidity, but more so by temperature, as was the fine particle fraction. At both high 
temperature and humidity the fine particle fraction was about 6% lower than the maximum 
value. Statistically, actuator, throat and fine particle fraction data sets exhibited statistical 
differences.
For the actuator a pvalue of <0.001 resulted for the following combinations: low 
temperature low relative humidity and both high temperature low relative humidity and 
high tempertaure hgh relative humidity. And also for the low temperature high relative 
humidity compared to the high temperature high relative humidity testing conditions. The 
particle size deposition patterns of the throat returned a p value of 0.001 for the low 
temperature low relative humidity condition compared to both the high temperature low 
relative humidity and high temperature high relative humidity conditions. The fine particle
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fraction data, p= 0.02, had only one set of conditions that reached significance: the low 
temperature low relative humidity when compared to the high temperature low relative 
humidity conditions.
The extent of aerodynamic force, calculated in the throat region, can be seen from the 
change in Weber number from 4°C through to 37°C. As temperature is increased for the 
hydrophilic salt the Weber number increases. A simplified calculation, based on standard 
data, illustrates this change:
2R p(AU )2
We = ----------------------  Equation 5.1
<J
Where all usual nomenclature applies and calculations are based on dimensions and 
suppliers physical and chemical data:
2R= D = 10pm particle, AU2 = 9040ms'1, D of USP Andersen throat 19 mm 
p=0.0174,0.0323, 0.0504 kgm'3 at 4,25 and 37°C and a = 4.23x1 O'4, 3.10x1 O'4, 2.29x1 O'4 
kgs’2 at 4, 25 and 37°C for a 10:90 ethanol 134(a) solution.
Assuming a dry environment, (as humidity alters gas viscosity) for a 10 micron particle at 
4°C, We = 11.2, at 25°C We = 28.2, and finally at 37°C, We = 59.6. For a 5 micron 
particle at the ascending temperatures described the We = 5.58, 14.1 and 29.8 
respectively. (For a 1 micron particle the Wecr is 1/10th the 10 micron particle value)
These trends were confirmed from comparison of the data in table 5.1 by comparing LT: 
LRH and HT: LRH environments. The actuator data indicated an increase of 
approximately 2.45 fold (the Wecr drops by about 2.11) due to the increase in Wecr. The 
throat data also indicated a reduction by approximately 3.47 fold. This may be due to the 
larger particles exceeding the critical dimensions and undergoing breakup. The MMAD 
values from table 5.0 indicated a reduction in MMAD, about 0.75 times the LT: LRH when 
compared to the HT: LRH value, as a result of the increased particle breakup. From the 
idealized calculation it becomes evident that as the Wecr decreases the particle size 
decreases and so smaller particle experience less aerodynamic force.
Humidity had a similar effect,by increasing the actuator deposition and reducing the throat 
deposition, but in this instance to a lesser extent, see table 5.1 LT:HRH conditions versus
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the corresponding low RH data. This may be due to an increase in viscosity of the 
dispersed phase potentially hindering atomisation. This effect can be observed in the 
HT:HRH condition, which has the greatest actuator deposition. The FPF increases from 
LRH to HRH at the extremes of temperature and the MMAD decreases (as a result of 
probable density changes that will be discussed later) from, which one can infer 
hygroscopic growth as the water-soluble species may act as nucleation sites for water 
vapour molecules.
5.6.1 (b) Evaluation of the data relating to the Hydrophobic salt
The particle size deposition patterns for the hydrophobic salt were, in general, less 
affected by temperature and humidity than its hydrophilic counterpart, as the data depicts 
in table 5.4 The throat deposition was higher in relative terms than the actuator for the low 
temperature low relative humidity conditions. All other conditions had the reverse trend 
with higher actuator deposition and lower throat deposition, and overall the relative 
percentage changes were small. The actuator deposition changed, and increased, from 
6% at low temperature to 16%, 19% and 20% for low temperature high relative humidity, 
high temperature low relative humidity and high temperature high relative humidity 
environments respectively. The throat decreased from 17% to 7%, and 8% to 7% for 
these conditions respectively.
The Wecr numbers calculated above also apply to the oleate or hydrophobic salt. As the 
formulations were similar in overall volatile component composition: 10.62: 89.38 
(ethanol: 134(a)), for the hydrophobic salt versus 9.98: 90.02 for the maleate salt then any 
differences should, in theory, be due to the physicochemical and colligative properties of 
the derivative. The reduced amount of deposited drug as compared to the hydrophilic 
counterpart at LT:LRH would indicate a reduction in surface tension for particles of this 
formulation. This seems counterintuitive given the salt is at a concentration of 0.41 %w/w 
as compared to 0.19% w/w for the hydrophilic derivative.
Statistical differences were only observed on the actuator for this data set, which returned 
a value of 0.01 for combinations of the low temperature low relative humifidt condition 
when compared to bith the high temperature low relative humidity and high temperature 
high relative humidity.
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Again tables 5.0 and 5.1 summarise the critical data. As with the hydrophilic salt, the 
hydrophobic salt formulation once aerosolised undergoes modification via the primary 
mechanism indicated by similar changes in actuator and throat deposition: an increase to 
17% at the actuator and a reduction on the throat.
5.6.1 (c) Conclusion: The effects of the environment of the major primary and 
secondary particle production mechanisms
In conclusion, at this stage, evaluation of the growth rate per se can be derived from the 
calculated "growth rate ratios”: the change from low to high RH at constant temperature 
(see table 5.0). As a surrogate and, as far as possible, a direct, correlation to "in-vivo” 
conditions both salts indicated an increase when HT: LRH was evaluated against HT: 
HRH. For the hydrophilic/maleate salt this generated a ratio of 1.09; for the 
hydrophobic/oleate this resulted in a value of 1.30. Both results are in the orders 
determined by previous workers in the field, (See literature values in appendix A.5.0), 
even though different experimental conditions and laboratory equipment were utilised. 
The "growth” of the hydrophobic organic salt solution may in part be correlated to the 
hypothesis set out in appendix 5.1. whereby Bell and Ho suggested that the reduction in 
growth of isoproterenol saline solutions with glycerol was retarded probably due to 
surfactant molecules hydrogen bonding to water molecules on the particles surface 
reducing water bv vapour molecules transferring to the particles core. In this particular 
case, as the formulation contains no hydrophilic active molecule only excipients namely 
ethanol; so, it is postulated here that the surfactant portion of the derivative aligns at the 
particle surface in a humid or water laden environment and said molecules bind to the 
surface possibly via van der Waals or dipole interactions at the double bond. This may 
help to reduce the surface pressure and so evaporation and, or, may lock water 
molecules on to the particle surface effectively increasing the MMAD. The comparison 
between the throat depositions of both salts at LT: LRH indicated a significant change in 
deposition. As discussed, this may be due to a reduction in surface tension of the emitted 
particles. This seems plausible as surfactants reduce surface free energy. The maleic 
acid molecules contain a free hydroxyl group that may form both intra and inter molecular 
hydrogen bonds redressing the balance of the competing vapour pressure effects of the 
curved surface. Matrix effects may also occur, but analysis of the particle during its 
trajectory (experimentally difficult) and post plate deposition would be required.
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5.7 Data evaluation and discussion of the possible mechanisms 
resulting in the particle size deposition patterns of novel solution pMDI’ 
formulations
From the preceding data, it was shown that temperature and humidity influenced both the 
primary and secondary aerosolisation processes, which may directly affect aerosol 
delivery when preconditioned within in the respiratory tract. Furthermore, the effect of 
drug salt derivative, contrary to related experimental investigations, had a major impact on 
particle deposition within an in-vitro apparatus with varying environmental testing 
conditions. This was confirmed from both data evaluated on an inter-formulation, stage- 
by-stage basis when the major parameters, section 5.6, were statistically evaluated. For 
these parameters, not previously documented, significant differences for the actuator, 
throat and fine particle fractions. These differences are depicted in table 5.8
Parameter Maleate Oleate P Value
Environmental Condition












LT:LRH LT:LRH LT:HRH HT:LRH HT:HRH 0.004
Table 5.8: Statistical differences encountered for key particle size parameters when
compared on an interformulation basis.
The main objective of the study was to evaluate the effect of hygroscopicity on the 
delivery of salbutamol salts to the lung. Hygroscopicity, in aerosol mechanics, is standard 
nomenclature for describing the interactive effects of water molecules with droplets and 
sprays, and in this study has shown to have a significant effect when coupled with 
temperature.
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General Discussion: Possible effects of Drug derivative effects on cloud dynamics
Before discussing the effects of hygroscopicity and the impact of environmental testing 
conditions on drug delivery, consideration should be given to the process of atomization 
and cloud dynamics based purely on the character of drug the derivative alone: review of 
the data generated under standard conditions (the control conditions) described as those 
of low temperature and low relative humidity. Theoretically, deposition patterns for the two 
salts should follow similar trends, even though the concentrations of the active were 
different. Concentration effects have been shown historically to affect MMAD, and 
theoretically, the oleate should have had a larger MMAD. This was not however observed 
in this study.
Primary atomisation is described by the oscillations and perturbations that affect the liquid 
jets that emanate from the spray orifice, whereas secondary atomisation proceeds via 
disintegration of the initial droplets, which exceed a critical size and further disintegrate, 
influenced by aerodynamic forces. Data suggested the effect of salt derivative was 
affecting the secondary atomisation process, to a greater degree, with varying 
environmental conditions. (It should be noted that the testing apparatus removed a large 
portion of aerosol droplets from the initial burst produced from atomization; these resulted 
in particle sizes greater or equal to 9 microns in mass weighted diameter). It is likely that 
these particles would have undergone further breakup. This could be rationalised, as the 
actuator deposition data were similar for both formulations, but the review of the 
subsequent impactor stages indicated heavier drug loading on lower plates and a 
fundamental character namely the MMAD was significantly different. The LT: HRH 
condition was an exception, but results are discussed, further, later. Also, the dose 
impacted to a greater degree on the throat stage for the hydrophilic salt: salbutamol cis 
butenediaotae / maleate. The throat deposition was over double that for the hydrophobic 
derivative at low temperature conditions, but was similar although still slightly increased at 
high temperature variations. MMAD values for particle depositions were greater for the 
maleate salt at all testing environments except for the low temperature high relative 
humidity.
For this process to occur, it is theorised that an increase in injection pressure on the 
emerging liquid ligament from the orifice would be required resulting from a change in 
liquid mass flow rates. This suggests that the mass flow rate through the orifice may have 
been significantly greater then for the oleate salt and thus, in turn, impart a greater
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coefficient of discharge upon actuation. A further implication here is that the densities of 
the liquids in the metering chamber are different, as the mass flow rate is related to the 
square root of the liquid density; however, density changes of the magnitude required are 
unlikely, and not supported by individual shot weight data. The individual salts, however, 
do have different densities: 1.305 vs. 1.095 gem'3 for the maleate and oleate, respectively. 
This may have an important effect on the microscopic, individual droplet scale.
Again, on a microscopic scale viscosity may be very different. The increased 
concentration of the hydrophobic-based surfactant derivative would be expected to 
produce a more viscous drug solution. Also the increased concentration of hydrophobic 
drug derivative may affect heat transfer from the surrounding environment by changing 
the heat capacity, and thus possibly affecting an increase in size. Viscosity has a complex 
effect on particle size distributions. In general, it lowers the Reynolds number and 
dampens instabilities in liquid jets dischsrged from an orifice. This in turn would delay 
disintegration and increases particle size. Therefore a more viscous oleate solution would 
be expected to again produce a larger MMAD. However the data contradicts the 
preceding hypothesis. However, in a hollow cone such as an actuator tube and spray 
orifice, viscosity can increase flow rate by increasing the liquid film and surface area over 
and around the orifice. Increasing the mass flow rate would accelerate spray, increase the 
discharge coefficient, increase the velocity of liquid discharge and decrease the MMAD. 
(Lefebvre 1989). The surface chemistry of the derivative may also be important here, 
assisting in rationalization of the pressure change-viscosity theory. The oleate is a 
surfactant-based acid adduct. This may in turn affect as indicated above flow by 
spreading and subsequently depositing on the mouthpiece. Here shear stress values 
could be different, for the different formulations and drug concentrations. Rapid multiple 
actuations as performed in this study, may precipitate drug on the actuator orifice and 
mouthpiece. For a solid material namely the maleate salt, a potential reduction or slow 
down in discharge rate may result and ultimately may affect particle size. A surfactant 
would behave differently. A liquid coating, the oleate salt, may reduce shear stress 
between the passage of formulation and the walls of the spray orifice. Energetically, the 
minimum amount of energy required for atomisation is equal to the product of the surface 
tension and the surface area. An increase in surface area would therefore reduce the 
critical value. A spreading liquid surfactant will increase surface area in relation to a solid 
deposited, suggesting the surfactant formulation may remain ’wet’ upon aerosolisation. 
The aerosolized droplets for different salt forms may therefore have different 
morphologies post aerosolisation as a result of the possible production of a "dry” 
hydrophilic particle and a "wet” hydrophobic particle. This effect has indeed been
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observed by scanning electron micrographs of particles deposited on stage plate 4 of the 
cascade impactor. These are illustrated for the maleate and oleate salt in figures 5.18 A 
and B, respectively. The scanning electron micrographs illustrated the unexpected 
changes in particle morphology, which may result from variations in the structure of the 
salt. The maleate produced classic spray dried amorphous spheres, whereas the oleate 
indicated a liquid amorphous morphology.
Figure 5.18 A: A scanning electron micrograph of salbutamol maleate recovered from a 
cascade impactor stage 4.
Figure 5.18 B: A scanning electron micrograph of salbutamol oleate recovered from a 
cascade impactor stage 4.
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The SEM of the fixed oleate salt figure 5.18 B indicates the presence of "liquid pools and 
streams” possibly due to the lower viscosity of the aerosol droplets upon collection. An 
alternative explanation may be that the collapse of the salbutamol oleate hydrophobic salt 
particles resulting from a phase change due to the uptake of moisture and temperature 
changes during SEM preparation. A phase change at effectively ambient temperature 
would require physicochemical properties similar to mixtures of natural lung surfactants. 
(For an amorphous material, a glass transition temperature is more applicable related to 
the viscosity of the material exceeding a critical value) In conjunction, it may be possible 
that with even a small amount of water vapour in the testing atmosphere (30.3% in this 
case), molecules of vapour may adsorb to the particle surface and remain trapped until 
deposition providing a liquid air interface for subsequent spreading. To verify this fact 
bespoke experimentation would need to be performed over a range of humidities and on 
all impactor stages. Ultimately, surface chemistry of the different derivatives indicated 
significance differences and their choice in the future must be considered in aerosolised 
therapy. The severe and dramatic differences in distribution patterns and FPD signified, it 
was hypothesized, that aerodynamic forces on the oleate derivative were greater than that 
of the maleate. It was inferred from these data that the surface tension, (Weber number) 
and the viscosity (Reynolds number) figures of the maleate droplet were greater than that 
of the oleate. Thermodynamics may have also impacted on particle size distributions. 
Upon aerososlisation, particles may have experienced a drop in temperature due to 
propellant evaporation, which could subsequently act as cloud condensation nuclei. Two 
phenomena may occur post actuation: all volatile components may vaporize leading to 
the rapid precipitation of a solid particle, or the highly volatile component vaporizes 
preferentially leaving an ethanol and drug liquid droplet. Either way, an increase in MMAD 
and in fine particle fraction should result. From the data a dry particle is theorised for the 
maleate and a liquid particle for the oleate; this can be explained by the following rationale 
and is supported by the SEM micrographs in figures 5.18A and B. A decrease in MMAD 
occurred for the hydrophilic aerosol, but the fine particle dose increased. This apparently 
contradictory behaviour can be explained by hygroscopic growth. As the dry hydrophilic 
aerosol particle sorbs water the density decreased from about 1.305 gem'3 to 
approximately 1 .Ogcm'3. As the aerodynamic diameter is equivalent to the product of the 
density and the particle diameter then a simple calculation predicted a drop of MMAD to 
roughly 1.30 (1.35 actual) for the maleate, and an increase to 1.35 for the oleate (1.42 
actual). In-vitro deposition data confirmed this supposition. Further, the fine particle dose 
increased from 42 to 53% for the maleate but dropped slightly from 72 to 67% for the 
oleate.
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The Effects of Environmental Conditions on Drug Delivery
Air temperature of the environment was shown to have a significant effect on cloud 
behaviour, since as temperature increased so did the formulation vapour pressure and so 
would the rate of evaporation of the volatile formulation components. Under these 
conditions the MMAD should therefore decrease with increasing temperature. This was 
substantiated for both salts, with the added effect of increasing MMAD when water vapour 
was present. A question now presented itself: was the increase at high relative humidity 
due to vapour suppression, did hygroscopic growth occur or did a combination of the two 
processes occur?
The data suggested a vapour suppressive type mechanism for the hydrophobic 
unsaturated fatty acid derivative. Consider the high temperature varying humidity 
deposition profile (figure 5.9) coupled with the actuator, throat and fine particle fraction 
(figure 5.13). The actuator, throat and fine particle deposition remained relatively 
unchanged over the environmental testing conditions. The stage depositions indicated 
similar patterns, which increased at the higher stages, but the low relative humidity 
condition dominated the very fine particle dose. For the oleate the MMAD increased: the 
growth ratio was 1.12 for the low temperature conditions and 1.30 at high temperature 
under elevated humidity testing conditions. As the active is water insoluble it is possible 
that the water vapour as intimated adsorps physically to the surface via dipole-dipole 
interactions, and potentially forms an electrostatic attraction between the unsaturated 
double bond and the oxygen-hydrogen bonds of the water vapour molecules. The latter 
assumption would need to be confirmed by NMR studies as ethanol present may alter 
molecular orientations. The surfactant present may interfere with the heat transfer, 
namely evaporation and diffusion at the particle interface.
For the hydrophilic unsaturated carboxylic acid, the data, it is inferred, indicated two 
different mechanisms. The actuator deposition increased with temperature and humidity 
(figures 5.2, 5.4, 5.6, and 5.8). In conjunction, the fine particle dose increased with 
humidity until the combination of high temperature and low humidity condition and 
dropped slightly at the high temperature high humidity condition. (Figure 5.8 and table 
5.1). The inter stage depositions (figure 5.17) indicated a greater loading for the high 
humidity condition at stage five with a decrease over the very fine particle dose stages.
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Hygroscopic growth or activation of an aerosol particle to enable growth into a larger 
droplet occurs when the environmental supersaturation exceeds the critical 
supersaturation of the particle. This process is controlled by the rate of generation of 
potential supersaturation, the net rate of mass transport of water vapor to the ensemble of 
particles, the thermodynamic driving force for condensation, and the release of latent 
heat. During aerososlisation environmental supersaturation may occur and condensation 
of water vapor onto the activated cloud droplets the I initial aerosol particles may occur, in 
a manner similar to cloud activation by soluble aerosol particles. For water soluble 
species the formation of a dry particle is proposed, which dissolves and subsequently 
grows. The insoluble species, it is proposed, does not grow via a hygroscopic 
mechanism, and remains as a wet droplet protected by the formation a surfactant layer on 
the surface. Water vapour concentration and pressure may cause a layer of water 
molecules to physically adsorb to the droplet surface. To corroborate the prior 
assumptions and illustrate hygroscopic versus vapour suppression mechanisms, the 
reader is directed to tables 5.0 and 5.1 and figures 5.12 and 5.13 respectively. Comparing 
the low relative humidity and varying temperature environments the data changes are 
similar with the exception of the throat, which has been explained by viscosity changes 
and the increasing critical Weber number Wecr.
Humidity affects both salts when comparing LT: LTH and LT: HRH, but for the 
hydrophobic salt this is suppressive as the FPF remains unchanged: 72% versus 68%. 
The FPF for the maleate salt however increased from 43 to 53%, and although not 
significant was a major increase. The change in MMAD, a reduction, it was conjectured 
resulted from a change in density via water uptake.
Comparing the range of conditions, there was increase from LT: LRH to HT: HRH: 
ambient laboratory versus those mimicking physiological "in-vitro”. The individual GRR’s 
were 0.75 for the hydrophilic and 0.89 for the hydrophobic respectively, but the inter 
formulation GRR’s over these conditions indicated an increase of 1.07 for the hydrophilic 
salt. The respirable fraction also indicated a change as the FPF increased by about 15% 
for the hydrophilic salt, a significant increase over the hydrophobic salt, which increased 
by about only 5% with the results not effectively attaining significance.
Overall, the data indicates that testing at the normal lab conditions does not give an 
accurate reflection of particle size changes that occur when these two novel solution 
based pressurized inhalers were tested. Also the selection of drug derivative is critical in 
determining the cloud dynamics of solution-based pMDI’s.
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6 CONCLUSIONS AND RECOMMENDATION FOR FUTURE 
WORK
The aim of this thesis was to investigate the effects of temperature and humidity on the 
fundamental, characteristic properties of aerosol particle clouds emitted via novel HFA 
solution based inhaler formulations of salbutamol.
The basis of this pharmaceutics study covered the following areas:
(i) The chemistry of bronchodilator synthesis and crystallisation,
(ii) Physico-chemical characterisation,
(iii) The effect of formulation variables and modelling of aerosol clouds, and
(iv) The effects of simulated environmental conditions on the particle size distribution of 
aerosol clouds generated by pressurized solution systems.
General Conclusion to Chapter one
The introductory chapter highlighted that pressurised inhaler technology has been largely 
static, over the last four decades, and also the chemistry of drug selection and formulation 
science has largely been empirically based. The bronchodilator salbutamol sulphate, it 
was inferred, was chosen merely on the differences in pKa value in order to expedite 
rapid crystallisation, and not based on the rationale of its pharmaceutical properties. The 
change from CFC to HFA propellants has also had a major impact on formulation 
development of pMDIs. This complication, has been mainly related to the partial solubility 
of the active ingredients in HFA propellants, and that the majority of the accepted 
surfactants are insoluble. Thus, the rational for drug salt selection has been largely 
overlooked and been based on commercial drivers and challenging technical issues.
Further Work associated with chapter one
Further work in this area should focus on literature searches and investigations into 
archived work on inhalation therapy, e.g. the Egyptian Ebers, probably the oldest medical 
texts in existence, indicate the use of vapour inhalation. Mechanisms into producing drug 
vapours or compounds which sublime may improve deposition and reduce losses in the 
throat; systemic drug delivery would also benefit from this approach to drug delivery.
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The search for novel surfactants, although not within the scope of this thesis, utilised not 
only to stabilise suspensions, but more appropriately to enhance solubility would be of 
interest to manipulate particle growth kinetics. Polyfluorinated carboxylic acids, under the 
trade name Fomblin HC have been cited in the literature for this purpose. However, other 
toxilogically safe fluorinated materials may also be evaluated for this purpose. The US 
military have utilised fluorinated hydrocarbons to enhance breathing in high-pressure sub­
aqua applications and it is feasible that these compounds are HFA soluble.
General conclusions to chapter two
Chapter two focused on the selection and synthesis of novel bronchodilator derivatives. 
Salbutamol was chosen as the drug of choice since this has been the gold standard in 
relief therapy for asthma and RAO’s for several decades. The selection of salt derivatives, 
although not new, was novel in this application of solution-based systems.
In this thesis, several novel salt derivatives of salbutamol were synthesised, and the 
choice of reaction conditions allowed the development of a pre-formulation screening tool 
to be incorporated into the synthetic method. Of the all the derivatives synthesised, the 
carboxylic salts proved to be the most soluble in ethanol. Further, it was established that 
unsaturated carboxylic acids were highly soluble with the reasons for enhanced solubility 
discussed. Indeed, stereoselectivity was shown in this study to have an influence on 
physical solution stability and solubility. Cis-trans isomerism was important as fumaric 
acid, trans butenedioic acid, proved to be insoluble, whereas, the cis form maleic acid 
was shown to be highly soluble.
It was shown that by careful selection of solvents and anti-solvent systems that even 
highly soluble salts could be manufactured in-situ within the pMDI canister. Although not a 
structured part of the research, formation of particles from a batch manufacturing process 
perspective for labile compounds may be of commercial and technological interest. 
Further, given the fact crystallisation could be achieved in-situ, as was visually observed 
by particle induction in the canister, it could be possible with careful reaction 
thermodynamics and kinetics to produce monodisperse particles. Altering the process 
conditions, of not only the salt solution, but also the anti-solvent (HFA 134(a)) namely its 
temperature and pressure may provide a means of modifying particle size and its 
behaviour.
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The drug derivatives have also been extensively characterised as documented in this 
chapter. Structural identification was conclusively proved by X-Ray crystallography.
Further work associated with chapter two
The area of crystallisation is a complex interplay of thermodynamics and kinetics, and has 
been shown to be highly influenced by selection of solvent systems. At present, no work 
in this thesis has been performed investigating the existence of polymorphism of the salt 
derivatives. By utilising different anti-solvent systems different polymorphs may be 
synthesised. Indeed, in this thesis, melting points from DSC when compared to standard 
compounds indicated differences. The effect of polymorphism will impart many 
differences in character and may improve solubility. Alternatively, other inhalation systems 
such as dry powder inhalation preparations may benefit from selective salt formation. This 
may provide a novel means of influencing particle interactions with carrier excipients, 
plastics and polymers such as those found in reservoirs and blisters, while maintaining 
environmental stability and delivery. The effect of structural stereoselectivity has been 
demonstrated on solubility, but chiral effects have not been investigated. As the R- 
enantiomer is the pharmacologically active molecule, further work involving this 
compound should be investigated not only in terms of solubility, but, also, in cloud 
formations and deposition patterns from aerosol clouds. The effect of reaction conditions 
on drug synthesis in the final container should possibly be investigated. From initial 
experiments, it was observed that manipulating the amount of ethanol, and water in the 
final contained could produce 2 phase systems. It is possible that the final material may 
be crystallised for suspension-based systems by carefully controlling the rate and 
temperature of addition of anti-solvent (HFA134(a)); the handling of concentrated drug 
solutions prior to manufacture may have advantages over micronised powders. The use 
of sonication energy on crystal character has been investigated, (Mar and Ulrich 1999) 
and could potentially be utilised to produce crystals of a specific size and quality for 
inhalation.
Further work may centre on investigating the effects of solvate, hydrate or polymorph 
production from synthesis or conversely from long-term storage in different solid and 
liquid propellant systems. As particle morphology upon deposition has been shown to 
change, investigations into effects on pharmacokinetics and pharmacodynamics may be 
beneficial.
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General conclusions to Chapter Three
As the antithesis to chapter two, where the main focus was on preparation and 
crystallisation of salts from solution, in this chapter the enhancement of solubility in polar 
and non-polar solvent systems was the main objective. The HFA propellants are poor 
solvents for the majority of surfactants, but have been shown to dissolve certain drugs to 
varying degrees Ultimately, this can decrease the physical stability of suspension 
formulations, and the mechanisms for these changes were considered. Ironically, the HFA 
propellants intrinsic characteristics should be better solvents per se This is discussed and 
evaluated in appendices A 3 and concluded is not the whole argument.
A novel approach has been taken to model the solubility of components in solution based 
metered dose inhalers using data obtained in pure propellant, pure co-solvent, and 
mixtures thereof. Theoretically, it was proposed that if the solubility of the active in the 
formulation mixture exceeded the drug concentrate at a predetermined temperature then 
solubility and solution integrity would be maintained. Both theory and experiment 
correlated well, and deviations were discussed via the formation of metastable regions.
Further work associated with chapter three
Progression of work associated with this chapter would focus on the improvement of the 
solubility apparatus, and the solution solubility model, so that accurate solubility 
predictions may be reached by relating both the chemical structure, and drug 
concentration in tandem. This would assist as evidence from visual studies, rather than 
formulation selection on visual studies alone. Solubility theory could be extended by 
investigation into effect of polymorphism and surface energy properties.
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General conclusions to Chapter four
Chapter four reviewed, briefly, the general mechanisms of liquid disintegration into 
aerosols of aerosol clouds, and the effect of formulation variables on the particle size 
distributions of novel solution based pMDI systems, when compared to a suspension 
based system of similar composition: a hydrophilic salt within a propellant co-solvent 
mixture of 15% w/w co-solvent and 85% propellant 134(a). In general, there were little 
differences between identical co-solvent level formulations. Inter co-solvent levels 
indicated a statistical significance when analysed at both 4°C and 37°C respectively. 
MMAD’s and polydispersity increased with the level of co-solvent added, but were lower 
at higher temperature and thus higher vapour pressures. This may be related to viscosity 
and surface tension effects, and to a change of the critical Weber number of the aerosol 
droplets. A total mass balance incorporating stem deposition was not analysed, and this 
may have accounted for the discrepancies seen in high ethanol formulations.
Fine particle dose recoveries followed the anticipated trend. Higher vapour pressures and 
lower co-solvent levels gave higher fine particle fractions. The effect of formulation 
variables was shown to statistically effect particle deposition when formulations were 
equilibrated at high and low temperatures, as compared to ambient. Finally, a semi- 
empirical equation has was derived that predicted the MMAD of aerosols based upon 
drug character and excipient physicochemical constants that held to with ± 3% of 
experimental results.
Further work associated with chapter Four
The semi-empirical equation derived should be expanded upon, by comparing additional 
experimental data of novel and conventional formulations with the theory. Additional 
components that alter surface tension and viscosity should be incorporated to test the 
robustness of the theory and expand upon it, and alternative particle sizing methods such 
as laser diffraction could be employed to evaluate the differences of MMAD. Ranges of 
actuator orifice diameter, and valve build (metering chamber) should also be tested, as 
they have been previously shown to impart effects on aerosol formation. Fundamental 
physicochemical assessment of vapour pressures of ethanol and 134(a) mixtures over a 
range of temperatures would also be invaluable, as data so far has been generated at
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ambient. Clear deviations from the positive vapour pressure erstwhile described have 
been shown.
General conclusions to Chapter five
The testing environment clearly affected the aerosol clouds generated from the novel 
solution pMDI’s. In addition, it was also noted that the salt derivative itself, when 
formulated at the lowest acceptable co-solvent level necessary to attain short-term 
stability, had a marked effect particle size distribution, and it was inferred that the salt 
derivative itself was affecting both primary Equated to the large, non-respirable dose and 
secondary (respirable dose range) aerososlisation mechanisms.
Hygroscopicity and its effects of aerosolised on salt forms of medicaments were a primary 
goal of this thesis, providing the question: what changes occur in fundamental aerosol 
parameters, when evaluated under non-standard testing conditions?
Data generated indicated that a particle size increase occurred for the hydrophobic 
(Oleate) salt when humidity was increased at both temperature extremes. Whereas, the 
hydrophilic (Maleate) salt, which would have been expected to increase actually 
decreased at low temperature and increased in relative terms less than its hydrophobic 
counterpart, at high temperature. Explanations for this behaviour are postulated by the 
fact that the aerosol particles are essentially different after discharge from the actuator 
orifice: the hydrophilic are "dry” post actuator and the hydrophobic are "wet” . This was 
partially confirmed from SEM images of the cascade impactor stage 4. As a dry particle, 
the density would decrease on acquisition of moisture from its surroundings, and the 
MMAD would also decrease. For a wet particle (ethanol only, assuming the propellant is 
effectively removed and the less volatile co-solvent remains) the particle density 
conversely would increase and the MMAD also increase. The differences in experimental 
MMAD may be due to the fact that the surfactant (hydrophobic salt) partitions between the 
liquid vapour interface and may increase the critical supersaturation and decrease the 
size preferable for growth.
During the discussion of chapter five a question presented itself: did the change in MMAD 
at high temperature result from hygroscopic growth or retardation of propellant/co-solvent 
evaporation? The data from figures 5.18 A and B indicated a suppressive mechanism for 
the hydrophobic salt. This was justified by considering the data at high temperature high 
relative humidity, and high temperature low relative humidity’s respectively. No change in
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fine particle fraction was observed (secondary aerosolisation mechanism), nor any 
significant changes in actuator or throat deposition (primary aerosolisation mechanism).
For the hydrophilic salt it was postulated that hygroscopic growth occurred. This 
statement was qualified by the fact that similar data reviewed (figure 5.3) indicated an 
increase in fine particle dose, which at high temperature would be unlikely. The increases 
in MMAD of the particles rather than suppression of volatiles evaporation were confirmed 
from the data in figure 5.5. Here the actuator deposition increased at these conditions, 
rather than decreased.
Further work associated with chapter five
Particle changes not only in distribution, but morphology were observed. Investigations 
into particle morphology and pharmacokinetic effects warrant further study. Delivery of 
surfactant containing species may be of benefit not only in valve function and device 
performance, but may alter the adsorption and duration kinetics of the drug, as aerosol 
growth kinetics is a complex and multi-functional discipline. Two different salt forms have 
been shown to exhibit different dynamic growth characteristics contrary to theory. The 
effect of salt form indicated changes not only particle size, but also particle polydispersity 
and deposition on the pMDI hardware. Further work should be undertaken to review 
processes essential for production of a monodisperse aerosol. The reduction of throat 
deposition by actuator modifications, utilising humidified air would be therapeutically 
advantageous to the asthmatic population as a whole.
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APPENDICES FOR CHAPTER 1
A 1.1: Anatomical and Physiological characteristics of the human lung

















Trachea 0 1 1.8 12.0 2.54 30.5
Main Bronchus 1 2 1.22 4.76 2.33 11.25
Lobar Bronchus 2 4 0.83 1.90 2.13 3.97
Lobar Bronchus 3 8 0.56 0.76 2.00 1.52
Seg Bronchus 4 16 0.45 1.27 2.48 3.46
Seg Bronchus 5 32 0.35 1.07 3.11 3.3
Bronchus 6 64 0.28 0.90 3.96 3.53
Bronchus 7 128 0.23 0.76 5.10 3.85
Bronchus 8 256 0.186 0.64 6.95 4.45
Bronchus 9 512 0.154 0.54 9.65 5.17
Bronchus 10 1,024 0.130 0.46 13.4 6.31
Term Bronchus 11 2,048 0.109 0.39 19.60 7.56
Term Bronchus 12 4,096 0.095 0.33 28.8 9.82
Bronchiole 13 8,192 0.082 0.27 44.5 12.45
Bronchiole 14 16,384 0.074 0.23 69.4 16.40
Bronchiole 15 32,768 0.066 0.20 113.0 21.70
Ter Bronchiole 16 65,356 0.060 0.165 180.0 29.70
Res. Bronchiole 17 1.31x105 0.054 0.141 300.0 41.80
Res Bronchiole 18 2.62x10s 0.050 0.117 534.0 61.80
Res. Bronchiole 19 5.24x10s 0.047 0.099 944.0 93.20
Alv.duct 20 1.49x10s 0.045 0.083 1,600 139.50
Alv.duct 21 2.10x10® 0.043 0.070 3,220 224.30
Alv.duct 22 4.19x10® 0.041 0.059 5,880 350.00
Alv.sac 23 8.39x10® 0.041 0.050 11,800 591.00
156
A 1.2: Adrenergic receptor sub-types and their function.
Effector Organ Response Adrenergic Receptor involved
Heart
Rate of contraction Increase fix
Force of contraction Increase Pi
Blood vessels
Arteries Constriction a{
Skeletal muscle dilation Pi
Veins Constriction a2
Bronchial tree Dilation Pi
Splenic capsule Contraction a  i
Genito-urinary
Uterus Contraction (X\
Vas Deferens Contraction ax
Prostatic capsule Contraction ax
Kidney




Gl tract Relaxation a2
Eye
Radial Muscle Contraction ax
Ciliary muscle Relaxation Pi
Liver
Fat cells Lipolysis Pi
Pancreatic insulin release Decrease a2
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APPENDICES FOR CHAPTER 2
A 2.1: DSC melting point data of salbutamol salts synthesised and
screened.






NB the Fumarate was insoluble in ethanol even though its only difference to the maleate was 




NB The adipate and state mp differs from that described by Jashnani et al probably due to the 
solvents used in the synthesis
Mesylate Degrades after 124










A 2.2: I.R. band assignments for stretching and bending vibrations with
associated intensities.
Functional
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wagging
C-N (shifts on H- 
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A 2.3: A tom ic coordinates (xIO4) and equivaient isotropic displacement 
param eters (A2x  103) for (jt2x) Salbutam ol Oleate. U (eq) is defined as one 
th ird o f the trace o f the orthogonalized UU tensor.
X y z U(eq)
C(1) 9936(2) 7164(1) 10068(2) 26(1)
C(2) 8429(2) 6703(1) 9375(2) 26(1)
C(3) 9402(1) 6791(1) 9085(2) 20(1)
C(4) 9496(2) 7201(1) 7943(2) 27(1)
C(5) 9336(1) 5503(1) 8201(2) 20(1)
C(6) 9948(1) 4889(1) 7848(2) 20(1)
C(7) 9402(1) 4327(1) 7166(2) 19(1)
C(8) 8772(1) 3896(1) 7695(2) 19(1)
C(9) 8228(1) 3405(1) 7081(2) 17(1)
C(10) 7584(1) 2926(1) 7684(2) 21(1)
C (ll) 8295(1) 3352(1) 5880(2) 19(1)
C(12) 8912(2) 3783(1) 5334(2) 22(1)
C(13) 9466(2) 4254(1) 5975(2) 22(1)
C(14) 2058(2) 5851(1) 9055(2) 26(1)
C(15) 3022(2) 6085(1) 9271(2) 35(1)
C(16) 3615(2) 5660(2) 8515(2) 40(1)
C( 17) 4609(2) 5840(2) 8737(2) 39(1)
C(18) 5207(2) 5367(2) 8002(2) 43(1)
C(19) 6198(2) 5513(2) 8238(2) 43(1)
C(20) 6787(2) 5023(2) 7548(2) 44(1)
C(21) 6851(2) 5209(2) 6284(2) 44(1)
C(22) 7425(2) 5870(1) 6058(2) 37(1)
C(23) 7882(2) 5984(1) 5124(2) 35(1)
C(24) 7874(2) 5522(1) 4050(2) 35(1)
C(25) 7702(2) 5966(1) 2941(2) 33(1)
C(26) 6791(2) 6334(1) 2866(2) 32(1)
C(27) 6612(2) 6784(1) 1773(2) 35(1)
C(28) 5688(2) 7144(2) 1703(2) 38(1)
C(29) 5510(2) 7639(2) 660(2) 39(1)
C(30) 4589(2) 7978(2) 598(2) 43(1)
C(31) 4438(2) 8519(2) -389(3) 57(1)
N (l) 9823(1) 6042(1) 8970(1) 17(1)
0(1) 10390(1) 4563(1) 8849(1) 21(1)
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0(2) 7988(1) 2260(1) 8095(1) 26(1)
0(3) 7751(1) 2868(1) 5297(1) 25(1)
0(4) 1548(1) 6219(1) 8360(1) 26(1)
0(5) 1807(1) 5291(1) 9571(1) 33(1)


















Completeness to theta = 28.29°
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [l>2sigma(l)]
R indices (all data)
Largest diff. peak and hole
jt2x






a = 14.9781(11) A D =90o.
b = 18.3004(14) A 0=93.2510(10)°







-19<=h<= 18, -15<=k<=24, -14<=l<=12 
19250
7296 [R(int) = 0.0569]
92.8 %
Full-matrix least-squares on F2
7296 / 0 /3 41
0.918
R1 =0.0554, wR2 = 0.1343
R1 =0.1146, wR2 = 0.1504 
0.720 and -0.347 e.A“3
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A 2.5: A tom ic coordinates (x 104)  and equivalent isotropic displacem ent 
param eters (A*x 1(fl) for salbutam ol maleate. (U  (eq) is defined as one third  
o f the trace o f the orthogonalized UU tensor)
x y z U(eq
C(l) -2156(5) 9076(4) 7744(4) 49(1)
C(2) -1205(5) 9841(3) 6235(4) 42(1)
C(3) -1023(7) 10581(3) 7849(5) 58(2)
C(4) -967(5) 9717(3) 7318(3) 33(1)
C(5) 1330(5) 9191(2) 8409(3) 27(1)
C(6) 2692(5) 8540(3) 8347(3) 38(1)
C(7) 3399(5) 8448(3) 9353(3) 30(1)
C(8) 2845(5) 7799(3) 9942(4) 41(1)
C(9) 3342(5) 7722(3) 10870(3) 39(1)
C(10) 4382(5) 8313(3) 11256(3) 34(1)
C (ll) 4981(5) 8982(3) 10692(3) 33(1)
C(12) 4482(5) 9032(3) 9723(3) 29(1)
C(13) 5952(6) 9682(3) 11135(5) 55(2)
N (l) 674(4) 9324(2) 7423(2) 28(1)
0(1) 3739(4) 8815(2) 7660(3) 50(1)
0(2) 4801(4) 8280(3) 12205(3) 50(1)
0(3) 7372(4) 9368(2) 11590(3) 44(1)
0(4) 3166(5) 6957(3) 3061(3) 37(1)
0(5) 1788(4) 6216(3) 4136(3) 34(1)
0(14) 2473(6) 6918(3) 3840(4) 26(1)
0(15) 2505(7) 7701(4) 4472(4) 34(1)
0(16) 1859(7) 7848(4) 5321(4) 38(1)
0(17) 837(6) 7276(4) 5934(4) 29(1)
0(6) 594(4) 6496(2) 5684(3) 31(1)
0(7) 347(6) 7589(3) 6729(3) 31(1)
0(4') 3880(20) 7359(13) 3309(14) 59(5)
0(5') 3020(20) 8322(10) 4276(14) 50(5)
C(14') 3010(30) 7537(12) 3986(17) 48(6)
0(15') 2200(30) 6846(15) 4546(16) 45(6)
0(16') 1390(30) 6867(13) 5372(14) 38(5)
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A 2. 5 (continued)
C(1T) 1064(19) 7623(10) 6013(12) 23(4)
0(6') 1381(18) 8351(9) 5738(11) 37(4)
0(7') -120(20) 7587(10) 6550(12) 31(4)


















Completeness to theta = 28.29°
Refinement method
Data / restraints / parameters
Goodness-of-fit on F^
Final R indices [l>2sigma(l)]
R indices (all data)
Absolute structure parameter 
Largest diff. peak and hole
jtlx






a = 8.4487(8) A □= 90°.
b = 15.4327(15) A □= 90°.







-11<=h<=7, -19<=k<=16, -17<=l<=18 
10650
3861 [R(int) = 0.0335]
96.0 %
Full-matrix least-squares on F^
3861 IQ 1227  
1.029
R1 = 0.0790, wR2 = 0.2077 
R1 =0.1099, wR2 = 0.2318 
0(2)
0.920 and -0.367 e.A'3
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A 2.7: HPLC equipment
Equipment Make Model
Pump Jasco PU 980
Autosampler Jasco AS950
Detector Jasco UV 975 UVA/is
pH meter Jenway 3305
Reagents Supplier Batch Lot / No
Methanol / HPLC grade Fisher Various
Water Lab prepared MilliQ resistivity >15MQ
Glacial Acetic acid (G.A.A) BDH K25686717 838













MeOH: H20: G.A.A 
12.5 x 5cm i.d.
164
APPENDICES FOR CHAPTER 3
A 3.1: Statistical data: One-way Analysis o f Variance for determination o f
optim al solution solubility equilibration times
Source DF SS MS F P
2 0.0000025 0.0000012 0.98 0.400
Error 14 0.0000178 0.0000013
Total 16 0.0000203
Individual 95% Cl’s For Mean based on Pooled Std Dev
Level N Mean Std Dev- +----------+----------+------
1 5 0.001923 0.001820------------(------------- *-------------- )
2 6 0.001067 0.000898 (------------ *------------- )
3 6 0.001101 0.000317 (--------------*------------ )
 +  +  + --------
Pooled Std Dev = 0.001127 0.00080 0.00160 0.00240
Tukey's pairwise comparisons
Family error rate = 0.0500 
Individual error rate = 0.0203 
Critical value = 3.70




3 -0.000964 -0.001737 
0.001668
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A 3.2 ; Physicochemical properties o f pM D I media and their effect on solvent 
pow er
The change facilitated in the search for non-ozone depleting propellants identified two 
HFA’s as suitable candidates, as they appeared to possess the necessary 
physicochemical properties required. Primarily they had a comparative toxicity to their 
CFC counterparts, they were non-ozone depleting, non-flammable, and had sufficient 
vapour pressures. However, it became apparent that they were not going to be direct 
substitutes (Dalby et al 1990). The reduced power of the solvents with respect to 
dissolution of conventional pharmaceutical surfactants, even though they were relatively 
polar, was not anticipated (Byron et al 1994). Such reasons need to be interpreted from 
intrinsic physico-chemical properties. These inherent characteristics are indicated in table 
A 4.1.
Table A 3.1 compares the major physicochemical properties of both the HFA and CFC 
propellants. On first inspection, the HFA’s have comparable boiling points, solubility 
parameters, and display superiority with respect to dipole moments and dielectric 
constants. Therefore they should elicit a similar propensity for surfactant dissolution, and 
none of the conventional markers of solubility explained practical observations.
One potential reason for the reduction in solubility was proposed by Vervaet and Byron 
(Vervaet and Byron 1999). They suggested the polarisability of the HFA’s are smaller than 
their CFC counterparts. The high electronegativity of the fluorine atoms reduces the 
number of van der Waal’s interactions (induced dipoles), and, thus, the effective 
polarisability (Byron et al 1994). However, this explanation has been postulated from 
vapour phase data and does not account for the liquid solubility. Indeed, it is true that 
larger molecules (an increase in atomic number and size i.e. the change from fluorine to 
chlorine) do exhibit greater polarisabilties. Conventional surfactants by their nature are 
highly oxygenated polymeric compounds and oxygen itself being electronegative would 
result in electron cloud-cloud repulsion. The non-polar CFC11 with its high polarisability 
volume, small molecular size, less polar nature and lower electronegativity would 
enhance its approach and interaction with surfactants.
The affinity for water is also greater for the HFA’s than the CFC’s, likely due to hydrogen 
bonding, which exists because of the aforementioned electronegativity values, assisted by 
the anomalous covalent structure of water. Fluorine itself corroborates this observation 
this producing hydrated fluoride derivatives whereas other halides are anhydrous.
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Intrinsic Property CFC 11 CFC 12 CFC 114 HFA 134(a) HFA 227ea
Boiling Point (°C) 24 -30 4 -26 -16
Vapour Pressure (kPa) 89 566 182 572 390
Density (Kg cm'3) 1490 1330 1470 1230 1420
Viscosity (Pa s'1) 430 200 300 210 270
Surface tension (Nm'2') 0.018 0.009 0.011 0.021 0.027
Enthalpy (kJ mol'1) 25.1 17.2 22.1 18.6 19.6
Dielectric constant
(J'1 C '1 m'1)
2.3 2.1 2.2 9.5 4.1
Dipole moment ( D) 
(1D = Cm'1)
0.24 0.51 0.58 2.1 1.2
Induced Polarisation 
(m'3 mol'2 x 105)
2.8 2.3 3.2 6.1 6.1
Solubility Parameter 
(Hilderbrand units)
7.5 6.1 6.4 6.6 6.2
Kauri-Butanol Value 60 18 12 9 13
Log P (oct / water) 2.0 2.2 2.8 1.1 2.1
Water solubility (ppm) 130 120 110 2200 610
Polarisability Volume
(10'24 cm'3 molecule 9.5 7.9 8.5 5.4 5.8
vapour)
Table A 3.1(a): Physicochemical properties of pMDI media
The fact that the solubility of conventional surfactants is reduced within the new 
propellants is not the whole story. Induced polarization, increased dielectric constants and 
dipole moments refute poor solvent power and indicate improved solvent characteristics. 
Thus various respiratory medicaments are, to some degree, soluble in HFA’s, which has 
necessitated the total solubilisation of medicaments with use of a co-solvent, usually 
ethanol, to obviate Oswald ripening.
Dissolution and hence the disruption of long-range electrostatic interactions resulting from 
coulombic charges between ions, is decreased in a solvent or solvent system as the 
effective field strength is reduced. (Chemical potential therefore and resultant energy is 
favoured by interaction of ionic atmospheres). Solvents with high relative permittivity 
values (Dielectric constants) perform this function well (Genzer and Kolafa 2003). For 
example, in aqueous systems coulombic fields are reduced by nearly 2 orders of
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magnitude (water has a high dielectric constant). And, in conjunction, the presence of the 
“’ionic atmosphere” of an ion tends to “’shield” it further reducing the electrostatic 
potential, as the coulombic interaction falls off as the distance from the nucleus according 
to:
fO /  \  -  r
— e x p
\ r ) l rD J Equation A 3.1(a)
Where, r  is the distance and rD the shielding or Debye length
.The Debye-Huckel theory allows calculation of the shielding length for dilute aqueous 




Equation A 3.1 (b)
Where, r  is the shielding radius (nm), R is the universal gas constant, T temperature, L is
Avogadro’s constant, P is the density of the m edium ,^is the charge on a proton, and I  
the Ionic strength. To illustrate the “’effective strength” of the propellants and the 
necessity for the requirement of a co-solvent, the shielding length was calculated for the 
salbutamol salts in CFC 11, HFA 134(a) and ethanol respectively, assuming the ions were 
spherical points. And the approach of the relationship between dilute aqueous solutions 
and and organic systems were equivalent. The results for individual salts are tabulated in 
table A 3.1(b)
Shielding length Shielding length Shielding length
CFC 11/nm HFA 134(a) / nm Ethanol /nm
Salbutamol Maleate 5.40x1 O'10 1.14x1 O'9 2.14x10*9
Salbutamol Oleate 4.40x1 O’10 9.29x1 O'10 1.75x1 O'9
Table A3.1(b) Shielding lengths (rD /  m) of various propellant/co-solvent components used 
in pMDI formulations.
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The calculated Debye lengths are in general agreement with practical observations. The 
effects of ion concentration and permittivity are illustrated: as the concentration of ions are 
increased, the Debye length is decreased from increased shielding, and when the relative 
permittivity is high, the ionic atmospheres are diffuse and the central nuclear charge effect 
suffers from a reduction in strength. HFA 134(a) therefore, from these crude calculations, 
is approximately 2.1 times more effective at shielding than the CFC 11 for each salt at 
their therapeutic concentration; and, the co-solvent is approximately 3.98 times as 
effective as shielding as the CFC11 but only 1.88 times as 134(a)
Formulation 
EtOH / %w/w
Storage condition Timepoint Observation
10/12.5 25 °C initial clear some dust fibres
10/12.5 25°C 3 days clear some dust fibres
10/12.5 25°C 10 days
large crystals 
0.2-0.5mm
15/20/30 25°C Initial 10 days clear some dust fibres
15/20/30 -23.5°C 14 days clear some dust fibres
15/20/30 -23.5°C 56 days clear some dust fibres
Table A 3.1(c) The visual Solubility of Salbutamol Maleate in Ethanol /  HFA 134(a) (active 
concentration approx. 0.25% w/w RMM 355.38)
Formulation 
EtOH / %w/w
Storage condition Timepoint Observation
10/12.5 25°C initial clear some dust fibres
10/12.5 25°C 3 days clear some dust fibres
10/12.5 25°C 10 days
No crystals. A ring of oleate formed at 
the liquid vapour interface
15/20 25°C Initial 10 days
No crystals. A ring of oleate formed at 
the liquid vapour interface
30 25°C Initial 10 days clear some dust fibres
30 -23.5°C 14days clear some dust fibres
30 -23.5°C 56 days clear some dust fibres
Table A 3.1(d) The visual Solubility of Salbutamol Oleate in Ethanol /  HFA 134(a) (active 
concentration approx. 0.37% w/w RMM 521.78)
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Formulation 
EtOH /  %w/w
W ater / ppm Timepoint Observation
15 5000 Initial Clear
8wks @ -23.5°C Crystals /  uniform 2PS
15 50000 Initial 2 PS
8wks @ -23.5°C 2PS
20 5000 Initial Clear
8wks @ -23.5°C clear
20 25000 Initial Clear
8wks @ -23.5°C 2PS clears on warming
20 50000 Initial 2 PS
8wks @ -23.5°C 2PS
30 5000 Initial Clear
8wks @ -23.5°C Clear
30 25000 Initial Clear
8wks @ -23.5°C Clear
30 50000 initial Clear
8wks @ -23.5°C Clear
Table A 3.1(e) The visual Solubility of Salbutamol Maleate in Ethanol /  HFA 134(a) /  Water 
systems (active concentration approx. 0.25% w/w RMM 355.38)
Tables 3.1(c-e) inclusive illustrate the visual observations that relate formulation 
composition to solution stability.
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APPENDICES FOR CHAPTER 4
A4.1 Equations predicting particle size and vo lum etric  flow  rate  
A 4.1 (a) Particle size
Dm  = 6do(Re)°‘15 Equation A4.0
(Panasenkov 1951).
Where, Dm is the Median diameter, d0 is the spray orifice diameter, Re is the Reynolds 
number.
A 4.1 (b) Volumetric Flow rate
T T  QU = — Equation A 4.1
a
Where, 0 is  the Volumetric flow rate, a is the cross sectional area of the spray 
orifice.
A 4 .1(c) Volumetric flow through a restriction
Q ~ Cdad
Where, C j  is the drag coefficient, a^ , is the area of the orifice, AP  is the pressure









A 4.2 The effect Formulation variables on aerosol delivery
A 4.2 (a) Metering volume
There are several metering valve variants. Variations occur not only with the method of 
valve chamber filling, but also in valve componentry and geometry. The volume of the 
metering chamber nominally extends from 25-1 OOpI, and contains a representative 
amount of suspended or solubilised drug. Problems occur with valves and formulations as 
they can loose drug from the reservoir (commonly known as loosing its prime). If this 
occurs, drug variation in subsequent doses, and a smaller dose may be delivered. This 
property is valve and formulation dependent, but has been attributed to the viscosity of 
formulations leaking from metering chamber-filling orifices. Alternative valve designs are 
available, but, again, each has its limitations. (Schultz et al 1994) Various elastomers and 
resins inherent in metering valves can interfere with suspension formulations by nature of 
drug-surface-valve component interactions. In addition, the volume of the metering valve 
has been shown to influence on deposition pattern, presumably due to mass and heat 
diffusion parameters changing. (Newman et al 1982 and Moren 1978).
A 4.2(b) Study specific variables
A 50pJ inverted use metering valve (Bespak Kings Lynn) 20mm diameter of the capillary 
action type was used in this study, as this is a generally available commercially. The 
ferrule, core, spring, body, metering chamber seats and gaskets are standard HFA 
ethanol compatible materials.
A 4.2 (c) Vapour pressure
Propellant system vapour pressure has been shown to be arguably one of the most 
important factors in aerosol dynamics. (Polli et al 1969, Harnor et al 1993 Clark 1996 ). 
First principles of thermodynamics help us understand the rationale, as the molar Gibbs 




ju(p) = f f l  + R T  In Equation A 4.3
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Where is the chemical potential at pressure p ,^  is the standard chemical
potential, R is the universal gas constant, T \s the temperature, and f  the fugacity.
(NB: Fugacity, the equivalent of "activity" for a component in a mixture of gases. It has the
same physical meaning as the activity for a component in a solution)
In suspension systems the lowest particle size is limited by the size of individual or 
particle agglomerate, therefore, in theory there should be more "flexibility” in solution 
systems with respect to particle size manipulation. It has been shown that increasing the 
vapour pressure (274 to 502Kpa) of formulations containing Teflon spheres significantly 
increased the whole lung deposition, and reduced that of the extrathoracic region. 
(Newman et al 1982) It is hypothesised that the delivery of polydisperse or monodisperse 
aerosols may be achievable by careful control of formulation and hardware.
A 4.2 (d) Study specific variables
Vapour pressures utilised in this study varied according to temperature, and were 
measured experimentally using placebo formulations, crimped with a continuous spray 
valve tested with a pressure gauge (Pamasol Switzerland). Pressures ranged from 
approximately 1-7 bar dependent on formulation and temperature.
A 4.2 (e) Temperature
The easiest way to manipulate vapour pressure,aerosol dynamics and drug delivery is by 
temperature control. Particle size distributions from pMDI’s are routinely measured at 
ambient temperature (unless under research conditions), and are rarely taken to extremes 
of temperature for investigation: at freezing point, and at the upper end body temperature 
were the vapour pressure of 134(a) is in excess of 10 bar. It is known that mixtures of 
ethanol and HFA’s strongly deviate from Raoult’s law as higher equilibrium pressures are 
experienced (Tzou 1998). This may, ultimately, be to the advantage as a change in 
temperature may allow optimal delivery with a particular formulation blend. It was an 
objective of this chapter to investigate temperature extremes for blends of novel salt 
derivatives.
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A 4.2 (f) Study specific variables
In this study formulations were stored at three temperatures: -23.5, 4 and 37oC. 
Temperatures of 4 and 37oC were chose, as these are important for stability (4°C), and 
also emulate physiological temperature (37°C). The ultra low temperature was chosen, as 
this was an extreme of temperature and very close to the boiling point of HFA 134(a) 
where maximum instability may occur. Results from this temperature have not been 
documented as the majority of the aerosol cloud was deposited on the throat of the 
apparatus, and data did not approximate to log normal distributions. Previous low 
temperature studies have been performed on HFA suspension systems, (Stein and 
Stefely 2003) presumably utilising Airomir. A value of approximately 60% fine particle 
fraction was evaluated experimentally after equilibration at -20°C.
A 4.2 (g) Co-solvent level
The addition of co-solvents is necessary to aid dissolution of the drug. The first regulatory 
approved suspension and solution systems (3M Pharmaceuticals) contained ethanol at 
varying levels. Recently Smyth and Hickey (Smyth and Hickey 2003) and Gupta (Gupta et 
al 2003) investigated the effect of co-solvent in order to assess solubility effects, and also 
resulting particle size distributions, based of model drug alternatives and beclomethasone 
respectively. Smyth and Hickey concluded that drug solubility may be improved with 
addition of ethanol, and, due to the deviation from ideality of the mixtures utilised, 
formulations of up to 20% w/w ethanol were practically useful. In the former study, the 
concentrations of active in the formulations was at 0.01% w/w, and illustrated an increase 
in MMAD and GSD with increasing ethanol and a decrease in fine particle fraction. There 
was no correlation between device and throat deposition. Gupta et al, however, noted that 
MMAD increased significantly with active concentration, but did not with increasing 
ethanol level. They also indicated an increase in throat deposition of 125% when ethanol 
levels were increased by 15%, and a decrease in respirable fraction from about 50 to 25% 
when the ethanol level was increased from 5 to 20%, indicating that the efficiency of 
solution pMDI’s decreases with increased ethanol concentration. They also generated a 
variable, which they termed the "maximum respirable mass” (MRM). This is a product of 
drug solubility and delivered dose and is obviously is drug, formulation and actuator 
dependent.
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A 4.2(h) Study specific variables
Co-solvent levels were varied according to initial stability studies. Values ranged fro 15- 
30% w/w respectively.
A 4.2 (i) Non-volatile additives: actives and excipients
As previously intimated, the addition of low volatility additives affects the spray and 
resultant cloud distribution. As the drug mass is fixed in the formulation due to constraints 
of clinical dosage and physicochemical properties then the only alternative available to 
change particle size distribution is the use of physiologically acceptable excipients. 
Brambilla (Brambilla et al 1999) found, that, addition of glycerol to solution formulations 
containing steroids and anticholinergics increased the MMAD. Addition of such excipients 
will affect several parameters relating to liquid ligament deformation and droplet 
formation: surface tension of the ligaments will change, the molar volume of the liquid will 
increase, which from the Kelvin equation will endeavour to reduce the pressure of the 
droplet, and the resulting vapourisation rate will decrease. As a multi-component system, 
the mass and heat diffusion rates will also change. Convective droplet vapourisation, 
interaction with gas flows, and alterations of particle drag will combine to affect primary 
and secondary atomisation.
A 4.2 (j) Study specific variables
Drug loading varied according to a therapeutic equivalent to the free base, where 1.00 
was equivalent to 100pg of freebase, calculated from the relative molecular masses of the 
maleate salt and oleate respectively. The equivalents are calculated and presented in 
table 4.0:
Compound Relative Mol Mass Therapeutic Equivalent Drug loading %w/w 
Based on 10g fill wt
Salbutamol Base 239.31 1.00 0.175
Salbutamol Maleate 355.38 1.485 0.259
Salbutamol Oleate 521.78 2.180 0.382
Table A 4.2 The relative drug loading values for salbutamol salts equivalent to 100 
microgram’s freebase.
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A 4.2 (k) Actuator design
The actuator design is integral to the development of the aerosol cloud. It is debatable, 
but the actuator orifice, sump and valve stem arrangement are deemed to be some the 
most important factors. Airflow through the actuator, the design of the mouthpiece, and 
mouthpiece extensions are also important as they emulate spacer devices. It is theorised 
that these reduce orophayrngeal deposition by allowing evaporation and deceleration of 
larger droplets to occur. (Byron 1990). The spray orifice diameter has been shown to 
influence the MMAD as smaller diameters produce smaller particles and finer sprays 
(Clark 1992); and droplet diameters have been derived empirically and been shown to 
vary proportionally to the orifice diameter. Empirical equations relating MMD based on 
spray orifice diameter and liquid flow rate are illustrated in appendices 4.1 - 4.3 
respectively. Effectively the volumetric flow rate and hence the liquid velocity relative to 
the gas decreases. This will reduce the critical value of the Weber number and, so, 
ligament break up and droplet formation occurs quicker forming smaller droplets.
A 4.2 (I) In-vitro Vs In-vivo correlations
It is well known that particle deposition in the lung is dependent upon aerodynamic 
particle size, (Task Group in the lung 1966), and the parameters of MMAD and fine 
particle fraction do not totally correlate from in-vitro to in-vivo clinical efficacy. However, at 
present, in vitro testing materials are not ideal, and the differences are thought to stem 
from the use of unrealistic metallic throats. Improvements have been suggested by the 
use of anatomic throats from replica casts. (Olsson et at 1996) In fact replica lung casts 
are routinely used in research. (Martonen 1983). In this study, standard pharmacopeial 
aerosol testing techniques have been used with slight modifications where indicated.
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APPENDICES FOR CHAPTER 5
A 5.1 Particle growth ratios for a selection of inhaled medicaments
Drug aerosol Particle growth Ratio Relative Humidity (%)
(reference)
Albuterol 1.08 90
(Kim et al 1985)
Beclomethasone bipropionate 1.33 98
(Hiller et al 1980)
Cromolyn Sodium 1.31 98
(Smith et al 1980)
Epinephrine 1.11 90
(Kim et al 1985)
Isoetharine Phenylephedrine 1.10 90
(Kim et al 1985)
Isoproterenol 1.24 90
Phenyephedrine (Kim et al 1985)
Isoetharine 1.13 98
sulphate (Hiller et al 1980)
Metaproterenol 1.10 90
(Kim et al 1985)
Metaproterenol sulphate 1.29 98
(Hiller et al 1980)
Triamcinalone 1.17 90
Acetonide (Kim et al 1985)
Table A 5.0: Particle growth ratios of several medicinal aerosol formulations.
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A 5.2 Partic le  size distribution changes via the use o f both hydrophobic and  
hydrophilic drug derivatives
The particle size analysis of hydrophilic and hydrophobic aerosols has been has been of 
interest for several years. Atmospheric physicists and aerosol hygienists were probably 
the first groups to recognize the effects of hygroscopicity on atmospheric pollutants, and 
the incidences of respiratory disease in industrial urban areas. (Milburn et al 1957). 
Ferron, has thoroughly modelled the effects of deposition on salt particles; and, Martonen 
has extensively investigated the effects of hygroscopicity on pharmaceutical aerosols. (It 
should be noted several other authors have also extensively investigated such effects) On 
studies of aqueous based saline and isoproterenol hydrochloride solutions (some 
containing glycerin) in the upper respiratory tract, Bell and Ho studied the effects of dry 
monodisperse aerosols under different conditions of temperature and humidity and flow 
turbulence: investigation of effect of the Reynolds number. Experimental data indicated 
that isopreterenol solutions containing glycerin ‘’grew” at a slower rate than both saline 
and isopreterenol alone. The growth rate also increased when the Reynolds number 
Particle growth diameters and particle growth ratios, of solutions described at different 







R.H (%) Particle Growth ratio Reynolds Number
1.0 NA 0.010 93 1.15 1100-1200
1.0 NA 0.045 92 1.65 1100-1200
1.0 NA 0.250 93 2.15 1100-1200
0.5 Glycerol 0.02 93 1.10 1100-1200
0.5 Glycerol 0.120 95 1.40 1100-1200
0.5 Glycerol 0.225 94 1.60 1100-1200
1.0 NA 0.010 93 1.40 2100-3200
1.0 NA 0.150 93 2.45 2100-3200
1.0 NA 0.315 93 2.80 2100-3200
0.5 Glycerol 0.07 93 1.60 2100-3200
0.5 Glycerol 0.21 93 2.05 2100-3200
0.5 Glycerol 0.37 95 2.20 2100-3200
Table A 5.1: The effect of relative humidity on particle growth diameter of aqueous based
aerosolised isopreterenol solutions
The mechanism for the retardation of growth proposed centred on the fact that the 
glycerol hydrogen bonded to the water molecules at the surface of the droplet, and, so, 
environmental water molecules diffused more slowly across the interfacial boundary into
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the core. This theory has been also suggested by (Otanyi and Wang 1984) whereby they 
studied saline droplets with the addition of cetyl alcohol. Polydisperse aerosols were 
preconditioned in a controlled environment and passed into an elutriator for analysis. 
Growth rate of saline droplets was retarded by up to 99.5% resulting from a covering with 
a monolayer of surfactant.
Another study focused on fatty acid additives with dry powder formulations. A solid 
formulation, produced by solvent evaporation revealed post chemical analysis a 
surfactant matrix effect rather than surface-active effect (Hickey et al 1990). Aerosol 
experiments indicated a reduction in growth ratio for increasing fatty acid content. It was 
concluded that by varying the residence time of the aerosol in the system the growth rate 
kinetics could be possibly monitored. Corresponding in-vivo studies, using disodium 
fluorescein with varying amounts of capric acid coating, in beagle dogs, indicated 
enhanced uptake (Clark and Byron 1985). Two probable hypotheses resulted from the 
study: either the coating enhances particle uptake or since the coating resists moisture 
adsorption the particles deposited deeper in the lung .
Glycerol when formulated in solution based metered dose inhalers and tested at ambient 
conditions has been shown to increase the MMAD, primarily due to aerosol kinetics. The 
effect of humidity on aqueous glycerol aerosols has however been investigated. (Davis 
and Bubb 1978 and Lin and Cox 2003).
The effects of low and high humidity on metered dose bronchodilator solution and 
suspension aerosols was investigated by Hiller et al (Hiller et al 1980). Data indicated, 
(generated from a 30s holding time), that that both the number of particles in the 
measured range and the aerodynamic dose increased for both dosage forms, however 
the shift for the solution aerosols was greater indicating that the particles had increased 
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